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ABSTRACT 
Menopause is an age-related loss of ovarian hormone production that has been linked 
with obesity-associated metabolic dysfunction, increased visceral adiposity, and inflammation, 
although the mechanisms remain unclear. Obesity has been strongly linked with profound shifts 
in the gastrointestinal (GI) microbiota, disrupted gut barrier function, and inflammation, but little 
is known regarding the involvement of the GI tract in obesity associated with loss of ovarian 
hormone production. Herein, we hypothesized that GI tract and the gut microbiota are involved 
in the weight gain and inflammation that occurs with the loss of ovarian hormone production and 
that dietary interventions may affect these responses.  
The objective of aim 1 was to evaluate the impact of soy on metabolic health, adipose 
tissue inflammation, and the cecal microbiota in ovariectomized (OVX) rats bred for low-
running capacity (LCR), a model that has been previously shown to mimic human menopause. 
Forty 27-wk old LCR rats were either OVX or sham-operated (SHM) and fed either soy-rich 
(soy) or soy-free (control) diets for 28 wk. Soy consumption reduced (p<0.05) body weight gain, 
adiposity, circulating cholesterol concentrations, and improved insulin sensitivity of LCR rats. 
Principal coordinates analysis (PCoA) of weighted and unweighted UniFrac distances of cecal 
microbiota revealed a sharp separation (p<0.05) between soy- and control-fed groups. The soy-
fed group had a lower (p<0.001) Firmicutes:Bacteroidetes ratio compared to control. 
The objective of aim 2 was to determine the energy metabolism, lipid accumulation, and 
inflammation in adipose and liver tissues of OVX female C57BL/6J mice in response to a high-
fat diet (HFD). Forty 10-wk-old female C57BL/6J mice were fed either a high-fat diet (HFD; 
60% kcal from fat) or a low-fat diet (LFD; 10% kcal from fat). After a 2-wk acclimation period, 
mice underwent surgical intervention (OVX or SHM). As expected, OVX mice fed HFD had 
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substantially greater (p<0.05) body weight gain, adiposity, and hepatic triglyceride 
concentrations than OVX mice fed LFD. Compared to intact controls, ovariectomy led to greater 
(p<0.05) adipose and hepatic tissue inflammation, macrophage infiltration, oxidative stress, 
hindered insulin signaling and glucose uptake, and altered lipid and energy metabolism. 
Moreover, HFD feeding of OVX mice led to greater (p<0.05) inflammation and macrophage 
infiltration in gonadal adipose tissue. The degree of adiposity and inflammation resulting from 
HFD in OVX mice vs. SHM mice was dramatically greater than that observed in OVX mice vs. 
SHM control mice fed LFD. 
The objective of aim 3 was to examine the cecal microbial communities and barrier 
function in OVX or SHM mice fed a HFD or LFD for 12 wk. OVX/HFD mice had greater 
(p<0.05) serum lipopolysaccharide-binding protein than OVX/LFD mice. Cecal expression of 
inflammatory genes was not elevated due to ovariectomy, but the expression of B cell 
leukemia/lymphoma 2 (BCL2) was greater (p<0.05) in OVX mice than SHM mice, indicating 
greater apoptosis associated with loss of ovarian hormone production. Cecal permeability was 
not different among treatment groups. However, OVX mice had lower (p<0.05) cecal expression 
of occludin, claudin3, and AMP-activated protein kinase (AMPK) than SHM mice, suggesting 
that the cecal integrity was compromised due to loss of ovarian hormone production. Lower 
cecal expression of farnesoid X receptor (FXR) and fibroblast growth factor (FGF15) was 
observed in the OVX mice compared to SHM, suggesting an interaction between estrogen and 
the FXR-FGF15 pathway that is known to affect bile acid synthesis. PCoA of weighted and 
unweighted UniFrac distances of cecal microbiota revealed a distinct separation (p<0.05) 
between mice fed LFD and HFD. Despite the profound physiological changes of OVX/HFD vs. 
SHM/HFD mice, differential clustering of microbial communities was only observed between 
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OVX/LFD and SHM/LFD mice. HFD promoted a greater (p<0.05) Firmicutes:Bacteroidetes 
ratio and lower (p<0.05) species richness of the cecal microbial community. Ovariectomy led to 
greater (p<0.05) abundance of Lactobacillus and lower (p<0.05) relative abundance of 
Oscillospira, Ruminococcus, and an undefined genus in the order Clostridiales. 
Differential clustering of the cecal microbial community was observed only between 
OVX and SHM mice fed a LFD, suggesting that the impact of ovariectomy on the cecal 
microbiota was masked by the HFD intervention. Thus, the objective of aim 4 was to determine 
the bacterial -glucuronidase activity level and the longitudinal shifts of the gut microbiota 
following the loss of ovarian function and progression of obesity in mice fed a HFD. Fecal 
pellets were collected at baseline (wk 0, prior to ovariectomy surgery but 2 wk after diet 
interventions were initiated) and 4-, 8-, and 12-wk post-surgerical intervention. Fecal -
glucuronidase activity was elevated (p<0.05) in mice of the SHM/HFD group compared to those 
in the SHM/LFD group, but it was not different than mice in the OVX groups. PCoA of 
weighted UniFrac distances of fecal microbiota revealed a distinct separation (p<0.05) between 
diets. However, SHM and OVX mice only clustered differently in those fed a LFD. The 
Firmicutes:Bacteroidetes ratio was elevated at wk 8 and wk 12 of those fed the HFD, indicating 
that this elevation was due to increased adiposity instead of ovariectomy per se. The relative 
abundance of Clostridium and an undefined genus in the family Clostridiaceae was elevated in 
the OVX/HFD group at wk 4, but not SHM/HFD, indicating that this change may be due to the 
loss of ovarian hormone production. 
Our results indicate that ovariectomy impacts the composition of the gut microbial 
community, even though the signal was much weaker than that due to dietary intervention. 
However, ovariectomy promotes disrupted gut barrier function and the alteration of FXR and 
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FGF15 in the cecum, suggesting that signaling and regulation of inflammation and bile acid 
metabolism in the GI tract were impacted by ovariectomy. Metagenomic, transcriptomic, and 
metabolomic analyses will need to be conducted to better examine the involvement of the gut 
microbiome and host-microbial interactions in ovariectomy- and menopausal-associated obesity.  
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CHAPTER 1: INTRODUCTION 
Obesity is one of the major public health crises of the 21
st
 century and the leading cause 
of numerous chronic diseases, with annual treatment costs estimated to be $147 billion in the 
U.S. (1). Prevalence of obesity reaches 65% in women at post-menopausal age while 
approximately 35% of all U.S. men and women are obese (2, 3). Menopause is an age-related 
loss of ovarian hormone production, characterized by falling concentrations of estrogen and 
progesterone (4). Menopause in humans and ovariectomy in rodents is associated with increased 
adiposity, reduced physical activity and aerobic fitness, and the onset of metabolic diseases (5, 
6). In contrast, intact female mice are protected against weight gain, and remain more glucose 
tolerant, than weight-matched male mice after onset of obesity (7, 8); however, this protection is 
not as clear in humans, potentially due to other factors such as diet, genetics, and lifestyle. Loss 
of ovarian estrogen production is thought to contribute to the elevated obesity rates in post-
menopausal women, yet the exact mechanisms remain unclear. Obesity has been linked with 
disrupted gut barrier function and shifts in gut microbial composition that lead to increased 
systemic inflammation and dysfunctional host immune response (9-11). Administration of 
estrogen protects ovariectomized female rats against intestinal injuries, supporting the potential 
role of sex hormone modulation on intestinal health (12). Obesity has been induced by 
transferring gut microbes from obese mice to gnotobiotic mice without affecting food intake 
(13), suggesting that the gut microbiota affect the efficiency of energy harvest from indigestible 
components of the diet, alter energy utilization, and/or influence host energy balance and 
metabolism. However, little is known regarding the involvement of gastrointestinal (GI) barrier 
function and the gut microbiome in obesity and inflammation associated with the loss of ovarian 
estrogen production. 
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The overall objective of this research was to elucidate the effects of diet, including soy 
supplementation and a high-fat diet (HFD), and loss of ovarian hormone production, on GI 
barrier integrity and the gut microbial community, and identify associations among measures in 
the GI tract and those indicative of metabolic dysfunction. 
Our first aim was to evaluate the impact of soy on metabolic health, adipose tissue 
inflammation, and the cecal microbiota in ovariectomized (OVX) female rats bred for low-
running capacity (LCR), a model that has been previously shown to mimic human menopause. 
We hypothesized that soy consumption would improve whole body insulin sensitivity, hinder fat 
mass gain and adipose tissue inflammation, and beneficially impact the gut microbial community 
by increasing the relative abundance of known equol-producing bacteria such as Lactobacillus, 
Enterococcus, and Adlercreutzia, and decreasing the Firmicutes:Bacteroidetes ratio. 
Our second aim was to determine energy metabolism, lipid accumulation, and 
inflammation in adipose tissue and liver of OVX female mice in response to a HFD. We 
hypothesized that, compared to intact controls, ovariectomy would induce obesity and adiposity, 
increase inflammatory markers in adipose tissue and liver, and increase hepatic and adipose 
tissue steatosis when mice were fed the HFD. We also hypothesized that these dysfunctional 
metabolic outcomes would be more severe in the OVX mice fed HFD than those fed a control 
low-fat diet (LFD).   
Our third aim was to measure the cecal microbial communities and barrier function in 
mice with loss of ovarian function and fed a HFD or LFD. We hypothesized that ovariectomy 
would lead to disrupted gut barrier function, altered energy metabolism, and elevated intestinal 
inflammation, and that HFD would exacerbate the severity of these conditions. We also 
hypothesized that ovariectomy would shift the cecal microbial communities and lead to an 
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increased Firmicutes:Bacteroidetes ratio and decreased species richness compared to intact 
sham-operated mice. 
Our forth aim was to determine the bacterial -glucuronidase activity level and the 
longitudinal shifts in the gut microbiota in the progression of obesity associated with loss of 
ovarian function in mice fed a HFD. We hypothesized that the gut microbiota changes occurred 
early in the development and progression of obesity resulting from the loss of ovarian function. 
We also hypothesized that the bacterial -glucuronidase expression would be elevated in the 
OVX mice compared to the intact sham-operated mice, and that the degree of expression would 
be higher in the OVX mice fed a HFD than those fed a LFD.  
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CHAPTER 2: LITERATURE REVIEW 
Obesity  
Obesity, defined as an excessive accumulation of body fat, is commonly identified by 
using body mass index (BMI) in humans (Table 2.1). BMI is calculated as weight in kilograms 
divided by height in meters squared and is known to be associated with morbidity and mortality 
in a J- or U-shaped relationship, with both lower and higher ends of BMI having higher risks of 
morbidity and mortality (1).  
 
Obesity epidemic 
In the U.S., 35% of adults and 17% of adolescents are obese (2, 3). The prevalence of 
obesity has steadily increased over the past few decades, and the growing rate of obesity is 
associated with a rise in medical expenses. In 2008, the medical costs of obesity-related diseases 
were estimated to be $147 billion in the U.S., which was twice as much as in 1998 (4). Using 
data from the National Health and Nutrition Examination Survey (NHANES), Wang et al. (5) 
predicted that 51% of U.S. adults will be obese by 2030. Total healthcare costs related to obesity 
are predicted to double every decade and estimated to be about $900 billion by 2030 in the U.S. 
Table 2.1 Health risk classification and comorbidities by body mass index (BMI)  
Classification BMI (kg/m
2
) Risk of comorbidities 
Underweight <18.5 Low, but risk of other clinical problems increased 
Normal range 18.5-24.9 Average 
Overweight ≥25  
Pre-obese 25.0-29.9 Increased 
Obese class I 30.0-34.9 High 
Obese class II 35.0-39.9 Very high 
Obese class III ≥40.0 Extremely high 
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(5).  Globally, 37% of men and 38% of women were obese in 2013, which was about 10% higher 
than in 1980 (6). Moreover, prevalence of obesity has drastically increased in children and 
adolescents in developed countries, with ~23% of boys and girls being overweight or obese in 
2013 (6). The increase in obesity and overweight in adults was faster than in children, and faster 
in women than in men (5). Overweight and obesity were estimated to cause 3.4 million deaths in 
2010 worldwide (7). 
Prevalence and possible causes of obesity in postmenopausal women 
A higher prevalence of obesity was observed in women at post-menopausal age than 
those in pre-menopausal age in 2009-2010 (8). Regardless of race/ethnicity, 66-74% of the 
women at post-menopausal age are overweight or obese in the U.S., compared to a prevalence of 
56% at pre-menopausal age (8). The average age of menopause in developed countries is 50-52 
years (9, 10). With the increasing life expectancy of women in developed countries, most are 
expected to spend between one-third and one-half of their lives in a post-menopausal state. 
Despite the high prevalence, the causes of obesity in this population remain unclear. Controversy 
exists regarding the cause of midlife weight gain in women, with chronological aging, 
menopausal status, and lifestyle being some of the most likely contributors. 3,064 women from 
ages 42-52 were followed for up to 3 years through the Study of Women's Health Across the 
Nation (SWAN), and weight gain was observed over time, but an association between change of 
menopausal status and weight gain was not observed (11). Other studies also failed to find an 
association between menopausal status and fat mass in women (12, 13). Some, therefore, have 
drawn the conclusion that midlife weight gain in women is primarily influenced by aging, not 
loss of ovarian hormone production. However, a meta-analysis of >100 randomized trials in 
post-menopausal women concluded that the use of estrogen supplementation, with or without 
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progesterone, increases lean body mass and reduces abdominal fat, improves insulin resistance, 
and decreases blood pressure, suggesting that it may minimize the obese phenotype of this 
population, and supporting the theory that estrogen loss contributes to obesity (14).  
Nevertheless, menopause and aging are two mutually existing confounding factors that are 
extremely difficult to isolate. 
 
Menopause 
Definition and hormonal changes in menopause 
Menopause is an age-related loss of ovarian hormone production, characterized by falling 
concentrations of estrogen and progesterone (15). It is a natural biological process, although it 
also can happen artificially through surgery or use of drugs. According to Stages of Reproductive 
Aging Workshop (STRAW) nomenclature, menopause is defined as having complete cessation 
of menses for 1 year (9). During the menopausal transition stage, decreased numbers of oocytes 
lead to lower inhibin B (INH-B) concentrations, which is an important suppressor of follicle-
stimulating hormone (FSH). Post-menopausal women, therefore, have increased concentrations 
of FSH (10-15 times higher than women of reproductive age) that further accelerates follicular 
loss (16). Once the ovarian follicles are depleted, the ovaries fail to respond to the high FSH 
concentrations and estradiol concentrations subsequently decline (approximately 90% lower than 
women of reproductive age) (16).  
Impact of menopause on food intake, energy expenditure, and physical activity 
Estrogen is known to affect energy homeostasis in mammals (17). Reduced food intake 
around the time of ovulation has been observed in rhesus monkeys and humans (18, 19). 
Presence of estrous cycle variation affects food intake and it has been suggested that signals 
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generated from glucose and fatty acid metabolism control reproduction in a similar way as they 
control food intake (20). Removal of ovaries (i.e., ovariectomy) has been shown to lead to 
hyperphagia and weight gain in rats (21, 22); however, increased food/energy intake is not 
always observed (23). Injecting estradiol into ovariectomized (OVX) rhesus monkeys 
significantly suppressed hyperphagic behavior resulting from ovariectomy (24). In humans, 
weight gain after menopause is usually observed, but is not always accompanied with 
hyperphagia (25, 26). In mice, weight gain was shown to increase after ovariectomy without 
hyperphagia (27). Species differences and the inconsistent results demonstrated from various 
studies suggest that mechanisms other than increased caloric intake are involved in the loss of 
ovarian function-associated obesity. 
Ovariectomy, aromatase knockout, or estrogen receptor-α (ERα) knockout mice were 
shown to have decreased physical activity and energy expenditure (28-30), although these 
findings are not always consistent (31). In humans, a longitudinal study demonstrated that post-
menopausal women had an 11% increase in visceral adiposity, a 50% decrease in physical 
activity and free-living energy expenditure, and a 32% decrease in fat oxidation compared to 
themselves in the pre-menopausal stage (32). Increasing the level of physical activity improves 
fitness of the post-menopausal women (33), prevents bone loss (34), and is associated with a 
lower mortality rate (35).  
Estrogen receptors (ERs) exist and are expressed within the brain, which is thought to be 
the mechanism of food intake mediation through estrogen. A few decades ago, Wade and Zucker 
(36) reported a 36% decrease in food intake after inserting an estradiol implant into the 
ventromedial hypothalamus of OVX rats, demonstrating a direct stimulation of estradiol on 
feeding behavior through the hypothalamus. Because the hypothalamus is the primary region of 
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the brain that regulates energy balance, it has been the region of the brain that many researchers 
have focused on when trying to elucidate the molecular mechanisms of this phenomenon. 
However, the actions of ERs in the hindbrain (centered just caudal to the area postrema) seem to 
be involved in the modulation of estradiol on food intake as well (37). Estrogen also has been 
found to interact with hormones that are important in the satiety response, such as 
cholecystokinin (CCK) and leptin (38, 39). The impact of estrogen on host metabolism is quite 
significant and complex (discussed below), yet not well understood.  
Symptoms of menopause and medications in humans 
Common symptoms during menopausal transition include menstrual irregularity, hot 
flashes, night sweats, and sleep disruption, with these symptoms sometimes leading to anxiety 
(40, 41). These bothersome symptoms usually decrease after menopause. For post-menopausal 
women, vaginal dryness, vaginal and urogenital atrophy, and dyspareunia are some of the 
common symptoms (41, 42). Many post-menopausal women report memory loss, cognitive 
decline, and depression during this transition (42, 43). Increased bone loss or osteoporosis, risks 
of metabolic syndrome, and cardiovascular diseases also are conditions and diseases associated 
with menopause (44). The exact mechanisms by which these symptoms develop are not clear, yet 
estrogen therapy is considered the most effective way to counteract vasomotor-related 
menopausal symptoms. Unfortunately, chronic use of estrogen supplementation increases the 
risk of breast cancer, acute liver disease, and acute cardiovascular disease, especially in those 
with a history of these diseases (45, 46). Some studies also have suggested an adverse impact of 
estrogen therapy in post-menopausal women (47).  
An overloading of serotonin-receptor sites in the hypothalamus has been linked to the 
increased body temperatures in post-menopausal women. Although not as effective as estrogen 
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therapy, non-hormonal medications such as selective serotonin reuptake inhibitors (SSRIs) have 
been shown to alleviate vasomotor symptoms associated with menopause as well (48, 49). The 
specific mechanisms of how SSRIs alleviate these symptoms remain unclear (48). However, 
concerns of bone loss with use of SSRIs have been raised due to the discovery of serotonin 
receptors and transporters in osteoblasts, osteocytes, and osteoclasts (50). Selective ER 
modulator (SERM) is another non-hormonal medication that may help with the dyspareunia 
associated with menopausal vulvovaginal atrophy (51). However, common side effects of 
SERM, such as urinary tract infection, vulvar and vaginal mycotic infections, and headache, also 
are bothersome.  
Alternative and complementary medicine therapies for menopausal symptoms 
A significant number of post-menopausal women seek alternative remedies due to the 
fear of the potential serious adverse effects of chronic use of hormonal or non-hormonal 
medications (52, 53). According to Borrelli and Ernst (54), some of the main alternative and 
complementary medicine (CAM) therapies used to alleviate menopausal symptoms include 
supplementation with phytoestrogens, calcium, dehydroepiandrosterone (DHEA), herbal 
remedies, plant sterols, probiotics and prebiotics, physical exercise, meditation, and acupuncture. 
Phytoestrogens are plant-derived compounds that have a structure similar to the estrogens 
synthesized from the mammalian endocrine system. Due to their structural similarity, 
phytoestrogens are recognized as endocrine disruptors that can bind to ER (both ERα and ERβ) 
and act as estrogen agonists or antagonists (55). Unlike artificial endocrine disrupting 
compounds (EDCs) such as pesticides (e.g., DDT) and plasticizers (e.g., bisphenol A), 
phytoestrogens are generally viewed as natural compounds that exert health benefits and have 
anti-cancer, anti-atherosclerotic, and anti-osteoporotic properties (55, 56). Three major classes of 
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phytoestrogens include isoflavones, lignans, and coumestans. Isoflavones are present in high 
concentration in soybeans, soy products, and red clover. Lignans are present in wheat bran, 
flaxseeds, rhubarb, and kiwi, and coumestans are present in split peas, lima beans, and alfalfa 
(57).  
Absorption and metabolism of isoflavones 
Isoflavones usually exist in food as biologically inactive forms, such as genistin and 
daidzin, that are present in soy as β-D-glycosides (Figure 2.1). These glycosides can be 
hydrolyzed and deconjugated by β-glycosidases synthesized by the intestinal microbiota. 
Genistein and daidzein, the two major biologically active aglycone forms of isoflavones, are the 
products of these reactions. These aglycone forms of isoflavones then can be absorbed and 
further metabolized. Once absorbed, daidzein can be metabolized to equol and O-
demethyangolensin. It has been shown that S-(-)equol, the natural diastereoisomer of equol, 
which can be produced by equol-producing bacteria in the intestine of humans and rodents, has 
stronger binding affinity to ERβ than daidzein (58). Due to the high estrogenic potency of equol, 
it has been hypothesized that the ability of producing equol may be critical for obtaining the 
health benefits from a soy-rich diet (59). Certain Lactobacillus spp., such as L. mucosae (60) and 
L. Niu-O16 (61) are known equol-producing bacteria that can convert daidzein into equol in 
vitro. Other known equol-producing bacteria include Enterococcus faecium (62) and 
Adlercreutzia equolifaciens gen. nov., sp. nov. (63).  
Nevertheless, only 30-50% of humans are capable of converting daidzein to equol, 
whereas all rodents are equol producers (64, 65). Data obtained utilizing rodent models, 
therefore, should be interpreted with caution. It is important to point out that it is unclear whether 
the beneficial effects observed from isoflavone supplementation are associated with an 
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individual’s ability to convert isoflavones to equol, partly due to the complex metabolism of 
isoflavones. 
Fermented soy products, such as miso, natto, or tempeh, often contain higher 
concentrations of isoflavones in aglycone forms that can be absorbed more rapidly and in greater 
amounts than those in glucoside forms (67, 68). Whether consuming these fermented soy foods 
could lead to higher amounts of equol production in vivo is not fully known (69, 70).  
Commonly used animal models to study human menopause  
Animal models are essential for understanding the etiology and improving the 
management of diseases associated with menopause. Such models may be used to elucidate the 
specific causes of menopause and test the efficacy of potential treatments. Models such as non-
human primates, sheep, dogs, swine, and rodents all have been used to study menopause-related 
 
Figure 2.1. The molecular structures of biologically inactive and active forms of 
isoflavones; modified from Cederroth and Nef (66) 
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diseases, each having their own advantages and disadvantages (Table 2.2; adapted and modified 
from (71)).   
From the comparison above, it is clear that rodents are practical and cost-effective animal 
models to study diseases associated with menopause, even though disadvantages of these pre-
clinical models can affect the translation of the data obtained. Various rodent models have been 
established to mimic and study human menopause. In addition to performing ovariectomy, 
aromatase knockout mice, mice with natural mutations in the aromatase gene, and ER knockout 
mice are common models. Some of these commonly used models will be discussed further 
below.   
Table 2.2. Characteristics of animal models used for studying menopause-associated 
diseases 
Animal 
Non-human 
primates 
Sheep Dogs Swine Rodents 
Cost High Medium Medium-High Medium Low 
Handling/Trained 
technician 
Aggressive/Yes Docile/No No Aggressive/Yes 
Some training 
required 
Societal concerns High Low High Low Low 
Estrus cycle Polyestrous 
Seasonal-
polyestrus 
Diestrus 
Polyestrous 
(18-21d) 
Polyestrus  
(4-5d) 
Physiology Monogastric Ruminant Monogastric Monogastric Monogastric 
Advantages 
Highly 
resemble the 
human system 
Hormonal 
profile similar 
to humans 
Less expensive 
than primates, 
easier to work 
with 
Omnivore-
similar to 
humans 
Inexpensive, 
easy to house, 
shorter life 
span, many 
genetically 
specific strains 
available 
Disadvantages 
High cost, high 
maintenance 
Do not 
experience 
natural 
menopause at 
midlife; GI 
physiology is 
different from 
humans 
Physiological 
changes due to 
loss of ovarian 
function are 
not as 
profound as 
for humans; 
dogs are loud 
Pigs are loud, 
and the housing 
and handling 
can be difficult 
Do not 
experience 
natural 
menopause at 
midlife 
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Ovariectomy:  
Ovariectomy in rodents leads to rapid weight gain, increased adipose tissue accumulation 
and adipocyte size, decreased spontaneous physical activity and energy expenditure, and 
metabolic dysfunction, including decreased insulin sensitivity and glucose tolerance, and 
increased circulating fasting glucose concentrations (15, 72). A 20% increase in body weight was 
observed in OVX mice compared to sham (SHM)-operated counterparts 12 wk after the surgery 
(15). Spontaneous physical activity of OVX mice has been found to be 40% lower during the 
dark cycle than SHM mice, but did not differ during the light cycle (15, 73). A 4-5 fold increase 
in gonadal and subcutaneous fat pad weights and adipocyte volume were observed in OVX mice 
compared to SHM mice fed regular mouse chow that contained ~12% kcal from fat (15). Local 
inflammation in adipose tissues also has been observed in this model using gene expression 
analysis (15).  
Estrogen receptor knockout models:  
ERα and ERβ are the two subtypes of nuclear ERs known to mediate estrogenic actions. 
Both ERα and ERβ are known to be expressed in most of the tissues in humans; interestingly, 
prostate is an ERα-negative tissue that only expresses ERβ (74). Both ERα knockout (αERKO) 
and double ERα and ERβ knockout (αβERKO) mice are infertile and have a markedly higher 
accumulation of white adipose tissue, with increased size and number of adipocytes (75, 76). At 
2 mo of age, αERKO and αβERKO mice are 2.5 fold heavier than wild-type controls (77). Six-
mo-old αERKO mice have approximately 20% larger adipocytes in gonadal and perirenal 
adipose tissues than wild-type counterparts (75).  These knockout mice also display insulin 
resistance, impaired glucose tolerance, and a 2-fold increase in serum leptin concentrations (76, 
77). Body weight and adiposity of ERβ knockout (βERKO) mice, in contrast, remain similar to 
 17 
wild-type controls (77). Male βERKO mice are fertile, while females display infrequent 
pregnancy and reduced litter size. The ER KO mouse is an extraordinary model when it comes to 
elucidating the functional differences of these two subtypes of nuclear ER. However, it is now 
known that a membrane-bound ER may also be an important mediator of estrogen in 
cardiovascular health. The impact of these membrane-bound ER on the αERKO or βERKO mice 
in regards to estrogen metabolism and host health is unclear (78).  
 Aromatase insufficiency:  
Aromatase, a cytochrome P450 enzyme, is responsible for estrogen biosynthesis. It does 
this by converting androgens to estrogens. Aromatase is widely expressed in the body, including 
bone, breast, skin, brain, adipose, and muscle tissues (79, 80). Therefore, aromatase insufficiency 
has an impact on various organs and systems. Natural mutation-induced aromatase insufficiency 
in humans, for instance, leads to ambiguous genitalia, amenorrhea, failure of secondary sex 
characteristic development, and cystic ovaries (81, 82). Serum estrogen concentrations of female 
aromatase knockout (ArKO) mice are almost undetectable, and the basal concentrations of FSH 
and luteinizing hormone (LH) are greater than in the wild-type counterparts (83, 84). ArKO mice 
are infertile, and the weight of their ovaries decreases with age. Further, ArKO mice present 
characteristics of metabolic dysfunction, including elevated visceral adiposity, insulin resistance, 
dyslipidemia, and hepatic steatosis (85, 86). 
  
 18 
Estrogen 
Estrogen metabolism 
As mentioned above, estrogens are synthesized by the aromatase enzyme located in the 
endoplasmic reticulum of estrogen-producing cells (87). Aromatase converts testosterone into 
17β-estradiol (E2), the most potent estrogen in humans, followed by estrone (E1) and estriol (E3) 
(Figure 2.2). E2 is the predominant form of estrogen secreted by ovaries in pre-menopausal 
women (88). During pregnancy, E3 becomes the predominant form secreted from ovaries, 
whereas ovaries secret E1 at post-menopausal stage.  
Aromatase expression is regulated by many factors, including cAMP, cytokines, PGE2, 
and glucocorticoids (79). In women of reproductive age, estrogen production mainly occurs in 
the ovaries, resulting in high concentrations of circulating estrogen. Once menopause manifests, 
ovarian production of estrogen falls, leading to a significant decrease in circulating estrogen. 
After menopause, adipose tissue is thought to become the primary site of estrogen synthesis (79, 
87, 89, 90). This action of peripheral estrogen synthesis is enhanced by an increase in mRNA 
expression and activity of aromatase, which is efficient in converting androstenedione to estrone 
(89, 91). The increased conversion from androstenedione to estrone has been shown to be 
positively correlated with body weight in pre- and post-menopausal women, and was 
dramatically increased in obese post-menopausal women (89, 92). Aromatase activity in adipose 
tissue has also been shown to increase with aging (93-96).  
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Enterohepatic circulation of estrogen: relationship with intestinal microbiota 
A large amount of estrogen-derived metabolites (~50%) are excreted in the bile, mostly 
in conjugated forms. Only a small fraction of these metabolites appear in the feces, however, 
with the majority being hydrolyzed and reabsorbed in the intestine (97, 98). Administration of 
antibiotics leads to a 60-fold increase in the fecal excretion of conjugated estrogen in women, 
indicating that the gut microbiota play an important role in the recycling of estrogens (99, 100). 
The gut microbiota are involved in estrogen metabolism and recycling through an enterohepatic 
circulation pathway (101, 102). In the liver, E3 is conjugated and converted to estriol-16-
glucuronide (E3-16-G), a compound that can be rapidly excreted in the urine (Figure 2.3). 
 
Figure 2.2. Estrogen metabolism. 
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However, the majority of the E3-16-G is further converted into E3-3-sulfate-16-G and enters the 
intestinal tract. E3-3-sulfate-16-G then is hydrolyzed by the gut microbiota to E3-16-G, which 
can return back to the liver or be hydrolyzed further into free E3 by bacterial β-glucuronidase for 
reabsorption via the intestine. E3 can also be converted to E3-3-G, a compound that is incapable 
of being further conjugated and, therefore, can only be excreted in the urine (not recycled). Using 
an in vitro system, gut microbiota have been shown to be able to convert E1 into E2, as well as 
16-α-hydroxyestrone into E3 under aerobic culture conditions (103). The functions of these 
estrogen-derived metabolites are unclear, but it has been hypothesized that this enterohepatic 
recirculation is able to affect the half-life and systemic concentrations of estrogens (104, 105). 
Bacterial species Bacteroides, Peptostreptococcus, Fusobacterium, Propionibacterium, 
Clostridium, Eubacterium, and Bifidobacterium isolated from fresh human feces have been 
identified to exert activity of β-glucuronidase (106).  Escherichia coli (107) and Streptococcus 
agalactiae (108) have also been shown to have β-glucuronidase activity, but a comprehensive list 
does not exist. Fecal β-glucuronidase activity was shown to be encoded by two genes, gus and 
BG. Phylum Firmicutes has been shown to account for 96% of the amplified gus gene sequences 
and that Bacteroidetes and Firmicutes were both amplified by BG gene sequences (59% and 
41%, respectively) in human feces (109). 
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Impact of estrogen on host metabolism  
Through ER-mediated actions, estrogen is an important mediator of lipid metabolism, 
such as lipogenesis, lipolysis, and development in adipogenesis, and may indirectly regulate 
appetite, energy expenditure, or metabolism (110). Estrogen has been shown to inhibit 
adipogenesis through the regulation of PPARγ in white adipose tissue and increase fatty acid 
oxidation in both skeletal muscle and liver tissues (111-113). A recent study demonstrated that 
bilateral salpingo-oophorectomy (i.e., surgical removal of fallopian tubes and ovaries) in women 
resulted in a significant increase in total circulating triglycerides, total cholesterol, and low 
density lipoprotein cholesterol (114). Impaired glucose tolerance and insulin sensitivity observed 
in αERKO/αβERKO and ArKO mice indicate that estrogen is also important in glucose 
metabolism. Indeed, estrogen has been shown to increase glucose-stimulated insulin secretion in 
 
Figure 2.3. Enterohepatic circulation of estrogen. E1: estrone; E2: estradiol; E3: 
estriol; G: glucuronide. 
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isolated islets (115). ERα and ERβ are also known to modulate glucose uptake though glucose 
transporter 4 (GLUT4) in skeletal muscle (116). 
 
Gut barrier function, microbiota, and obesity/metabolic diseases 
Obesity, disrupted gut barrier function, and gut microbial community 
The GI tract is an important first line of defense against ingested noxious agents, 
preventing bacterial pathogens from entering the systemic circulation (117). Obesity has been 
strongly linked with disrupted gut barrier function and shifts in gut microbiota composition that 
leads to increased systemic inflammation and a dysfunctional host immune response (118) 
(Figure 2.4). Lipopolysaccharides (LPS), a gut microbial-derived endotoxin that promotes 
inflammation by activating toll-like receptor 4 pathways and affects host health (119), is elevated 
in obese individuals but remains at low concentrations in lean and healthy individuals (120). 
Lower expression of tight junction (TJ) membrane proteins, such as occludin (Ocln) and zonula 
occluden 1 (Zo-1), has been reported in ob/ob mice compared with wildtype controls (121). 
Furthermore, disrupted intestinal barrier function and altered Ocln protein distribution has been 
reported in obesity-prone rats compared with obesity-resistant rats, supporting the association 
between gut barrier disruption and obesity (122).  
Over the past decade, profound changes in the gut bacterial communities between lean 
and obese individuals have been revealed (123, 124). The ratio of the two predominant bacterial 
phyla, Bacteroidetes and Firmicutes, is altered in leptin-deficient ob/ob mice (125) and in obese 
human subjects (126, 127), although not all studies have observed a change in the 
Firmicutes:Bacteroidetes ratio with obesity (128-130). Given the complexity of the gut 
microbiota, analyses must move beyond the mere comparison of the Firmicutes:Bacteroidetes 
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ratio and to a level that may identify the taxa and/or genes involved and the potential 
implications on host health. For instance, we and others have shown that prebiotic 
supplementation improves GI histomorphology and barrier function of obese mice along with 
significant shifts in gut microbiota (131, 132). Cani and colleagues (132) further showed that 
systemic inflammation was ameliorated in obese mice fed prebiotics and that glucagon-like 
peptide-2 (GLP-2) signaling is involved. In our obese mice fed non-digestible fructan prebiotics, 
we observed a marked elevation in the relative abundance of Akkermansia, which was positively 
correlated with cecal crypt depth (131). Akkermansia muciniphila, a mucin-degrading gram-
negative anaerobe, is the only species that has been identified within the Akkermansia genus 
(133). Higher abundance of fecal Akkermansia has been found in healthy subjects than 
obese/diabetic patients or animal (134, 135) with a positive association being demonstrated 
between A. muciniphila and improvements in lipid metabolism, glucose tolerance, and metabolic 
disorders (135, 136). Moreover, direct oral gavage of A. muciniphila lowered fat-mass gain, 
metabolic endotoxemia, adipose tissue inflammation, and insulin resistance in diet-induced obese 
mice  (135), supporting the concept of host-microbial interactions. 
A gut microbial community with higher species richness (i.e., higher α-diversity) has 
been hypothesized to be a healthier ecosystem (137). Hadza hunter-gatherers, whose diets 
contain fresh and wild foods with high-fiber content, have higher microbial species richness 
when compared to individuals living in a westernized nation (138). In a diseased population, 
individuals with inflammatory bowel diseases (IBD) have lower bacterial species richness 
compared to their healthy twin counterparts, which further supports the hypothesis that higher 
species richness makes for a healthier gut ecosystem (139). Species richness of the gut bacteria 
has been shown to decrease in obese twins when compared to their lean counterparts (123).  
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Similarly, the richness of gut microbial genes is also lower in obese compared to non-obese 
individuals (140). While the altered species richness might be true in diseased populations or 
between populations that ingest distinct diets, our previous study demonstrated that prebiotic 
supplementation of a semi-purified high-fat diet decreased bacterial species richness in the cecal 
digesta of mice (131).  More in-depth studies are needed to elucidate the physiological changes 
associated with specific populations of gut microbiota.  
 
Microbiota-induced obesity 
Germ-free mice, mice that are free of any microorganisms, are protected against HFD-
induced obesity (141). Conventionally raised mice are known to have a 40% higher body fat 
mass than germ-free mice, independent of food intake (141). After colonization of gut 
microbiota, germ-free recipients have a significant increase in body fat, absorption of 
monosaccharides, de novo hepatic lipogenesis, and suppression of fasting-induced adipocyte 
factor (Fiaf in humans; Angptl4 in rodents), which leads to increased triglyceride deposition in 
the adipose tissues through elevated LPL activity (141). Fiaf is also known to upregulate PGC1 
expression in skeletal muscle independent of AMPK signaling, which promotes mitochondria 
fatty acid oxidation (142).  
Obesity has been induced by transferring gut microbes from obese mice to gnotobiotic 
mice without affecting food intake (125), suggesting that the gut microbiota affect the efficiency 
of energy harvest from indigestible components of the diet, alter energy utilization, and influence 
host energy balance and metabolism. Short-chain fatty acids (SCFA), such as butyrate, 
propionate, and acetate, are the end-products of gut microbial fermentation of indigestible 
substances. SCFA, especially butyrate, is the main energy source of colonocytes, supplying 
 25 
approximately 60% of the energy needs of these cells in culture (143). The production of SCFA 
is thought to be the mechanism of energy harvest from gut microbiota in the colon via otherwise 
non-digestible substances. However, a recent study has shown that fecal transplantation from 
mice administrated risperidone, an antipsychotic drug known to cause weight gain, led to weight 
gain and decreased energy expenditure in recipient mice (144), suggesting that gut microbiota 
can regulate energy metabolism in ways other than altering energy harvest. 
Not many microbiota-induced obesity studies have been conducted in humans for ethical 
reasons. A previous study whereby transplanted intestinal microbiota from lean donors to 
individuals with metabolic syndrome was performed resulted in greater butyrate-producing 
bacteria (Roseburia intestinalis and Eubacterium hallii) and insulin sensitivity 6 wk after the 
transplantation (145). In another study, a patient with recurrent Clostridium difficile infection 
underwent a fecal microbial transplantation (FMT) using stool from her teenage daughter, who 
was in the transition of gaining weight at the time of FMT (146). After FMT, the mother 
(recipient) experienced unintentional rapid and uncontrollable weight gain with a medically-
supervised liquid protein diet and exercise program. Although it is a single case report, it has 
undoubtedly strengthened the concept of microbial-induced obesity and highlighted the need for 
caution when using such therapies.  
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Summary 
Loss of ovarian estrogen production, or menopause, is associated with increased visceral 
adiposity, inflammation, and metabolic dysfunction although the mechanisms remain unclear. 
Obesity has been strongly linked with profound shifts in the gut microbial community, disrupted 
gut barrier function, and inflammation, but little is known regarding the involvement of the GI 
tract in menopause-associated obesity. Because women now spend more than one-third of their 
lives after menopause due to an increased life expectancy, elucidating the etiology of 
menopause-associated obesity is important for the prevention and treatment of obesity and 
related chronic diseases. The gut microbiota play an important role in estrogen metabolism, 
specifically in the enterohepatic circulation that can potentially affect systemic levels of 
estrogen, and may contribute to the physiological responses observed with menopause. 
Therefore, investigation to elucidate the involvement of the gut microbiota in menopause-
associated obesity is justified. 
 
Figure 2.4. Changes in gut microbiota and host physiology associated with obesity. CHO: 
carbohydrates; SCFA: short-chain fatty acids; Fiaf: fasting-induced adipocyte factor; LPL: 
lipoprotein lipase. Adapted from Caricilli and Saad (147). 
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CHAPTER 3: SOY IMPROVES INSULIN SENSITIVITY, ADIPOSITY, 
AND INFLAMMATION AND ALTERS CECAL MICROBIOTA OF 
OVARIECTOMIZED RATS BRED FOR LOW AEROBIC CAPACITY 
ABSTRACT 
Soy is known to ameliorate menopause-associated obesity and metabolic dysfunction for 
reasons that are unclear. The gut microbial composition, such as greater Firmicutes:Bacteroidetes 
ratio, has been linked with the development of obesity and metabolic dysfunction. We aimed to 
determine the impact of soy on metabolic health, adipose tissue inflammation, and the cecal 
microbiota in ovariectomized (OVX) rats bred for low-running capacity (LCR), a model that has 
been previously shown to mimic human menopause. Forty 27-wk old LCR rats were either OVX 
or sham-operated (SHM) and fed either soy-rich (soy) or soy-free (control) diets for 28 wk in a 
2x2 factorial design (n=10): 1) OVX/soy; 2) SHM/soy; 3) OVX/control; 4) SHM/control. Body 
weight, food intake, adiposity, insulin sensitivity, circulating glucose and lipid profiles, liver 
triglycerides, energy expenditure, and adipose tissue hypertrophy and inflammation were 
examined. DNA from cecal digesta were extracted, followed by 16S rRNA amplicon Illumina 
MiSeq sequencing and analysis using QIIME 1.9.1. Soy consumption reduced (p<0.05) body 
weight gain, adiposity, and circulating cholesterol concentrations and improved (p<0.05) insulin 
sensitivity of LCR rats. Principal coordinates analysis (PCoA) of weighted and unweighted 
UniFrac distances of cecal microbiota revealed a sharp separation (p<0.05) between soy- and 
control-fed groups. The soy-fed group had lower (p<0.001) Firmicutes:Bacteroidetes ratio 
compared to control. In conclusion, soy ameliorates adiposity, insulin sensitivity, adipose tissue 
inflammation, and exerts a beneficial shift in gut microbial communities in a rat model that 
mimics human menopause. 
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INTRODUCTION 
Approximately 50% of post-menopausal women seek alternative remedies for 
menopausal-related symptoms due to the fear of potential serious adverse health effects that may 
come with chronic use of hormonal or non-hormonal medications (1, 2). Lower prevalence of 
common menopausal-related vasomotor symptoms, including hot flashes and night sweats, in 
Japanese and Chinese compared to Caucasian women has drawn attention to soy consumption 
(3). Soy and soy products are widely used as alternative and complementary medicine therapies 
to alleviate menopausal-related symptoms, and have been shown to reduce obesity and improve 
metabolic health in humans and rodents (4-6). Isoflavones are thought to be the active 
compounds in soy providing the beneficial effects due to their structural similarity to endogenous 
estrogens produced by mammals. These phytoestrogens can bind to estrogen receptors (ER)-
alpha and -beta and act as estrogen agonists or antagonists (7). Unlike artificial endocrine-
disrupting compounds such as pesticides (e.g., dichloro-diphenyl-trichloroethane; DDT) and 
plasticizers (e.g., bisphenol A; BPA), phytoestrogens are generally viewed as natural compounds 
that exert health benefits, having anti-cancer, anti-atherosclerotic, and anti-osteoporotic 
properties (7, 8). 
 Isoflavones usually exist in food as biologically inactive forms, such as genistin and 
daidzin, which are present in soy as β-D-glycosides. These glycosides can be hydrolyzed and 
deconjugated by β-glycosidases synthesized by the intestinal microbiota to form biologically 
active aglycone forms of isoflavones, such as genistein and daidzein. The aglycone isoflavone 
forms then can be absorbed and further metabolized into equol. S-(-)equol, the natural 
diastereoisomer of equol, is exclusively produced by equol-producing bacteria in the intestine of 
humans and rodents and has a higher estrogenic potency than other isoflavone forms. Although 
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still unclear, the ability of producing equol has been hypothesized to be crucial for obtaining the 
health benefits from a soy-rich diet (9), suggesting a critical role of intestinal microbes on 
isoflavone metabolism. 
 The mechanisms by which soy may ameliorate menopause-associated obesity and 
metabolic dysfunctions are unclear. The gut microbiota have been shown to mediate gut integrity 
and impact systemic inflammation associated with obesity. For instance, a lower 
Firmicutes:Bacteroidetes ratio of gut microbiota has been associated with lean phenotype (10). 
However, the association between the gut microbiota, soy consumption, and menopause- 
associated obesity has not been established. A previous study demonstrated that male Sprague-
Dawley rats fed a high-cholesterol diet with added soy-milk had a 2.3-fold increase in the 
relative abundance of Lactobacillus spp. compared to those fed the same high-cholesterol diet 
without soy supplementation (11). Certain Lactobacillus spp., such as L. mucosae (12) and L. 
Niu-O16 (13), are known equol producers that can convert daidzein into equol in vitro. 
Therefore, changes in the gut microbial communities may represent one potential mechanism for 
soy’s beneficial metabolic impacts on those with ovarian hormone insufficiency.  
Herein, we aimed to determine the impact of soy on insulin sensitivity, adiposity, adipose 
tissue inflammation, and the cecal microbiota of ovariectomized rats bred for low aerobic 
capacity, a model that has been previously shown by our research group to mimic human 
menopause (14). We hypothesized that soy consumption would improve whole body insulin 
sensitivity, hinder fat mass gain and adipose tissue inflammation, and beneficially impact the gut 
microbial community by increasing the relative abundance of known equol-producing bacteria 
such as Lactobacillus, Enterococcus, and Adlercreutzia, and decreasing the 
Firmicutes:Bacteroidetes ratio.  
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MATERIALS AND METHODS 
Animals, diet, and study design: All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Missouri, Columbia. The HCR/LCR rat 
model was established by Drs. Britton and Koch as previously described (15).  Briefly, these rats 
were selectively bred based on their endurance running capacity, which was determined by 
running time to exhaustion on a treadmill test. Forty 27-wk-old LCR female rats (generation 32) 
were either OVX or SHM and ad libitum fed either soy-rich (soy) or soy-free (control) diets for 
28 wk in a 2x2 factorial arrangement (n=10/group): 1) OVX/soy; 2) SHM/soy; 3) OVX/control; 
4) SHM/control. Rats were single-housed under controlled humidity and temperature with a 12-h 
light: 12-h dark cycle. Body weight (BW) and food intake were measured weekly. 
Intraperitoneal glucose tolerance test (IPGTT) was performed at 19 wk post-surgery. At 56 wk of 
age, rats were anesthetized with an intraperitoneal (IP) injection of pentobarbital sodium (50 
mg/kg) and euthanized via cardiac puncture. Individual fat depots, including perigonadal 
(PGAT), retroperitoneal (RPAT), omental, and subcutaneous (SQAT), then were dissected and 
weighed to determine regional fat distribution. Cecal digesta was collected and snap frozen in 
liquid nitrogen immediately and stored at -80°C until analysis. The study timeline is shown in 
Figure 3.1.  
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Diet formulation and analysis: Diets tested in the current study were purchased from Harlan 
Laboratories Inc. (Madison, MI), with the soy-rich diet formulated to provide an estimated 590 
mg/kg diet of isoflavones [genistein and daidzein (aglycone equivalents)]. Both diets were 
formulated to meet the nutrient requirements of adult rats. Ingredient and chemical composition 
of the experimental diets are reported in Table 3.1. Diet samples were analyzed for dry matter 
and organic matter according to AOAC (16). Crude protein was determined using a Leco 
Nitrogen/Protein Determinator (model FP-2000, Leco Corporation, St. Joseph, MI) (16). Fat 
concentrations were measured by acid hydrolysis (17) followed by ether extraction (18). Gross 
energy was measured using a bomb calorimeter (Model 1261, Parr Instruments, Moline, IL). 
Total dietary fiber concentrations were determined using methods described by Prosky et al. 
(19).  
 
Ovariectomy surgeries: Surgical procedures were followed as previously described (20). Briefly, 
rats were anesthetized using isoflurane during surgery. A one-inch incision was made at the 
midline of the dorsal surface, followed by two bilateral cuts through the muscle layer to expose 
the ovaries. The whole ovary, including the ovarian bursa and part of the oviduct, were removed. 
Sham operation was completed by externalizing the ovaries and replacing them before closing 
 
Figure 3.1. Study timeline. 
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the incision. The incision was closed using wound clips. Rats were administered acetaminophen 
(NSAID, 500 mg/kg) after the surgery for pain relief. OVX surgery effectiveness was 
determined at the conclusion of the study via verification of significant uterine atrophy. 
 
Intraperitoneal glucose tolerance test (IPGTT): IPGTT was performed at 46 wk of age. 
Following an overnight fast, a baseline blood sample was taken from the tail vein at time 0. Then 
an intraperitoneal injection of 50% dextrose (2 g/kg BW) was administered and blood samples 
were collected at 15, 30, 45, 60, and 120 min post-injection for glucose concentration 
measurements using a handheld glucometer (AlphaTRAK, Abbott Animal Health; Chicago, IL) 
and insulin concentrations using rat insulin ELISA kits per the manufacturer’s instructions 
(Alpco Diagnostics, Salem, NH). Glucose and insulin area under the curve (AUC) calculations 
were performed using GraphPad Prism software (GraphPad Software, La Jolla, CA). The 
Matsuda index also was calculated using the following equation: 
𝑀𝑎𝑡𝑠𝑢𝑑𝑎 𝑖𝑛𝑑𝑒𝑥 =
10000
√(𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 × 𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑖𝑛𝑠𝑢𝑙𝑖𝑛)(𝑚𝑒𝑎𝑛 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑂𝐺𝑇𝑇 × 𝑚𝑒𝑎𝑛 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 𝑂𝐺𝑇𝑇)
 
 
Intrahepatic lipid concentrations: Liver triglyceride concentrations were determined as 
described previously (21). Briefly, liver samples were homogenized in 1 mL of lipid extraction 
solvent composed of 1:2 vol/vol methanol-chloroform and then gently agitated overnight at 4°C. 
An equal part of 4 mM MgCl was added, vortexed, and centrifuged for 1 h at 1,000 x g at 4°C. 
The organic phase was evaporated and reconstituted in 3:2 vol/vol butanol-Triton X-114 mix 
(Sigma, St. Louis, MO). Liver triglyceride concentrations then were determined using a 
commercially available kit (Wako L-Type TG M; Wako Pure Chemical Industries, Ltd., Osaka, 
Japan) using a spectrophotometer.  
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Blood metabolites: Fasting serum glucose, triglyceride, total cholesterol, low-density lipoprotein 
cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and non-esterified fatty acid 
(NEFA) concentrations were performed by a commercial laboratory (Comparative Clinical 
Pathology Services, Columbia, MO) using an Olympus AU680 automated chemistry analyzer 
(Beckman-Coulter, Brea, CA). 
 
Energy expenditure, spontaneous physical activity, and respiratory quotient: At 56 wk of age, 
animals were placed in metabolic chambers (PromethION; Sable Systems International, Las 
Vegas, NV) to assess total energy expenditure (TEE), resting energy expenditure (REE), and 
respiratory quotient (RQ) via indirect calorimetry, and spontaneous physical activity (SPA) by 
the summation of x-, y-, and z-axis beam breaks. Body weight and food intake were measured 
before and after each 48-h assessment. Each 48-h run captured at least two light and two dark 
cycles.  
 
RNA extraction and RT-PCR: Perigonadal and brown (BAT) adipose tissues and liver samples 
were homogenized in TRIzol solution using a tissue bead homogenizer (TissueLyzer; Qiagen, 
Valencia, CA). Total RNA was extracted using RNeasy lipid tissue kit (Qiagen, Valencia, CA) 
and assessed for quality and quantity using a ND-1000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE). cDNA was reverse transcribed from total mRNA using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). All the 
mRNA data presented were derived using the CT approach, comparing gene expression 
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relative to the housekeeping gene (18S); data are expressed as fold difference relative to 
SHM/control. 
 
Cecal digesta DNA extraction, amplification, and sequencing: Total DNA from cecal digesta 
samples was extracted using Mo-Bio PowerSoil kits (MO BIO Laboratories, Inc., Carlsbad, CA). 
Concentration of extracted DNA was quantified using a Qubit® 3.0 Fluorometer (Life 
Technologies, Grand Island, NY). 16S rRNA gene amplicons were generated using a Fluidigm 
Access Array (Fluidigm Corporation, South San Francisco, CA) in combination with Roche 
High Fidelity Fast Start Kit (Roche, Indianapolis, IN). The primers 515F (5′-
GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′) that 
target a 252 bp-fragment of the V4 region were used for amplification (primers synthesized by 
IDT Corp., Coralville, IA) (22). CS1 forward tag and CS2 reverse tag were added according to 
the Fluidigm protocol. Quality of the amplicons was assessed using a Fragment Analyzer 
(Advanced Analytics, Ames, IA) to confirm amplicon regions and sizes. A DNA pool was 
generated by combining equimolar amounts of the amplicons from each sample. The pooled 
samples were then size selected on a 2% agarose E-gel (Life technologies, Grand Island, NY) 
and extracted using a Qiagen gel purification kit (Qiagen, Valencia, CA). Cleaned size-selected 
pooled products were run on an Agilent Bioanalyzer to confirm appropriate profile and average 
size. Illumina sequencing was performed on a MiSeq using v3 reagents (Illumina Inc., San 
Diego, CA) at the W. M. Keck Center for Biotechnology at the University of Illinois.  
 
Bioinformatics for cecal microbial analysis: Forward reads were trimmed using the FASTX-
Toolkit (version 0.0.13), and QIIME 1.9.1 (23) was used to process the resulting sequence data. 
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Briefly, high-quality (quality value ≥ 20) sequence data derived from the sequencing process 
were demultiplexed. Sequences then were clustered into operational taxonomic units (OTU) 
using UCLUST (24) through a closed-reference OTU picking strategy against the Greengenes 
13_8 reference database (25) with a 97% similarity threshold. Singletons (OTUs that were 
observed fewer than two times) and OTUs that had less than 0.01% of the total observation were 
discarded. A total of 1,365,605 16S rRNA-based amplicon sequences were obtained, with an 
average of 35,936 reads (range = 14,345-53,825) per sample. An even sampling depth 
(sequences per sample) of 14,345 sequences per sample was used for assessing alpha- and beta-
diversity measures. Beta-diversity was calculated using weighted and unweighted UniFrac (26) 
distance measures.  Correlations between the relative microbial abundances and physiological 
profile were assessed using Spearman correlation coefficient using QIIME. Multivariate 
Association with Linear Models (MaAsLin) analysis then was performed using default 
parameters with animal ID being the random effect to assess specific taxa changes 
(https://huttenhower.sph.harvard.edu/maaslin). 
 
Statistical analysis: All data were analyzed using the Mixed Models procedure of SAS 9.3 (SAS 
Institute, Cary, NC) with diet and surgery being fixed effects and animal ID being a random 
effect. When a main effect was significant, post hoc pairwise comparisons were performed using 
Tukey’s multiple comparison tests. Data are reported as least-squares means ± SEM with 
statistical significance set as p<0.05 and p<0.10 considered as trends. 
 
RESULTS 
Diet analysis 
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Diets utilized in the current study were isocaloric and comparable in protein, fat, 
digestible carbohydrate (i.e., nitrogen free extract), and total dietary fiber concentrations (Table 
3.1). Phytoestrogen was not detected in the control, soy-free diet, whereas soy-rich diet 
contained 585 mg/kg diet of total phytoestrogen.   
 
Soy consumption lowered weight gain and adiposity without affecting food intake 
The initial mean BW of rats was not different among treatment groups (data not shown), 
but OVX rats had a greater (p<0.05) final BW when compared to SHM rats (Table 3.2). 
Throughout the study, OVX rats gained more (p<0.05) weight than SHM rats; however, soy-fed 
rats gained less (p<0.05) weight than controls (Figure 3.2A). Similarly, OVX rats gained more 
(p<0.05) fat mass than SHM rats, but soy-fed rats gained less (p<0.05) fat mass than controls, 
whereas lean mass was not different among treatment groups (Figure 3.2B). Daily average food 
intake did not differ among treatment groups prior to sacrifice (Figure 3.2C). Total white 
adipose tissue weight (sum of PGAT, RPAT, omental, and SQAT fat pads) was higher (p<0.05) 
in the OVX than SHM groups, but soy-fed rats had lower (p<0.05) total white adipose tissue 
weight compared to controls (Figure 3.2D). Brown adipose tissue weight was lower (p<0.05) in 
rats fed soy than those fed the control diet (Figure 3.2D). White adipose tissue distribution was 
observed by dissecting and weighing each fat pad. Similar to the total white adipose tissue 
weight, the weights of PGAT, RPAT, and SQAT were greater (p<0.05) in the OVX rats than 
SHM, but soy-fed rats had smaller (p<0.05) fat pads than those fed the control diet (Figure 
3.2E). Omental fat pad weight was not affect by surgery, but was smaller (p<0.05) with soy 
consumption (Figure 3.2E). Adipocyte hypertrophy was observed in OVX rats than SHM rats, 
but was not affected by diet (Figure 3.2F and G).  
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Table 3.1. Ingredient and analyzed chemical composition of the diets 
  Control Soy 
Ingredient g/kg diet (as-fed basis) 
Corn gluten meal (60% protein) 188 0 
Soybean meal (48% protein) 0 260 
Corn 388 358 
Wheat, soft 231 230 
Wheat middlings 73.0 46.0 
DL-methionine, feed grade (99%) 1.0 1.0 
L-lysine HCl, feed grade (78%) 8.0 1.0 
Soybean oil 16.0 20.0 
Cellulose, Solka floc 58.9 50.6 
Mineral mix
1
 5.0 5.0 
Calcium phosphate 10.0 8.0 
Calcium carbonate 13.0 13.0 
Sodium chloride, iodized 2.5 2.5 
Magnesium oxide, feed grade (58%) 0.5 0.5 
Vitamin mix
2
 4.0 4.0 
Choline chloride, feed grade (60%) 1.6 0.4 
Analyzed chemical composition 
 Dry matter (DM, %) 85.2 90.7 
 --DM basis-- 
Organic matter (%) 95.6 94.2 
Ash (%) 4.4 5.8 
Crude protein (%) 22.2 20.8 
Acid hydrolyzed fat (%) 6.6 6.0 
Nitrogen Free Extract (%) 47.6 47.3 
Total dietary fiber (%) 19.2 20.1 
Insoluble dietary fiber (%) 16.8 19.3 
Soluble dietary fiber (%) 2.5 0.8 
Gross energy (kcal/g DM) 4.7 4.5 
Calculated metabolizable energy  
(Atwater factor, kcal/g DM) 
3.4 3.3 
Calculated metabolizable energy  
(modified Atwater factor, kcal/g DM) 
3.0 2.9 
Total phytoestrogen (mg/kg) 0 585 
Daidzin/daidzein (mg/kg) 0 290 
Genistin/genistein (mg/kg) 0 190 
Glycitin/glycitein (mg/kg) 0 105 
 
1
Mineral mix in the control diet consists of: calcium (9.7 g/kg);  phosphorus (total, 6.4 
g/kg; available, 3.9 g/kg); potassium (3.5 g/kg); sodium (1.3 g/kg); chloride (4.1 g/kg),  
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Table 3.1 (cont.) 
magnesium (1.6 g/kg); copper (16.4 mg/kg); iron (134.1 mg/kg); manganese (64.6 
mg/kg); zinc (54.8 mg/kg); selenium (0.2 mg/kg); iodine  (6.3 mg/kg). Mineral mix in the 
soy diet consists of: calcium (9.7 g/kg);  phosphorus (total, 6.3 g/kg; available, 3.8 g/kg); 
potassium (7.8 g/kg); sodium (1.3 g/kg); chloride (2.3 g/kg); magnesium (2.0 g/kg); 
copper (16.4 mg/kg); iron (90.4 mg/kg); manganese (75.5 mg/kg); zinc (60.1 mg/kg); 
selenium (0.1 mg/kg); iodine (6.3 mg/kg).  
2
Vitamin mix in the control diet consists of: vitamin A (12064 IU/kg); vitamin D (1200 IU/kg); 
vitamin E (87.1 IU/kg); vitamin K (40.1 mg/kg); thiamin (12.6 mg/kg); riboflavin (11.5 mg/kg); niacin 
(59.2 mg/kg); pantothenate (25.4 mg/kg); folic acid (2.9 mg/kg); biotin (0.3 mg/kg); choline (1367.3 
mg/kg); vitamin B6 (15.1 mg/kg); vitamin B12 (0.1 mg/kg); inositol (658.5 mg/kg). Vitamin mix in the 
soy diet consist of: vitamin A (12064 IU/kg); vitamin D (1200 IU/kg); vitamin E (80.9 IU/kg); vitamin K 
(40.1 mg/kg); thiamin (12.4 mg/kg); riboflavin (11.8 mg/kg); niacin (51.4 mg/kg); pantothenate (28.3 
mg/kg); folic acid (3.0 mg/kg); biotin (0.3 mg/kg); choline (1365 mg/kg); vitamin B6 (14.8 mg/kg); 
vitamin B12 (0.1 mg/kg); inositol (642 mg/kg).  
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Table 3.2 Body weight and fasting blood parameters of ovariectomized vs. sham-operated 
rats bred for low aerobic capacity fed either a soy-rich or soy-free diet
1
 
 
Control2 Soy  p values 
 
SHM OVX SHM OVX  Diet Surgery 
Diet* 
Surgery 
Final body weight (g) 313 ± 11.7 366 ± 13.1 288 ± 11.7 347 ± 11.7  0.07 <0.01 0.77 
Fasting insulin (μU/mL) 35.2 ± 11.5 61.9 ± 12.2 28.1 ± 10.9 54.8 ± 10.9  0.68 0.01 0.27 
Fasting glucose (mg/dL) 190 ± 18.3 217 ± 20.5 175 ± 18.3 182 ± 18.3  0.20 0.37 0.59 
Fasting triglycerides 
(mg/dL) 
126 ± 15.0 111 ± 16.7 90.2 ± 15.0 123 ± 15.0  0.43 0.58 0.13 
Fasting cholesterol (mg/dL) 123 ± 6.68 119 ± 7.47 95.0 ± 6.68 111 ± 6.68  0.02 0.39 0.14 
Fasting HDL-c (mg/dL) 40.5 ± 1.95 36.5 ± 2.17 34.3 ± 1.95 37.2 ± 1.95  0.18 0.79 0.09 
Fasting LDL-c (mg/dL) 5.60 ± 0.80 7.13 ± 0.90 4.30 ± 0.80 6.80 ± 0.80  0.10 <0.01 0.50 
Fasting NEFA (mmol/L) 0.69 ± 0.07 0.53 ± 0.08 0.56 ± 0.07 0.55 ± 0.07  0.46 0.23 0.31 
1
Values are means ± SEM, n = 8-10/group. Means in a row without a common superscript letter differ, p<0.05.  
2
 Control: soy-free diet; Soy: soy-rich diet; SHM: sham-operated; OVX: ovariectomized. 
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Figure 3.2. Body weight gain (A), fat and lean mass (B), food intake (C), white and brown 
adipose tissue mass (D), white adipose tissue depot mass (E), perigonadal adipose tissue 
(PGAT) mean adipocyte size (F), and representative H&E stains of PGAT (G) of 
ovariectomized (OVX) vs. sham-operated (SHM) rats bred for low aerobic capacity fed 
either a soy-rich (Soy) or soy-free diet (Control). Data are least-squares means ± SEM, n=4-
10. 
+
 denotes main surgery effect (OVX vs. SHM); 
*
 denotes main diet effect (Control vs. Soy), 
p<0.05. 
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Liver triglyceride concentrations and fasting blood parameters  
In the current study, OVX rats had elevated (p<0.05) liver triglyceride concentrations 
compared to that of SHM rats; however, soy consumption did not affect liver triglyceride 
concentrations compared to controls (Figure 3.3A). Fasting blood parameters measured are 
shown in Table 3.2. Ovariectomy led to greater (p<0.05) fasting insulin concentrations 
compared to SHM rats. Fasting glucose and triglyceride concentrations were not affected by diet 
or surgery. Soy-fed rats had lower (p<0.05) fasting cholesterol concentrations compared to 
controls. OVX rats had greater (p<0.05) fasting LDL-c concentrations than SHM rats, whereas 
HDL-c concentrations were not affected by diet or surgery interventions. Fasting serum NEFA 
did not differ among treatment groups.  
 
Soy-rich diet enhances whole body insulin sensitivity 
Glucose area under the curve (AUC) calculated based on the data obtained from IPGTT 
showed that OVX rats were less (p<0.05) glucose tolerant than SHM rats (Figure 3.3B). 
However, the Matsuda Index, which was calculated utilizing glucose and insulin concentrations 
obtained from IPGTT, indicated that even though OVX rats were more insulin resistant (p<0.05), 
the OVX/control group was the only treatment group that displayed whole body insulin 
resistance (i.e., Matsuda Index ≤ 2.5) (Figure 3.3C). According to the Matsuda Index, soy-fed 
rats had greater (p<0.05) insulin sensitivity compared to controls.  
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Figure 3.3 Concentrations of liver triglycerides (A), glucose area under the curve (AUC) 
(B), and Matsuda Index (C) calculated from intraperitoneal glucose tolerance test of 
ovariectomized (OVX) vs. sham-operated (SHM) rats bred for low aerobic capacity fed 
either a soy-rich (Soy) or soy-free diet (Control). Data are least-squares means ± SEM, 
n=4-10. 
+
 denotes main surgery effect (OVX vs. SHM); 
*
 denotes main diet effect (Control 
vs. Soy), p<0.05. 
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Ovariectomy leads to lower energy expenditure and spontaneous physical activity without 
affecting substrate utilization 
Total energy expenditure (TEE) was lower (p<0.05) in OVX rats compared to SHM rats 
(Figure 3.4A), and was attributed to the decrease in energy expenditure during the dark cycle 
(Figure 3.4B). Diet did not impact energy expenditure. Similarly, spontaneous physical activity 
(SPA) was lower (p<0.05) in OVX rats during the dark cycle compared to SHM rats, but was not 
affected by diet (Figure 3.4C). Respiratory quotient (RQ) did not differ among groups during 
light or dark cycles (Figure 3.4D), suggesting that substrate utilization was not affected by diet 
or surgery.  
 
Soy-rich diet and ovariectomy affect adipose mRNA expression 
Soy-fed rats had lower (p<0.05) mRNA expression of CD11c and IL-6 in PGAT and 
leptin in BAT compared to those fed the control diet (Figure 3.5). Ovariectomy led to greater 
(p<0.05) mRNA expression of TNF, IL-13, leptin, ER, and PGC1 in PGAT and UCP1 in 
BAT than SHM rats. OVX rats had lower (p<0.05) BAT mRNA expression of IL-13 and tended 
to have lower (p<0.10) mRNA expression of ER than SHM rats. Hepatic PGC1, CPT1, 
SREBP1, and eNOS mRNA expression did not differ among treatment groups (data not shown).  
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Figure 3.4 Total energy expenditure (TEE) (A), TEE during dark and light cycles 
(B), spontaneous physical activity (SPA) (C), and respiratory quotient (RQ) (D) of 
ovariectomized (OVX) vs. sham-operated (SHM) rats bred for low aerobic capacity 
fed either a soy-rich (Soy) or soy-free diet (Control). Data are least-squares means ± 
SEM, n=8-10. 
+
 denotes main surgery effect (OVX vs. SHM); 
*
 denotes main diet effect 
(Control vs. Soy), p<0.05. 
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Diet drastically impacts the composition of the cecal microbiota 
Principal coordinates analysis of unweighted (Figure 3.6A) and weighted (Figure 3.6B) 
UniFrac distances performed on the 97% OTU abundance matrix of cecal microbiota revealed a 
distinct separation (p=0.01) between rats fed control and soy diets. Beta diversity did not differ 
between OVX and SHM groups. Alpha diversity measures suggested that the soy diet led to 
lower (p<0.05) species richness than the control diet [observed OTUs at the 97% level: 430 ± 
44.1 compared with 471 ± 22.0 (soy diet compared with control diet, p<0.01); Chao 1 index: 476 
± 43.9 compared with 519.7 ± 18.9 (p<0.01); phylogenetic diversity whole tree matrix: 29.3 ± 
1.89 compared with 30.7 ± 1.23 (p<0.05)] (Figure 3.6C). Similar to beta-diversity, species 
richness did not differ between OVX and SHM groups.  
 
Microbial taxonomic shifts due to ovariectomy and soy-rich diet 
Greengenes classifier assigned usable raw reads to 11 phyla, 35 families, and 55 genera. 
The most abundant phyla included Firmicutes (66.9% of sequences), Bacteroidetes (20.3% of 
sequences), and Proteobacteria (10.3% of sequences). Rats fed a soy-rich diet had a lower 
(p<0.05) relative abundance of Firmicutes, but higher (p<0.05) relative abundance of 
Bacteroidetes, resulting in a lower (p<0.001) Firmicutes: Bacteroidetes ratio compared to those 
fed control diet (Figure 3.6D). Firmicutes: Bacteroidetes ratio between OVX and SHM rats was 
not different.  
 We utilized MaAsLin analysis to assess the specific taxonomic changes due to soy 
consumption and the loss of ovarian hormone production. Ovariectomy led to an increase 
(p<0.05) in relative abundance of Aggregatibacter and Anaerovibrio, but a decrease in the 
relative abundance of SMB53 (Figure 3.6E). Soy consumption was linked to a greater (p<0.05) 
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relative abundance of multiple genera, including Prevotella, an undefined genus in family 
Lachnospiraceae, Dorea, Phascolarctobacterium, rc4-4, Sutterella, an undefined genus in 
family Prevotellaceae, and an undefined genus in order YS-2 (Figure 3.6F). On the other hand, 
soy consumption was linked to a lower (p<0.05) relative abundance of Coprococcus, SMB53, an 
undefined genus in family Clostridiaceae, an undefined genus in family Desulfovibrionaceae, 
Adlercreutzia, Bifidobacterium, CF231, Desulfovibrio, Roseburia, Treponema, an undefined 
genus in order Bacteroidales, and an undefined genus in family Peptostreptococcaceae. 
Correlations between the relative microbial abundances and physiological profile revealed 
negative correlations (p<0.05) between inflammatory marker CD11c expression in PGAT and 
the relative abundance of genera Prevotella and Dorea (=-0.55 and -0.52, respectively). 
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DISCUSSION 
 Menopause is associated with increased adiposity, insulin resistance, dyslipidemia, and 
inflammation; many of these alterations contribute to elevated risks of metabolic dysfunction 
(27).  Soy and soy products are commonly viewed as a natural remedy of menopause-related 
vasomotor symptoms due to their high level of phytoestrogens, namely isoflavones. Meanwhile, 
soy supplementation has been shown to benefit metabolic function, but the mechanisms remain 
unclear. The gut microbiota are essential in transforming the biologically inactive forms of 
isoflavones present in food into active metabolites that have higher estrogenic potency. Hence, 
the association between soy consumption, menopause-related metabolic disorders, and the gut 
microbiota need to be established. Herein, we demonstrated that consumption of a diet high in 
soy and isoflavones significantly: 1) lowered BW gain, fat mass, and circulating cholesterol 
concentrations; 2) ameliorated insulin sensitivity; 3) lowered pro-inflammatory markers CD11c 
and IL6 expression in PGAT adipose tissue; 4) shifted the cecal microbial community; and 5) 
lowered Firmicutes:Bacteroidetes ratio in the cecal microbiota of rats selectively bred for low-
aerobic capacity. 
 Similar to the current study, previous studies have demonstrated that soy protein exerts 
anti-obesity effect in obese rodents (4, 5).  However, evidence of weight loss due to long-term 
soy supplementation is limited in obese humans (28), potentially due to the confounding factors 
of hypocaloric diet and physical activity interventions in most human trials. A recent clinical trial 
demonstrated that a low-calorie meal replacement high in soy protein led to a similar yet 
significant weight loss as the lifestyle group with dietary and physical activity modifications in 
obese men and women (6). Two groups of overweight or obese subjects either received dietary 
counseling sessions and fitness instruction to increase physical activity (lifestyle group) or 
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received low-calorie meal-replacements high in soy protein (meal replacement group) for six 
months. In that study, the group of obese individuals in the meal replacement group had a 
pronounced reduction in adipokines, fetuin A, and resistin compared to the lifestyle group, 
reinforcing the potential anti-obesity effect of soy in humans. 
Beneficial effects of soy supplementation are commonly attributed to its high isoflavone 
concentrations, including genistein, daidzein, and glycitein. Genistein has been most 
comprehensively assessed among all soy isoflavones due to its high binding affinity to the 
estrogen receptors. Kim et al. (29) demonstrated that feeding 1500 mg/kg of genistein for 21 d 
reduced fat pad weight in ovariectomized mice, whereas 150 mg/kg of genistein was not able to 
achieve a similar effect in adiposity. The soy-rich diet fed in the current study only provided 190 
mg/kg of genistin/genistein, but it appeared to reduce adiposity, suggesting that other 
components of the soybean matrix such as soyasaponins, phospholipids, other forms of 
isoflavones (e.g., daidzin/daidzein and glycitin/glycitein), or oligosaccharides could have 
complementary effects on weight reduction. Another clinical trial demonstrated that whole soy, 
but not daidzein, improved cardiovascular function in equol-producing postmenopausal women 
(30), supporting the notion that the food matrix may play a role in the health benefits of soy. 
Moreover, Kurrat et al. (31) reported that life-long, but not short-term, exposure to isoflavones 
protected Wistar rats from obesity after ovariectomy. Therefore, the weight loss benefits 
observed in the current study may be partly due to the length of dietary intervention. Although 
animal studies have shown promising metabolic outcomes, the effects of soy or daidzein on 
weight and fat mass loss in post-menopausal women are not conclusive (32, 33).  
Estrogen is known to affect cholesterol homeostasis through ER (34), and a sufficient 
amount of isoflavones has been shown to decrease the rate of cholesterol synthesis in human 
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infants (35). Herein, we demonstrated that soy decreased serum cholesterol concentrations in 
ovariectomized LCR rats. Similarly, an isoflavone-rich herb preparation was shown to reduce 
serum cholesterol concentrations in post-menopausal women (36). Elevated plasma and liver 
triglycerides (i.e., hepatic steatosis), and risks of cardiovascular diseases are also associated with 
menopause (37, 38). Previous evidence showed reduced hepatic steatosis in response to daidzein 
supplementation in mice fed a high-fat (36 kcal%) diet, but this effect only existed at a dose of 
500 mg daidzein/kg of diet (39). In the current study, the soy diet consisted of 290 mg of 
daidzin/daidzein and did not affect circulating or liver triglycerides, indicating that a higher dose 
of soy isoflavones may be required to impact lipid metabolism. 
Adipocyte hypertrophy is associated with cell death and adipose tissue macrophage 
infiltration, which leads to adipose tissue inflammation and affects obesity-associated adipose 
tissue remodeling and induced non-classical adipogenesis that transitions from a hypertrophic to 
hyperplastic obesity (40). In the current study, ovariectomy led to adipocyte hypertrophy and 
elevated expression of TNF in perigonadal adipose tissue, while soy consumption reduced 
mRNA expression of markers of adipose tissue infiltration (CD11c) and inflammation (IL-6). 
Although the exact compound responsible for this beneficial improvement is unclear, the soy 
peptide Phe-Leu-Val has been shown to reduce insulin resistance and TNF-induced 
inflammatory release of cytokines in vitro (41). Daidzein also has been shown to decrease 
proinflammatory TNF mRNA expression level in the adipose tissues of mice (39). However, in 
humans, the effects of lowering inflammation through long-term soy supplementation are 
inconclusive (42-44).  
Soy isoflavone concentrations that appear to provide beneficial effects in obese rodents 
do not seem to be as efficient in humans, possibly because rodent fermentative compartments 
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contain equol-producing bacteria but only 30-50% of humans harbor equol-producing bacteria 
(45, 46). S-(-)equol is an exclusively microbially-derived metabolite converted from daidzein, 
with selective affinity for ER. The conversion from daidzein to equol is thought to be essential 
for obtaining beneficial outcomes from ingesting a soy-rich diet (9), which stresses the 
importance of investigating the changes in gut microbial community with soy feeding. In the 
current study, the gut microbiota of rats fed the soy-rich diet clustered separately from those fed 
the soy-free control diet. Rats fed the soy-rich diet had a lower alpha diversity and 
Firmicutes:Bacteroidetes ratio. An increase in Firmicutes:Bacteroidetes ratio has been commonly 
associated with obesity and adiposity (47). The reduction in BW and fat mass gain coincides 
with the lowered Firmicutes:Bacteroidetes ratio found in soy-fed groups regardless of hormonal 
status, supporting the propitious role of soy.   
Soy milk has been shown to increase the relative abundance of Lactobacillus spp. in rats 
(11). Certain Lactobacillus spp., including L. mucosae (12) and L. Niu-O16 (13), are known 
equol producers that can convert daidzein into equol in vitro. Enterococcus faecium (48) is 
another known equol producer. The relative abundance of Lactobacillus spp. and Enterococcus 
spp. in the cecal microbiota was not altered by soy in the current study; however, confident 
identification of taxa was possible only at the genus level due to the limitations of the sequencing 
technique used. Therefore, the changes in the known equol-producing Lactobacillus and 
Enterococcus species are not known. Another known equol producer that was identified and 
isolated from human feces in the past decade is Adlercreutzia equolifaciens gen. nov., sp. nov. 
(49). The relative abundance of Adlercreutzia, however, was lower in the cecal microbiota of rats 
fed the soy diet. The actual abundance and activity level of Adlercreutzia should be further 
investigated. Other known equol producers such as Slackia spp. (50), Eggerthella spp. (51),  
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Finegoldia magna (48), Veillonella spp. (48), and Paraeggerthella spp. (52) were not identified 
in this study. Even though it is clear that gut microbiota play a critical role in the bioavailability 
of isoflavones, a complete profile of equol-producing bacteria is presumably not yet identified 
due to the continuous discovery of many novel equol-producing bacterial strains. Microbial 
function and metabolites will need to be assessed to evaluate whether the gut microbiome is 
associated with the beneficial metabolic improvement observed in the ovariectomized LCR rats.   
In summary, our study demonstrated that soy ameliorates insulin sensitivity, adiposity, 
and inflammation and alters the cecal microbiota of ovariectomized rats selectively bred for low 
aerobic capacity. Our study established a casual link between soy consumption and changes in 
gut microbial community that may contribute to the improvement in metabolic health in post-
menopausal women. Further investigations are needed to elucidate the host-microbial 
interactions from the impact of ovariectomy and soy consumption.  
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CHAPTER 4: IMPACT OF LOSS OF OVARIAN FUNCTION ON HOST 
ENERGY METABOLISM, LIPID ACCUMULATION, AND 
INFLAMMATION IN A HIGH-FAT DIET-INDUCED OBESE C57BL/6J 
MOUSE MODEL 
ABSTRACT 
Menopause is an age-related loss of ovarian hormone production that has been linked 
with obesity-associated metabolic dysfunction. The causes and mechanisms of menopause-
related obesity are unclear. Metabolic processes in response to long-term high-fat diet exposure, 
which recapitulates dietary patterns in modern Westernized society, are extremely understudied 
in ovariectomized female rodent models. In this study, we aimed to determine the gene 
expression associated with energy metabolism, lipid accumulation, and inflammation in adipose 
tissues and liver of ovariectomized (OVX) female mice in response to a high-fat diet. Forty 10-
wk-old female C57BL/6J mice were fed either a high-fat diet (HFD; 60% kcal from fat) or a 
low-fat diet (LFD; 10% kcal from fat). After a 2-wk acclimation period, mice were then either 
OVX or sham-operated (SHM), resulting in a 2x2 factorial arrangement (n=10): 1) SHM/LFD; 
2) OVX/LFD; 3) SHM/HFD; 4) OVX/HFD. Body weight, food intake, body composition, 
hepatic and adipose steatosis, circulating glucose and lipid profiles, and adipose tissue 
hypertrophy were examined. Gene markers associated with inflammation, macrophages, 
oxidative stress, hypoxia, and energy, lipid, and glucose metabolism were assessed in gonadal 
(GDAT) and subcutaneous (SQAT) adipose tissues and liver. Compared to LFD, HFD promoted 
substantially greater (p<0.05) body weight gain, adiposity, and hepatic triglyceride 
concentrations in ovariectomized mice. Energy intake did not differ between SHM and OVX 
mice fed a LFD; however, mice fed the HFD had a greater caloric intake immediately following 
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the OVX surgery than SHM/HFD mice. 8-wk post-surgery, energy intake of SHM/HFD mice 
gradually increased to that similar to OVX/HFD mice. OVX and HFD led to hypertrophy 
(p<0.05) in GDAT and SQAT compared to SHM and LFD, respectively. Ovariectomy led to 
greater (p<0.05) adipose tissue and hepatic inflammation, macrophage infiltration, oxidative 
stress, hindered insulin signaling and glucose uptake, and altered lipid and energy metabolism. 
However, HFD feeding to OVX mice led to markedly greater (p<0.05) inflammation and 
macrophage infiltration in GDAT compared to the other groups, potentially mediated by TLR2 
signaling. In conclusion, a high-fat diet dramatically exacerbates adiposity, hepatic steatosis, 
inflammation, macrophage infiltration, and alters lipid and glucose metabolism in female mice 
with loss of ovarian hormone production compared to those fed a LFD. Elucidating the 
underlying mechanisms of the interaction between dietary macronutrient composition and loss of 
ovarian hormone production may aid in identifying pharmaceutical or nutraceutical therapeutic 
targets for menopause-related obesity.  
 
INTRODUCTION 
Menopause in humans is linked to greater adiposity, weight gain, and risk of obesity, as 
well as lower physical activity, free-living energy expenditure, and fat oxidation (1). Obesity is 
one of the most prevalent diseases that leads to multiple metabolic dysfunctions such as insulin 
resistance, diabetes, cardiovascular diseases, and cancer (2). The excessive adipose tissue that 
develops with obesity has been shown to secrete more adipokines and chemokines that promote 
insulin resistance, macrophage infiltration and activation, and inflammation (3). Adipose tissue is 
also thought to have limited maximal capacity, and when the limit of expansion capacity has 
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been reached, lipids are stored in non-adipose tissue organs (ectopic lipid deposition) such as 
liver and skeletal muscle, causing metabolic disorders through lipotoxicity. 
We have previously demonstrated that intact female mice were protected against high-fat 
diet (HFD)-induced obesity compared to male mice, suggesting a protective role of ovarian 
hormones and one of the primary reasons for this sexual dimorphism (4). However, other factors 
such as testosterone level or chromosomal differences also could play a role. With a massive 
amount of biomedical research focusing on male animals due to the concern of increased 
variability due to the hormonal cycles of females, the metabolic consequences of a HFD on 
females is under-investigated and usually assumed to be the same as males. Most published 
studies investigating the metabolic consequences of loss of ovarian hormone production in 
rodent models utilized a normal chow diet in which the macronutrient and fiber composition 
does not recapitulate a Westernized diet consumed in modern society. To date, only one study 
has compared the long-term effects or high- vs. low- fat diet consumption in an ovariectomized 
rodent model, showing that HFD feeding exacerbates adiposity, ectopic lipid accumulation, and 
systemic inflammation in ovariectomized mice (5); however, a comprehensive assessment of 
transcriptional changes in liver and adipose tissue inflammation and energy metabolism has not 
been characterized. The objective of this study was to measure physiological and metabolic 
changes that occur in mice following the loss of ovarian hormone production, and to characterize 
the severity of inflammation and lipid accumulation in liver and adipose tissues of mice fed a 
high- or low-fat diet (LFD). We hypothesized that ovariectomy would induce obesity and 
adiposity, increase inflammatory markers in adipose tissue and liver, and increase hepatic and 
adipose tissue steatosis when fed a HFD compared to intact controls. We also hypothesized that 
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these dysfunctional metabolic parameters would be more severe in the ovariectomized mice fed 
HFD than those fed a control LFD.   
 
MATERIALS AND METHODS 
Animals, diets, and study design: All animal procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Illinois at Urbana-Champaign. Forty 10-
wk-old female C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME) and 
fed either a HFD (60% kcal from fat) or a low-fat diet (LFD; 10% kcal from fat) for 2 wk during 
the acclimation period. Both diets were formulated to meet the nutrient requirements of adult 
mice. Analyzed chemical compositions of these two diets are shown in Table 4.1. Mice then 
underwent either OVX or SHM surgery at 12 wk of age when sexually mature. This resulted in a 
2x2 factorial arrangement for a 12-wk feeding trial as follows (n=10/group): 1) SHM mice fed 
LFD (SHM/LFD); 2) OVX mice fed LFD (OVX/LFD); 3) SHM mice fed HFD (SHM/HFD); 4) 
OVX mice fed HFD (OVX/HFD). 
Mice were housed individually in a temperature-controlled room with a 12-h light: 12-h 
dark cycle at the Edward R. Madigan Laboratory of the University of Illinois at Urbana-
Champaign and had ad libitum access to food and water. Due to the high concentration of fat, the 
HFD was stored at -20°C to ensure freshness and quality of the ingredients. Fresh HFD was 
provided to mice every 3-4 d to avoid food aversion caused by rancid fat. Food intake was 
measured twice per week, and BW was monitored weekly. Body composition was measured 
using EchoMRI
TM
 (EchoMRI LLC, Houston, TX) at 4, 8, and 12 wk after surgery and dietary 
intervention (Figure 4.1).  
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Ovariectomy surgery: Mice were anesthetized using isoflurane throughout the procedure. The 
site of operation was sterilized by swabbing the abdomen with alternating Povidine/Iodine swabs 
and ethanol swabs 3 times. A vertical incision was made through the skin above each side of the 
ovary fat pad, followed by a horizontal incision via the muscle layer to expose the ovaries. For 
OVX mice, ovaries were removed using cauterizing scissors. Mice were subcutaneously 
administered Carprofen (NSAID, 5 mg/kg) before the surgery and a drop of Bupivacaine 
(0.25%) was given on top of the muscle wall to help relieve pain before the incisions were 
closed. The incisions then were closed using 9 mm wound clips (Becton, Dickinson and 
Company, Franklin Lakes, NJ). Carprofen was subcutaneously administrated 24 h and 48 h post-
surgery. OVX surgery effectiveness was determined at the conclusion of the study via 
verification of significant uterine atrophy. 
 
Necropsy, tissue processing, and fasting blood glucose: Mice were euthanized with CO2 after a 
4-h fast, and blood was collected via cardiac puncture and centrifuged (2,300 x g for 15 min at 
4°C) to separate serum after allowing it to clot at room temperature for 20 min. Serum samples 
were aliquoted and stored at -80°C until analysis. Fasting blood glucose was measured using a 
 
 
Figure 4.1. Study timeline. 
• Mice arrive
• Dietary 
intervention
•Fecal 
collection
•Ovariectomy
wk -2 wk 0
•Fecal collection
•EchoMRI
wk 4 wk 8 wk 12
•Fecal collection
•EchoMRI
•Fecal collection
•EchoMRI
•Sacrifice
10-wk-old 12-wk-old 16-wk-old 20-wk-old 24-wk-old
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glucometer from the tail vein. Subcutaneous (SQAT) and gonadal adipose depots (GDAT) were 
dissected, weighed, and divided into sections for histopathology and stored at -80°C for gene 
expression analyses. The liver was dissected and divided into sections for gene expression, 
histopathology, and liver triglyceride measurements. 
 
Serum chemistry: Serum was used to measure triglycerides, non-esterified fatty acids (NEFA), 
alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) 
(Comparative Clinical Pathology Services; Columbia, MO).  
 
Hepatic steatosis: Hepatic steatosis was determined by histopathology and liver triglyceride 
analysis. Formalin-fixed, paraffin-embedded liver sections were sectioned and stained with 
hematoxylin and eosin (H&E) and the severity of hepatic steatosis was blindly evaluated by a 
pathologist at the University of Illinois. Liver triglyceride concentrations were determined as 
described previously (6). Briefly, liver samples were homogenized in 1 mL of lipid extraction 
solvent composed of 1:2 vol/vol methanol-chloroform and then gently agitated overnight at 4°C. 
An equal part of 4 mM MgCl was added, vortexed, and centrifuged for 1 h at 1,000 x g at 4°C. 
The organic phase was evaporated and reconstituted in 3:2 vol/vol butanol-Triton X-114 mix 
(Sigma, St. Louis, MO). Liver triglyceride concentrations then were determined using a 
commercially available kit (Sigma, St. Louis, MO) with a spectrophotometer (Synergy HT, 
BioTek, Winooski, VT).  
 
Adipocyte sizing: Formalin-fixed, paraffin-embedded SQAT and GDAT were sectioned and 
stained with H&E. Images were taken using a Nanozoomer (C9600, Hamamatsu Photonics, 
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Japan). The severity of adipose tissue steatosis was blindly evaluated by a pathologist at the 
University of Illinois. Adipocyte volume was calculated using the cross-sectional area obtained 
from perimeter tracings through ImageJ software (http://imagej.nih.gov/ij/).  
 
Hepatic and adipose gene expression for inflammation, energy sensing, and lipid metabolism: 
Total RNA was extracted from liver, SQAT, and GDAT tissues. Genes related to inflammation, 
energy sensing, glucose and lipid metabolism, apoptosis, and hypoxia were measured through 
real-time RT-PCR analysis using Fluidigm Biomark HD Real-Time PCR device (Fluidigm 
Corporation, South San Francisco, CA). The list of genes assessed is shown in APPENDIX A. 
Briefly, primers designed by and purchased from Fluidigm Deltagene Assays were pooled at 1 
uL per assay for specific target amplifications using Taqman PreAmp Master Mix (Thermo 
Fisher, San Jose, CA). Thermal protocol of this step was 10 min of initial denaturation at 95°C, 
followed by 13-14 amplification cycles of 15 s at 95°C and 4 min at 60°C. Exonuclease 
treatment then was used to remove excess primer using Exonuclease I (New England BioLabs, 
Beverly, MA). Evagreen Supermix (BioRad Laboratories, Hercules, CA) was used for real-time 
amplification and detection under the following thermal protocol: 40 min at 70°C, 30 s at 60°C, 
and 1 min at 95°C, followed by 30 amplification cycles of 5 s at 96°C and 20 s at 60°C. A 
dissociation curve for each primer was produced with a programmed temperature ramp from 60-
95°C in 2 min, from which the melting temperature (Tm) was calculated. Analysis was performed 
using Fluidigm Real-Time PCR analysis Software 4.1.3.  
 
Statistical analysis: All data were analyzed using the MIXED procedure of SAS 9.3 (SAS 
Institute, Cary, NC) with diet and surgery being fixed effects and animal being a random effect. 
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When a main effect was significant, post hoc pairwise comparisons were performed using 
Tukey’s multiple comparison tests. Data normality was checked using the UNIVARIATE 
procedure and Shapiro-Wilk statistic. Data are reported as means ± SEM with statistical 
significance set as p<0.05 and p<0.10 considered as trends.  
 To evaluate the changes of genes assessed within GDAT, SQAT, and liver, heat maps 
were generated using gplots package in R (http://www.R-project.org/) (7). The relative 
concentration of each data point was calculated based on the dilution curves generated for each 
gene and all data points then underwent a Log2 transformation. The mean of each house keeping 
gene (ACTB, PPIA, and RPS13) was calculated for each sample and subtracted from each data 
point. Hierarchical clustering then was used to elucidate the similarity in expression patterns.  
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Table 4.1 Ingredient and analyzed chemical composition of the high-fat (HFD) and low-fat 
diets (LFD) fed to mice 
  LFD HFD 
Ingredient g/kg diet (as-fed basis) 
Casein, 80 mesh 189.6 258.5 
L-cystine 2.8 3.9 
Cornstarch 479.8 0.0 
Maltodextrin 10 118.5 161.5 
Sucrose 65.2 88.9 
Cellulose, Solka floc 47.4 64.6 
Corn oil 23.7 32.3 
Lard 19.0 316.6 
Mineral mix
1
 9.5 12.9 
Dicalcium phosphate 12.3 16.8 
Calcium carbonate 5.2 7.1 
Potassium citrate 15.6 21.3 
Vitamin mix
2
 9.5 12.9 
Choline bitartrate 1.9 2.6 
Analyzed chemical composition 
 Dry matter (DM, %) 90.2 93.3 
     --DM basis-- 
Organic matter (%) 96.6 95.4 
Ash (%) 3.4 4.6 
Crude protein (%) 18.2 24.1 
Acid hydrolyzed fat (%) 7.8 39.5 
Nitrogen free extract (%) 65.5 25.8 
Total dietary fiber (%) 5.1 6.1 
Gross energy (kcal/g diet) 4.5 6.3 
Calculated metabolizable energy  
(Atwater factors, kcal/g DM) 
4.1 5.5 
Calculated metabolizable energy  
(modified Atwater factors, kcal/g DM) 
3.6 5.1 
1 
Each kg of mineral mix consists of: ammonium molybdate tetrahydrate (0.3 g); copper carbonate (1.05 
g); ferric citrate (21 g); magnesium sulfate heptahydrate (257.6 g); manganese carbonate hydrate (12.25 
g); chromium potassium sulfate (1.93 g); potassium iodate (0.04 g); sodium chloride (259 g); sodium 
fluoride (0.2 g); sodium selenite (0.04 g); zinc carbonate (5.6 g); magnesium oxide (41.9 g).  
2
Each kg of vitamin mix consists of: biotin, 1% (2 g); calcium pantothenate (1.6 g); folic acid (0.2 g); 
Vitamin K as menadione sodium bisulfite (0.08 g); niacin (3 g); pyridoxine-HCl (0.7 g); riboflavin (0.6 
g); thiamine-HCl (0.6 g); vitamin A acetate (0.8 g, 500,000 IU/g); vitamin B12; 0.1% mannitol (1 g); 
vitamin D3 (1 g, 100,000 IU/g); vitamin E acetate, 50% (10 g). 
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RESULTS 
Animal characteristics 
Loss of ovarian hormone production led to elevated BW gain, but the magnitude of those 
fed a HFD was much more severe than those fed a LFD (Figure 4.2A). HFD-fed mice consumed 
more (p<0.05) calories than LFD-fed animals (Figure 4.2B). Energy intake did not differ 
between SHM and OVX mice fed a LFD; however, mice fed HFD had a greater (p<0.05) caloric 
intake immediately following the OVX surgery than SHM/HFD mice. 8 wk post-surgery, energy 
intake of SHM/HFD gradually increased to that similar to OVX/HFD mice. Body composition at 
4-, 8-, and 12-wk post-surgery are shown in Figure 4.3.  
 
 
Figure 4.2. Average body weight over 12 wk of ovariectomized (OVX) or sham-
operated (SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD). Data are 
shown as least-squares means ± SEM, n=8-10/group. 
*
 denotes main diet effect; 
+
 denotes 
main surgery effect; # denotes interactions, p<0.05. 
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 Final BW of mice was measured before sacrifice. OVX/HFD mice were heavier (p<0.05) 
than all other treatment groups, whereas SHM/LFD mice were lighter (p<0.05) than all other 
groups (Figure 4.4A). Final BW of OVX/LFD and SHM/HFD mice did not differ. In HFD-fed 
groups, body weight of OVX mice was 37% greater than SHM mice, but in the LFD-fed groups, 
body weight of OVX was only 19% greater than SHM mice. SQAT and GDAT weights of 
OVX/HFD mice were heavier (p<0.05) than that of SHM/HFD mice, and these two groups both 
had heavier (p<0.05) fat pads than mice fed LFD (Figure 4.4B and C). However, OVX/LFD 
mice did not have heavier (p>0.05) SQAT or GDAT compared to SHM/LFD mice, even though 
a numerical increase with ovariectomy appeared to exist. Mesenteric fat pad weight was heavier 
(p<0.05) in OVX/HFD mice compared to all other treatment groups (Figure 4.4D).  
 
Figure 4.3. Body composition of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) 4-, 8-, and 12-wk post-
surgery. Data are shown as means ± SEM, n=8-10/group. 
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Uterine atrophy 
OVX surgery effectiveness was determined at the conclusion of the study via verification 
of significant uterine atrophy. Representative pictures of uteri from sham-operated and OVX 
mice are shown in Figure 4.5. 
   
 
Figure 4.4. Body and fat pad weight of ovariectomized (OVX) or sham-operated 
(SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) for 12 wk. (A) Final 
body weight before sacrifice, (B) subcutaneous, (C) gonadal, and (D) mesenteric fat pad 
weights are shown as means ± SEM, n=8-10/group. Interactions were denoted by 
superscript letters, with means lacking a common letter being different (p<0.05). 
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Figure 4.5. Image of representative uteri from sham-operated (SHM) and 
ovariectomized (OVX) mice. 
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Fasting blood metabolites 
Fasting blood glucose concentrations were higher (p<0.05) in HFD-fed mice than those 
fed LFD (Figure 4.6A) but not different between SHM vs. OVX mice. Fasting serum 
triglycerides, NEFA, AST, and ALT were not different among treatment groups (Figure 4.6B, 
C, E, and F). Fasting serum ALP concentrations were lower (p<0.05) in the HFD-fed mice 
compared to those fed LFD (Figure 4.6D). 
 
Histopathology of liver and adipose tissue steatosis 
The severity of steatosis in liver, SQAT, and GDAT was blindly evaluated by a 
pathologist at the University of Illinois (Table 4.2). In the liver, ovariectomy led to greater 
(p<0.05) hepatic steatosis than SHM, whereas HFD did not alter the severity of steatosis. 
However, HFD-fed mice had greater (p<0.05) steatosis in GDAT than those fed LFD. In SQAT, 
OVX/HFD and SHM/LFD groups had greater (p<0.05) steatosis scores than OVX/LFD group. 
Table 4.2 Histopathology scoring of liver and adipose tissue steatosis
1
 
 
LFD 
 
HFD 
 
p values 
Tissue SHM OVX 
 
SHM OVX 
 
Diet Surgery Diet*Surgery 
Liver
2
 0.44 ± 0.33 1.56 ± 0.35 
 
0.38 ± 0.35 1.89 ± 0.33 
 
0.71 <0.01 0.57 
GDAT
3
 0.44 ± 0.23 0.38 ± 0.25 
 
1.63 ± 0.25 2.11 ± 0.23 
 
<0.01 0.40 0.26 
SQAT 1.44 ± 0.19
a
 0.38 ± 0.21
b
   1.00 ± 0.21
ab
 1.33 ± 0.19
a
   0.21 0.07 <0.01 
1 Values are least-squares means; n=8-10. LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: ovariectomized; 
GDAT: gonadal adipose tissue; SQAT: subcutaneous adipose tissue. Interactions were denoted by superscript letters, with 
means lacking a common letter within each tissue being different (p<0.05). 
2 Hepatic steatosis/lipidosis based on a severity scale of 0-5 (0, normal; 1, minimal; 2, mild; 3, moderate; 4, marked; 5, severe; 
6, very severe). 
3 Adipose tissue steatitis based on a severity scale of 0-5 (0, normal; 1, minimal, focal or multifocal interstitial aggregates of 3-
5 histiocytes/lymphocytes involving less than 25% of the area of adipose on the slide; 2, mild, multifocal interstitial 
aggregates of 3-5 histiocytes/lymphocytes involving more than 25% of the area of adipose on the slide; 3, moderate, 
multifocal interstitial aggregates of 5-10 histiocytes/lymphocytes involving less than 25% of the adipose tissue on the slide; 4, 
marked, multifocal to locally extensive interstitial aggregates of 5-10 histiocytes/lymphocytes involving 25-50% of the 
adipose on the slide; 5, severe, multifocal to locally extensive interstitial aggregates of >10 histiocytes/lymphocytes involving 
>50% of the adipose on the slide. 
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Figure 4.6. Fasting blood parameters of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) for 12 wk. (A) Blood glucose, 
(B) serum triglyceride, (C) serum non-esterified fatty acid, (D) serum alkaline phosphatase, 
(E) serum aspartate aminotransferase (AST), and (F) serum alanine aminotransferase (ALT) 
concentrations are shown as means ± SEM, n=8-10/group. * denotes main diet effects, 
p<0.05. 
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Liver triglyceride concentrations 
Representative H&E stains of liver and liver triglyceride concentrations are shown in 
Figure 4.7. Liver triglyceride concentrations were higher (p<0.05) in OVX/HFD mice than all 
other treatment groups.  
 
Adipocyte sizing 
Representative H&E stains of GDAT and SQAT, and the average size of adipocytes are 
shown in Figure 4.8. HFD-fed mice had larger (p<0.05) adipocytes in both GDAT and SQAT 
than those fed LFD, and OVX mice had larger (p<0.05) adipocytes in both fat pads compared to 
SHM mice.  
 
 
Figure 4.7. Representative H&E stains of liver and liver triglyceride concentrations of 
ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) or 
low-fat diets (LFD) for 12 weeks. Data are shown as means ± SEM, n=8-10/group. 
Interactions were denoted by superscript letters, with means lacking a common letter being 
different (p<0.05). 
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Gonadal adipose gene expression 
Gene markers associated with inflammation, macrophages, oxidative stress, hypoxia, and 
energy, lipid, and glucose metabolism were assessed in gonadal adipose tissue (APPENDIX A). 
By using a hierarchical clustering strategy based on similarity of the expression patterns, the heat 
map demonstrated visually an astonishing modulation of gene expression among treatment 
groups (Figure 4.9). Substantial clustering was shown between SHM/LFD and OVX/HFD 
 
Figure 4.8. Representative H&E stains of gonadal and subcutaneous adipose tissue and 
average size of adipocytes of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) for 12 wk. Data are shown as 
means ± SEM, n=8-10/group. 
*
 denotes main diet effect; 
+
 denotes main surgery effect, 
p<0.05. 
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groups, with OVX/HFD demonstrating upregulation of inflammatory and macrophage markers, 
and downregulation of genes associated with mitochondria biogenesis, glucose uptake, lipolysis, 
and adipokines [adiponectin (ADIPOQ) and retinol binding protein 4 (RBP4)] in GDAT. 
Remarkably, the OVX/HFD group had greater (p<0.05) relative GDAT expression of Adgre1 
(also known as F4/80), ARG1, ITGAM (also known as CD11B), ITGAX (also known as 
CD11C), CD68, TLR2, TNF, CCL2 (also known as MCP1), and CCL3 compared to all other 
treatment groups (Figure 4.10). HFD led to greater (p<0.05) relative expression of IFNG, IL1B, 
and IL6 in GDAT than LFD. Moreover, ovariectomy led to elevated (p<0.05) relative expression 
of IL1B and IL6 than SHM mice. Relative expression of cytotoxic and pro-inflammatory NOS2 
was greater (p<0.05) in LFD/OVX, HFD/SHM, and HFD/OVX groups than in LFD/SHM group, 
suggesting that OVX and HFD promote M1 killer macrophages phenotype. 
 The relative expression of insulin receptor substrate-1 (IRS1) was lower (p<0.05) in 
OVX and HFD than SHM and LFD-fed mice, respectively (Figure 4.11A), whereas IRS2 was 
not altered in GDAT (data not shown). Similarly, the relative expression of SLC2A4 (also 
known as GLUT4) and PCK1 (also known as PEPCK) was lower (p<0.05) in OVX and HFD 
than SHM and LFD-fed mice, respectively. Alterations in lipid metabolism also were observed 
in the current study, with OVX and HFD having lower (p<0.05) relative expression of LIPE 
(also known as HSL) and PPARGC1A (also known as PGC1) than SHM and LFD-fed mice, 
respectively. The relative expression of CPT1A was greater (p<0.05) in OVX and HFD 
compared to SHM and LFD-fed mice, respectively. The OVX/HFD group had lower (p<0.05) 
relative expression of LPL than both groups fed LFD, whereas SHM/HFD had lower (p<0.05) 
relative expression of LPL than OVX/LFD but did not differ from other treatment groups. 
OVX/LFD had lower (p<0.05) relative expression of lipogenic ACACA (also known as ACC1) 
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than the SHM/LFD group, but higher (p<0.05) than both groups fed HFD. The relative 
expression of ADIPOQ and RBP4 was lower (p<0.05) in OVX and HFD than SHM and LFD-
fed mice, respectively, whereas the expression of leptin (LEP) was higher in OVX and HFD than 
SHM and LFD-fed mice, respectively (Figure 4.11B). The OVX/HFD group had greater 
(p<0.05) relative expression of UCP2 among all treatment groups, whereas the relative 
expression of UCP3 was lower (p<0.05) in OVX and HFD than SHM and LFD-fed mice.  
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Figure 4.9. Heat map of relative gonadal adipose tissue (GDAT) mRNA expression with 
hierarchical clustering based on similarity. Values represent the log2 ratio over housekeeping 
genes with scaling to obtain relative expression among samples within each gene. Each row 
represents a specific gene of interest and each column represents one sample with color code 
denoting treatment groups (SHM/LFD: red; OVX/LFD: blue; SHM/HFD: green; OVX/HFD: 
yellow).  LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: ovariectomized. 
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Figure 4.10. Relative GDAT expression of genes associated with inflammation.  
*
 denotes main diet effects; 
+
denotes main surgery effects; interactions were denoted by 
superscript letters, p<0.05. LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; 
OVX: ovariectomized. HKG: housekeeping gene. 
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Figure 4.11. Relative GDAT expression of genes associated with (A) glucose and lipid 
metabolism and (B) adipokines and energy metabolism.  
*
 denotes main diet effects; 
+
 denotes main surgery effects; interactions were denoted by 
superscript letters, p<0.05. LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: 
ovariectomized. HKG: housekeeping gene. 
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Subcutaneous adipose gene expression 
Gene markers associated with inflammation, macrophages, oxidative stress, hypoxia, and 
energy, lipid, and glucose metabolism were assessed in SQAT (APPENDIX A). Similar to 
GDAT, hierarchical clustering revealed visually a substantial modulation of gene expression 
among treatment groups (Figure 4.12). However, the response of HFD-fed groups appears to be 
more variable than those fed LFD. Although having less clear clustering within OVX/HFD or 
SHM/HFD groups compared to GDAT, a clear modulation of diet was demonstrated with HFD-
fed animals showing upregulation in inflammation, angiogenesis, and macrophages infiltration 
than those fed LFD.  
 The relative SQAT expression of Adgre1 (also known as F4/80), IL1B, IL6, ITGAM, 
MRC1, NOS2, TLR2, TNF, CCL3, and IKBKB was greater (p<0.05) in HFD than LFD-fed 
mice (Figure 4.13). OVX mice, on the other hand, had lower (p<0.05) relative expression of 
ARG1 and NFKBIA, and greater (p<0.05) NOS2, TNF, and CCL3 expression, suggesting that 
ovariectomy promotes M1 killer phenotype of macrophages and inflammation in SQAT. An 
interaction was found in several genes, with the OVX/HFD group having the greatest (p<0.05) 
expression of ITGAX, CCL2, and CD68 in SQAT among treatment groups. The relative SQAT 
expression of LPL was greater (p<0.05) in OVX and HFD than SHM and LFD-fed mice, 
respectively (Figure 4.14A). Similar to GDAT, the relative SQAT expression of PPARGC1A, 
PCK1, SLC2A4 (GLUT4), and CPT1A was lower (p<0.05) in HFD-fed than LFD-fed mice. 
OVX and HFD-fed mice had lower (p<0.05) ACACA than SHM and LFD-fed mice, 
respectively. The relative expression of ADIPOQ was not altered among treatment groups, 
whereas HFD caused lower (p<0.05) expression of RBP4 (Figure 4.14B). The OVX/HFD group 
had greater (p<0.05) relative expression of LEP than the SHM/HFD group, and both HFD-fed 
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groups had greater (p<0.05) LEP expression than both groups fed the LFD. The relative 
expression of UCP2 and UCP3 was both lower (p<0.05) in mice fed HFD than LFD.      
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Figure 4.12. Heat map of relative subcutaneous adipose tissue (SQAT) mRNA expression 
with hierarchical clustering based on similarity. Values represent the log2 ratio over 
housekeeping genes with scaling to obtain relative expression among samples within each gene. 
Each row represents a specific gene of interest and each column represents one sample with 
color code denoting treatment groups (SHM/LFD: red; OVX/LFD: blue; SHM/HFD: green; 
OVX/HFD: yellow). LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: 
ovariectomized. 
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Figure 4.13. Relative SQAT expression of genes associated with inflammation.  
*
 denotes main diet effects; 
+
 denotes main surgery effects; interactions were denoted by 
superscript letters, p<0.05. LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; 
OVX: ovariectomized. HKG: housekeeping gene. 
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Figure 4.14. Relative SQAT expression of genes associated with (A) glucose and lipid 
metabolism and (B) adipokines and energy metabolism.  
*
 denotes main diet effects; 
+
 denotes main surgery effects; interactions were denoted by 
superscript letters, p<0.05. LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: 
ovariectomized. HKG: housekeeping gene. 
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Hepatic gene expression 
Gene markers associated with inflammation, macrophages, oxidative stress, hypoxia, and 
energy, lipid, and glucose metabolism were assessed in the liver (APPENDIX A). Hierarchical 
clustering did not reveal a clear pattern or clustering of the treatment groups, suggesting that the 
metabolic processes of liver in response to OVX and/or HFD are not as consistent as that of 
adipose tissue in regards to the functional genes examined (Figure 4.15).  
 The relative hepatic expression of anti-inflammatory maker and its receptor, IL10 and 
IL10RA, was lower (p<0.05) in OVX than SHM mice (Figure 4.16A). Ovariectomy led to 
greater (p<0.05) expression of pro-inflammatory marker CCL2 in comparison with SHM mice. 
However, the relative hepatic expression of IL6 and TLR4 were both lower (p<0.05) in OVX 
than SHM mice. The relative expression of TLR2 was greater (p<0.05) in HFD-fed than LFD-
fed mice. Markers of oxidative stress, GSTA2 and CAT, both had greater (p<0.05) expression in 
HFD-fed than LFD-fed mice (Figure 4.16B). Moreover, GSTA2 expression was also greater 
(p<0.05) in OVX than SHM mice.  
 Metabolically, OVX mice had lower (p<0.05) expression of MGLL, SLC2A1, and 
AHSG (also known as fetuin-A) than SHM (Figure 4.17). The relative hepatic expression of 
LIPE, CPT1A, and DGAT2 was greater (p<0.05) in HFD-fed than LFD-fed mice; in contrast, the 
expression of PPARGC1A and SLC2A4 was lower (p<0.05) in HFD-fed than LFD-fed mice.  
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Figure 4.15. Heat map of relative hepatic mRNA expression with hierarchical clustering 
based on similarity. Values represent the log2 ratio over housekeeping genes with scaling to 
obtain relative expression among samples within each gene. Each row represents a specific 
gene of interest and each column represents one sample with color code denoting treatment 
groups (SHM/LFD: red; OVX/LFD: blue; SHM/HFD: green; OVX/HFD: yellow). LFD: low-
fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: ovariectomized. 
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Figure 4.16. Relative hepatic expression of genes associated with (A) inflammation and 
(B) oxidative stress. 
*
 denotes main diet effects; 
+
 denotes main surgery effects, p<0.05. 
LFD: low-fat diet; HFD: high-fat diet; SHM: sham-operated; OVX: ovariectomized; HKG: 
housekeeping gene. 
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Figure 4.17. Relative hepatic expression of genes associated with glucose and lipid 
metabolism. 
*
 denotes main diet effects; 
+
 denotes main surgery effects, p<0.05. LFD: low-fat 
diet; HFD: high-fat diet; SHM: sham-operated; OVX: ovariectomized; HKG: housekeeping 
gene. 
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DISCUSSION 
Ovariectomy, or loss of ovarian hormone production, has been linked to greater 
adiposity, risk of metabolic syndrome, and cardiovascular diseases. The interactions between 
loss of ovarian hormone production and environmental factors, such as diet, are not well known 
but extremely important considering that obesity is a multifactorial disease. Herein, we 
demonstrated that 12 wk of HFD feeding significantly exacerbated weight gain, adiposity, 
hepatic steatosis, adipose tissue inflammation, and macrophage infiltration in OVX female mice. 
 The body weight and food intake were measured and recorded weekly in the current 
study. OVX/HFD group gained substantial amounts of weight and body fat, as expected; 
however, the degree of weight gain observed between OVX vs. SHM mice was much greater in 
those fed HFD than LFD. A similar interaction between diet and ovariectomy status was reported 
by Ludgero-Correia et al. (5); however, the magnitude of weight gain of OVX/HFD group was 
markedly greater in the current study with a shorter intervention period (29.68  1.22 g after 18 
wk of dietary intervention vs. 41.36  1.37 g after 12 wk). Both HFD contained 60% kcal from 
fat, but a combination of soybean oil and lard was chosen in the previous study (5), while we 
utilized a combination of corn oil and lard to avoid potential phytoestrogens present in the 
soybean oil. It is plausible that phytoestrogens in the tested diet, if they exist, could counter the 
effect of ovariectomy and lead to less weight gain in the previous study conducted by Ludgero-
Correia and colleagues. It has been reported that ovariectomy in mice does not lead to 
hyperphagia. This statement is true for LFD-fed mice in the current study, but HFD-fed mice 
were hyperphagic (both the amount and the calories of food consumed) immediately after the 
removal of ovaries. Interestingly, we observed a delay in hyperphagia in the SHM/HFD group. 
The reason for this delayed response to HFD challenge is unclear, but estrogen may potentially 
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play a role in the initial resistance of weight gain. Adipocyte hypertrophy is associated with cell 
death and adipose tissue macrophage infiltration, which leads to adipose tissue inflammation and 
affects obesity-associated adipose tissue remodeling and induced non-classical adipogenesis that 
transitions from a hypertrophic to hyperplastic obesity (8). Similar to our observation in Chapter 
3, ovariectomy led to adipocyte hypertrophy and HFD feeding worsened this condition. 
Inflammatory status was examined in GDAT, SQAT, and liver of OVX or SHM mice fed 
either a LFD or HFD for 12 wk. Differential response was observed between adipose depots, 
with OVX/HFD having the greatest degree of inflammation and macrophage infiltration among 
treatment groups in GDAT. This phenomenon could be mediated by TLR2 and TLR4 signaling 
pathways. These two toll-like receptors recognize dietary fatty acids and NEFA as ligands, and 
can further activate NFB pathway and eventually lead to increased inflammatory cytokines and 
insulin resistance (9, 10). TLR4 also recognize lipopolysaccharides (LPS), a component of gram-
negative bacteria, which can bind to TLR4 receptors of adipose tissue if they enter into the 
systemic circulation when the gastrointestinal barrier function is compromised (11). In the 
current study, GDAT mRNA expression of TLR4 was not altered from experimental treatments, 
whereas TLR2 was markedly higher in the OVX/HFD group, suggesting that the elevated 
inflammatory status could be TLR2 dependent. TLR2 polymorphism has been associated with 
elevated circulating concentrations of triglyceride and fasting insulin, and insulin resistance in 
obese women (12). Furthermore, TLR2 knockout male mice are protected against HFD-induced 
adipose tissue inflammation (13). TLR2 expression in blood has been examined in post-
menopausal women, and a positive correlation was found between TLR2 and pro-inflammatory 
cytokine IL-6 concentrations (14). Whether post-menopausal women have elevated TLR2 
expression compared to pre-menopausal women is not known; however, the presence of ER is 
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known to be critical for TLR2 signaling (15).  In contrast to the differential inflammatory 
response observed in GDAT, most of the upregulated inflammatory genes observed in SQAT 
were affected by ovariectomy and/or HFD. Exceptions were CCL2 and CD68, which had the 
greatest response in the OVX/HFD group.  
 The mRNA expression of IRS1 and GLUT4 was lower in GDAT of OVX and HFD-fed 
mice, suggesting impaired insulin signaling and glucose uptake. A previous study examined the 
degree of insulin resistance in two groups of people who were at high risk of developing type 2 
diabetes (T2D): healthy individuals with a family history of T2D and individuals with morbid 
obesity (16). Low IRS1 expression and protein level in the abdominal subcutaneous adipose 
tissue was observed in 30% of the individuals and this subset of individuals had greater 
concentrations of circulating insulin, glucose, and triglycerides. The mRNA expression of 
PGC1, a key regulator of energy metabolism, decreased with HFD across tissues examined, 
and was lower with ovariectomy in GDAT, suggesting mitochondria biogenesis may be 
compromised. Interestingly, ovariectomy and HFD feeding led to elevated LPL expression in 
SQAT compared to SHM and LFD feeding, respectively, while CPT1A was upregulated only by 
HFD feeding, suggesting that OVX/HFD mice burn less but store more fat in SQAT than 
SHM/HFD mice.  
 Elevated circulating fetuin-A, also known as alpha-2-HS glycoprotein (AHSG), has been 
commonly linked with obesity, T2D, metabolic syndrome, and non-alcoholic fatty liver disease 
in humans (17-19). High-fat diet feeding has been shown to increase hepatic fetuin-A protein 
level and circulating fetuin-A in male rats (20, 21) and it has been suggested that fetuin-A is an 
endogenous ligand of TLR4 that can mediate downstream NFB pathways to induce 
inflammation and insulin resistance (22, 23). Fetuin-A also is involved in bone metabolism that 
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promotes mineral deposition from the serum to bone (24). In the current study, we observed 
lower expression of hepatic fetuin-A and TLR4 with ovariectomy, and the expression of these 
genes was not elevated by HFD feeding. Similar to our findings, it has been shown that 
ovariectomized osteopenic rats (a post-menopausal osteoporosis rodent model) had lower hepatic 
fetuin-A expression compared to sham controls (25). Circulating fetuin-A concentration in 
women also has been shown to drop after menopause and restored after receiving estrogen 
replacement therapy (26, 27). Due to the lack of fetuin-A upregulation in response to HFD 
feeding in this study, we speculate that bone metabolism outweighs inflammatory response in 
regards of hepatic fetuin-A-TLR4 signaling.  
 In summary, this work demonstrated differential responses of loss of ovarian hormone 
production when the composition of dietary fat/energy was altered. As we expected, ovariectomy 
induced obesity, adiposity and adipocyte hypertrophy, hepatic steatosis and adipose tissue 
inflammation. We also showed that these dysfunctional metabolic parameters were more severe 
in ovariectomized mice fed a high-fat compared to low-fat diet. The mechanisms of the dramatic 
adiposity and inflammation caused by the combination of high-fat diet feeding and ovariectomy 
is unclear. We speculate that the gastrointestinal barrier function may be compromised, 
contributing to this inflammatory response. Elucidating the underlying mechanisms of this 
interaction between dietary macronutrient composition and loss of ovarian hormone production 
may aid in identifying pharmaceutical or nutraceutical therapeutic targets for menopause-related 
obesity.  
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CHAPTER 5: IMPACT OF LOSS OF OVARIAN FUNCTION ON CECAL 
BARRIER FUNCTION AND MICROBIAL COMMUNITIES WITH OR 
WITHOUT OBESITY INDUCED BY A HIGH-FAT DIET IN C57BL/6J 
MICE 
ABSTRACT 
Menopause-associated obesity and insulin resistance are likely attributed to the loss of 
ovarian hormone production. However, little is known in regards to how this loss in hormone 
production and consequent obesity and inflammation affect gut barrier function and the gut 
microbiota. We hypothesized that the loss of ovarian hormone production would lead to 
disrupted gut barrier function and inflammation, and altered cecal microbial communities. Forty 
10-wk-old female C57BL/6J mice were purchased and ad libitum fed either a low-fat diet (LFD; 
10% kcal from fat) or high-fat diet (HFD; 60% kcal from fat) for 2 wk. Mice then underwent 
either ovariectomy (OVX) or sham (SHM) surgery at 12 wk of age, resulting in 4 treatment 
groups (n=10/group): 1) SHM/LFD; 2) OVX/LFD; 3) SHM/HFD; 4) OVX/HFD. Mice were fed 
their allotted diets for 12 wk and then euthanized at 24 wk of age. Gastrointestinal permeability 
was evaluated by multiple assessments: 1) circulating lipopolysaccharide-binding protein 
(LPSBP) concentrations, 2) cecal transmural resistance determined ex vivo using a modified 
Ussing chamber system, and 3) cecal mRNA expression of genes related to tight junction 
proteins by real-time RT-PCR analysis. Expression of cecal genes related to inflammation, bile 
acid metabolism, short-chain fatty acid receptors, and energy sensing also was assessed. DNA 
from cecal digesta was extracted, followed by 16S rRNA gene-based amplicon Illumina MiSeq 
sequencing and analysis using QIIME 1.9.1. Quantitative measurements of specific taxa in the 
cecal microbiota were assessed using qPCR. OVX/HFD mice had greater (p<0.05) serum 
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LPSBP than OVX/LFD mice. Cecal expression of inflammatory genes was not elevated due to 
ovariectomy, but the expression of BCL2 was greater (p<0.05) in OVX mice than SHM mice, 
indicating greater apoptosis associated with loss of ovarian hormone production. Cecal 
permeability was not different among treatment groups. However, OVX mice had lower 
(p<0.05) cecal expression of occludin, claudin3, and AMPK than SHM mice, suggesting that the 
cecal integrity was compromised due to loss of ovarian hormone production. Lower cecal 
expression of FXR and FGF15 was observed in the OVX mice compared to SHM, suggesting an 
interaction between estrogen and the FXR-FGF15 pathway that is known to affect bile acid 
synthesis. Principal coordinates analysis (PCoA) of weighted and unweighted UniFrac distances 
of cecal microbiota revealed a distinct separation (p<0.05) between mice fed LFD and HFD. 
Despite the profound physiological changes of OVX/HFD vs. SHM/HFD mice, differential 
clustering of microbial communities was observed only between OVX/LFD and SHM/LFD 
mice. HFD promoted a greater (p<0.05) Firmicutes:Bacteroidetes ratio and lower (p<0.05) 
species richness of the cecal microbial community. Ovariectomy led to greater (p<0.05) 
abundance of Lactobacillus and lower (p<0.05) relative abundance of Oscillospira, 
Ruminococcus, and an undefined genus in order Clostridiales. In summary, loss of ovarian 
function is associated with disrupted gastrointestinal integrity and lower cecal FXR-FGF15 
mRNA expression. Diets with distinct macronutrient compositions differentially impact cecal 
microbial communities of ovariectomized vs. intact female mice. 
 
INTRODUCTION 
The gastrointestinal (GI) tract is an important first line of defense against ingested 
noxious agents, preventing bacterial pathogens from entering the systemic circulation. GI 
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integrity is known to be compromised in obese animal models, leading to elevated plasma 
lipopolysaccharide (LPS), a gut microbiota-derived endotoxin, which promotes inflammation 
and affects host health (1). In humans, LPS concentrations have been reported to be elevated in 
obese patients, while it normally remains at low concentrations in lean and healthy individuals 
(2). Besides disrupted GI integrity, obesity also has been linked with changes in the composition 
of gut microbiota that affect energy balance, glucose metabolism, and inflammation (1, 3-6). 
However, changes in gut microbial communities associated with menopause in humans or 
ovariectomy in rodents are unclear, and whether this ecosystem contributes to host metabolism 
and health are not known. 
The gut microbiota are involved in estrogen metabolism and recycling through an 
enterohepatic circulation pathway via bacterial β-glucuronidase (7, 8). Bacterial β-glucuronidase 
deconjugates a large amount of estrogen-derived metabolites in the distal gut, allowing these 
metabolites to be reabsorbed by the host, whereas the conjugated estrogen-derived metabolites 
remain in the bile and are eventually excreted in the feces. It has been shown that fecal β-
glucuronidase is negatively correlated with fecal total estrogen in post-menopausal women, but 
not pre-menopausal women, suggesting that the activity of bacterial β-glucuronidase is altered 
after menopause (9). Furthermore, it has been demonstrated that female rats are more protected 
against intestinal injury and inflammation than males, suggesting potential modulation of sex 
hormones on GI health (10). Despite the importance of gut microbiota in modulating estrogen 
metabolism, no published work has evaluated the gut microbial communities between pre-
menopausal and post-menopausal women and only one peer-reviewed publication has attempted 
to decipher the gut microbial changes with loss of ovarian function in the high/low capacity 
running (HCR/LCR) rat model (11).  
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Herein, we aimed to examine the composition of cecal microbial communities and GI 
barrier function in OVX vs. SHM mice fed a high- or low-fat diet. Association between 
microbial taxa and physiological and metabolic measurements was also assessed. We 
hypothesized that ovariectomy would lead to disrupted gut barrier function, intestinal 
inflammation, shift the cecal microbial communities, and lead to an increased 
Firmicutes:Bacteroidetes ratio and decreased species richness compared to SHM mice. We also 
hypothesized that HFD feeding will further exacerbate these conditions. 
 
MATERIALS AND METHODS 
Cecum and cecal digesta collection: The cecum and cecal digesta were collected from mice 
described in Chapter 4 after 12 wk of dietary and surgical interventions. Cecal tissue was 
collected for intestinal permeability measurement and gene expression analyses. Cecal digesta 
was collected and stored at -80°C for microbiota analysis. 
 
Intestinal permeability measurement: Gut barrier function was assessed ex vivo using a modified 
Ussing chamber system. Ussing chambers allow for precise assessment and comparison of the 
physiological intestinal permeability of intestines without influencing other potential 
confounding variables (12, 13). Briefly, a section of cecum was resected, cut longitudinally, and 
mounted into modified Ussing chambers exposing 0.031 cm
2
 of the mucosal and serosal sides. 
After allowing 10-20 min to reach equilibrium, transmural resistance (Ohm x cm
2
) was 
measured. 
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Lipopolysaccharide-binding protein (LPSBP) Assay: Serum LPSBP was analyzed using a 
commercial kit (HK205-02 Mouse LBP ELISA Kit, Hycult Biotech Inc., Plymouth Meeting, 
PA).  
 
Cecal expression of genes related to tight junction proteins, short-chain fatty acid (SCFA) 
receptors, energy sensing, and inflammation: Total RNA was isolated from cecal tissue using 
RNeasy kits (Qiagen, Valencia, CA). RNA concentration was determined using an ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE). cDNA was synthesized using 
SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). Genes related to tight junction 
proteins, SCFA receptors, energy sensing, bile acid metabolism, lipolysis, inflammation, and 
apoptosis were measured by real-time RT-PCR analysis using Fluidigm Biomark HD Real-Time 
PCR device (Fluidigm Corporation, South San Francisco, CA). Genes of interest and associated 
primers sequences are listed in APPENDIX B. Briefly, primers designed and purchased from 
Fluidigm Deltagene Assays (Fluidigm Corporation, South San Francisco, CA) were pooled at 1 
uL per assay for specific target amplifications using Taqman PreAmp Master Mix (Thermo 
Fisher, San Jose, CA). The protocol of this pre-amplification step was 10 min of initial 
denaturation at 95°C, followed by 13-14 amplification cycles of 15 s at 95°C and 4 min at 60°C. 
Exonuclease treatment then was used to remove excess primers using Exonuclease I (New 
England BioLabs, Beverly, MA). Evagreen Supermix (BioRad Laboratories, Hercules, CA) was 
used for real-time amplification and detection under the following thermal protocol: 40 min at 
70°C, 30 s at 60°C, and 1 min at 95°C, followed by 30 amplification cycles of 5 s at 96°C and 20 
s at 60°C. A dissociation curve for each primer was produced with a programmed temperature 
ramp from 60-95°C in 2 min, from which the melting temperature (Tm) was calculated. Analysis 
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was performed using Fluidigm Real-Time PCR analysis Software 4.1.3 and the heat map was 
generated using the gplots package in R (http://www.R-project.org/) (14). The relative 
concentration of each data point was calculated based on the dilution curves generated for each 
gene and all data points then underwent a Log2 transformation. The mean of the housekeeping 
genes (ACTB, PPIA, and RPS13) was calculated for each sample and subtracted from each data 
point. Hierarchical clustering then was used to elucidate the similarity in expression patterns. 
 
Adipose gene expression of aromatase (Cyp19a1): Total RNA was extracted from gonadal and 
subcutaneous adipose depot and used to synthesize cDNA as described in Chapter 4. Due to the 
low signaling obtained from Cyp19a1 in adipose tissues, a pre-amplification step was performed 
using Taqman PreAmp Master Mix (Thermo Fisher, San Jose, CA) under 10 min of initial 
denaturation at 95°C, followed by 14 amplification cycles of 15 s at 95°C and 4 min at 60°C to 
increase the abundance of genes of interest. Taqman probes targeting Cyp19a1 were used to 
amplify the gene of interest using real time 2-step RT-PCR using an Applied Biosystems 
7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA). cDNA from ovaries 
and brain was used as positive controls. 
 
Cecal digesta DNA extraction, amplification, and sequencing: Total DNA from cecal digesta 
samples was extracted using MO BIO PowerSoil kits (MO BIO Laboratories, Inc., Carlsbad, 
CA). Concentration of extracted DNA was quantified using a Qubit® 3.0 Fluorometer (Life 
Technologies, Grand Island, NY). 16S rRNA gene amplicons were generated using a Fluidigm 
Access Array (Fluidigm Corporation, South San Francisco, CA) in combination with Roche 
High Fidelity Fast Start Kit (Roche, Indianapolis, IN). The primers 515F (5′-
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GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′) that 
target a 252 bp-fragment of the V4 region were used for amplification (primers synthesized by 
IDT Corp., Coralville, IA) (15). CS1 forward tag and CS2 reverse tag were added according to 
the Fluidigm protocol. Quality of the amplicons was assessed using a Fragment Analyzer 
(Advanced Analytics, Ames, IA) to confirm amplicon regions and sizes. A DNA pool was 
generated by combining equimolar amounts of the amplicons from each sample. The pooled 
samples were then size selected on a 2% agarose E-gel (Life Technologies, Grand Island, NY) 
and extracted using a Qiagen gel purification kit (Qiagen, Valencia, CA). Cleaned size-selected 
pooled products were run on an Agilent Bioanalyzer to confirm appropriate profile and average 
size. Illumina sequencing was performed on a MiSeq using v3 reagents (Illumina Inc., San 
Diego, CA) at the W. M. Keck Center for Biotechnology at the University of Illinois.  
 
Bioinformatics for cecal microbial analysis: Forward reads were trimmed using the FASTX-
Toolkit (version 0.0.13) and QIIME 1.9.1 (16) was used to process the resulting sequence data. 
Briefly, high-quality (quality value ≥ 20) sequence data derived from the sequencing process 
were demultiplexed. Sequences then were clustered into operational taxonomic units (OTU) 
through an open-reference OTU picking strategy using SortMeRNA (17) in combination with 
SUMACLUST against the Greengenes 13_8 reference database (18) with a 97% similarity 
threshold. Singletons (OTUs that were observed fewer than 2 times) and OTUs that had less than 
0.01% of the total observation were discarded. A total of 980,742 16S rRNA-based amplicon 
sequences were obtained, with an average of 29,719 reads (range = 23,594-40,387) per sample. 
An even sampling depth (sequences per sample) of 23,594 sequences per sample was used for 
assessing alpha- and beta-diversity measures. Beta-diversity was calculated using weighted and 
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unweighted UniFrac (19) distance measures.  Correlations between the relative microbial 
abundances and physiological profile, including the adipose and liver expression of mRNA 
examined in Chapter 4, were assessed using Spearman correlation coefficients using QIIME. 
Multivariate Association with Linear Models (MaAsLin) analysis then was performed using 
default parameters with animal ID being the random effect to assess specific taxa changes 
(https://huttenhower.sph.harvard.edu/maaslin). 
 
Assessing specific bacterial taxa using quantitative PCR (qPCR): qPCR was performed as 
previously described (20, 21) using a Bio-Rad CFX384 real-time PCR detection system (Bio-
Rad Laboratories, Inc., Hercules, CA). Sequences of primers targeting all bacteria (universal 
primer), specific phyla (Bacteroidetes and Firmicutes), specific family (Ruminococcaceae), and 
specific genera (Lactobacillus, Bifidobacterium, Blautia, Faecalibacterium, Fusobacterium, 
Turicibacter, Streptococcus, Enterococcus) and PCR conditions used are listed in APPENDIX C. 
qPCR data are expressed as the log DNA for each bacterial taxon/5 ng of isolated total DNA. 
 
Statistical analysis: Data were analyzed using the Mixed Models procedure of SAS 9.3 (SAS 
Institute, Cary, NC) with diet and surgery being fixed effects and animal being a random effect. 
When a main effect was significant, post hoc pairwise comparisons were performed using 
Tukey’s multiple comparison tests. Data normality was checked using the UNIVARIATE 
procedure and Shapiro-Wilk statistic. Data are reported as means ± SEM with statistical 
significance set as p<0.05 and p<0.10 considered as trends. 
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RESULTS 
LPSBP assay 
Serum LPSBP concentration was measured and an interaction (p<0.05) between diet and 
surgery was observed (Figure 5.1A). OVX/HFD mice had greater (p<0.05) serum LPSBP than 
OVX/LFD mice, but neither was different than the two SHM groups.  
 
Intestinal permeability measurements 
Surgery and diet interventions did not affect cecal transmural resistance in female 
C57BL/6J mice (Figure 5.1B).  
 
Cecal gene expression 
Hierarchical clustering did not reveal a clear pattern or clustering of treatment groups 
(Figure 5.2). Nevertheless, differences in cecal gene expression of tight junction proteins were 
observed despite the lack of differences found in cecal transmural resistance (Figure 5.3). OVX 
 
Figure 5.1. Serum lipopolysaccharide-binding protein (LPSBP) concentrations (A) and 
cecal transmural resistance (B) of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) for 12 weeks. Data are shown as 
means ± SEM, n=8-10/group. Interactions were denoted by superscript letters, with means 
lacking a common letter being different, p<0.05. 
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mice had lower (p<0.05) cecal claudin3 (CLDN3) and occludin (OCLN) expression compared to 
SHM mice. HFD-fed mice had lower (p<0.05) cecal expression of CLDN3, claudin5 (CLDN5), 
and claudin8 (CLDN8) than mice fed LFD. OVX/LFD, SHM/HFD, and OVX/HFD mice had 
lower (p<0.05) claudin4 expression compared to SHM/LFD mice. However, cecal gene 
expression of claudin1 (CLDN1), claudin2 (CLDN2), MUC2, and TJP1 (Zo-1) did not differ 
among treatment groups.  
Genes associated with energy sensing and bile acid, glucose, and lipid metabolism were 
assessed in cecal tissues (Figure 5.4). AMPK is a critical cellular energy sensor, but also has 
been shown to be involved in intestinal barrier function (22). We evaluated the expression of 
four subunits of AMPK (1, 2, 1, and 2), but only observed AMPK1 subunit (PRKAA1) to 
be different (p<0.05) among treatment groups. OVX mice had lower (p<0.05) cecal PRKAA1 
expression compared to SHM mice. Genes involved in thermoregulation and energy balance, 
UCP2 and UCP3, were assessed, with a decrease (p<0.05) in cecal UCP3 expression observed in 
HFD-fed mice compared to those fed LFD. Cecal UCP2 did not differ among treatment groups. 
OVX mice had lower (p<0.05) cecal FGF15 and NR1H4 (FXR) expression than SHM mice. 
Cecal expression of SLC10A2 (ASBT) and SLC51A (OSTA) was not different among treatment 
groups. The LFD/OVX mice had lower (p<0.05) cecal IRS1 than LD/SHM mice, and that OVX 
mice had lower (p<0.05) cecal IRS2 than SHM mice, suggesting that ovariectomy hinders the 
insulin signaling pathway. Adipose triglyceride lipase (ATGL; PNPLA2), the rate-limiting 
enzyme mediating triglyceride hydrolysis, was lower (p<0.05) in the cecum of OVX mice 
compared to SHM mice. Cecal expression of SCFA receptor FFAR3 (GPR41) was lower 
(p<0.05) in HFD-fed mice than LFD-fed mice. Other markers of lipid metabolism, PPARGC1A 
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(PGC1), Angptl4 (FIAF), FFAR2 (GPR43), and SIRT1 were not different among treatment 
groups.  
Genes associated with apoptosis, hypoxia, and inflammation were assessed in cecal 
tissues (Figure 5.5). Apoptosis regulator B-cell lymphoma 2 (BCL2) was greater (p<0.05) in 
OVX mice than SHM mice. However, the expression of caspase 3 (CASP3) was not different 
among groups. Cecal expression of NLRP3 inflammasome and its adapter apoptosis-associated 
speck-like protein containing a C-terminal caspase-recruitment domain (PYCARD; ASC), an 
important innate immune receptor and sensor that activates the production of IL1 and apoptosis 
through Caspase-1 signaling, was not different among treatment groups. Cecal expression of 
hypoxia-inducible factor 1-alpha (HIF1A) was greater (p<0.05) in HFD-fed mice than those fed 
LFD. However, the expression of inflammatory markers CCL2, CCR2, and IL1 was lower 
(p<0.05) in the cecum of HFD-fed mice than LFD-fed mice. 
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Figure 5.2. Heat map of relative cecal mRNA expression with hierarchical clustering 
based on similarity. Values represent the log2 ratio over housekeeping genes with scaling to 
obtain relative expression among samples within each gene. Each row represents a specific 
gene of interest and each column represents one sample with color code denoting treatment 
groups (SHM/LFD: red; OVX/LFD: blue; SHM/HFD: green; OVX/HFD: yellow). SHM: 
sham-operated; OVX: ovariectomized; LFD: low-fat diet; HFD: high-fat diet. 
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Figure 5.3. Relative cecal expression of genes associated with tight junction proteins of 
ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) or 
low-fat diets (LFD) for 12 weeks. Asterisk denotes main diet effect; plus sign denotes main 
surgery effect; interactions are denoted by superscript letters, p<0.05. HKG: housekeeping 
gene. 
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Figure 5.4. Relative cecal expression of genes associated with energy sensing and bile 
acid metabolism (A) and glucose and lipid metabolism (B) of ovariectomized (OVX) or 
sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD) for 12 
weeks. 
*
 denotes main diet effects; 
+
 denotes main surgery effects; interactions were denoted 
by superscript letters, p<0.05. HKG: housekeeping gene. 
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Figure 5.5. Relative cecal expression of genes associated with apoptosis and hypoxia (A) 
and inflammation (B) of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice 
fed high-fat (HFD) or low-fat diets (LFD) for 12 weeks. 
*
 denotes main diet effect; 
+
 denotes 
main surgery effect, p<0.05. HKG: housekeeping gene. 
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Cecal microbiota 
A total of 980,742 reads were obtained, with an average of 29,719 reads (range = 23,594-
40,387) per sample. An even sampling depth of 23,594 sequences per sample was used for 
assessing alpha- and beta-diversity measures. Alpha diversity measures suggested that HFD led 
to lower (p<0.05) species richness than LFD (Figure 5.6A, B, and C). However, species richness 
did not differ between OVX and SHM groups.  
PCoA of weighted and unweighted UniFrac distances performed on 97% OTU 
abundance matrices of cecal microbiota revealed a distinct separation (p=0.01) between HFD- 
and LFD-fed mice (Figure 5.7). Similar to species richness, beta diversity did not differ between 
OVX and SHM groups. Interestingly, differential clustering was observed between SHM/LFD 
and OVX/LFD groups, but not between SHM/HFD and OVX/HFD groups.  
 
Microbial taxonomic shifts due to ovariectomy and high-fat diet 
Greengenes classifier assigned usable raw reads to 7 phyla, 53 families, and 66 genera. 
The most abundant phyla included Firmicutes (78.6% of sequences), Bacteroidetes (18.4% of 
sequences), Actinobacteria (2.2% of sequences), and Verrucomicrobia (0.5% of sequences). In 
Figure 5.8A and B, we observed that the OVX/LFD group had a greater (p<0.05) relative 
abundance of Actinobacteria (Bifidobacterium) and that the composition of the cecal microbiota 
in the OVX/LFD group was distinctly different than the rest of the treatment groups at the genera 
level. The relative abundance of Firmicutes was greater (p<0.05) in HFD-fed mice compared to 
LFD-fed mice (Figure 5.8C). SHM/LFD and OVX/LFD groups both had lower (p<0.05) relative 
abundance of Bacteroidetes compared to SHM/HFD and OVX/HFD (Figure 5.8D). Thus, HFD 
promoted an increased (p<0.05) Firmicutes:Bacteroidetes ratio compared to LFD (Figure 5.8E).  
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MaAsLin was utilized to assess specific taxa changes to the cecal microbial community 
due to OVX and HFD. Ovariectomy led to greater (p<0.05) relative abundance of Lactobacillus, 
but lower (p<0.05) Oscillospira, Ruminococcus, and an undefined genus in order Clostridiales 
(Figure 5.9A). HFD contributed to greater (p<0.05) relative abundance of Adlercreutzia, 
Anaerotruncus, Dorea, Enterococcus, an undefined genus in the family Erysipelotrichaceae, 
Lactococcus, [Ruminococcus], an undefined genus in the order Clostridiales, an undefined genus 
in the family Lachnospiraceae, and an undefined genus in the family Ruminococcaceae and 
lower (p<0.05) relative abundance of Dehalobacterium, Turicibacter, Allobaculum, 
Bifidobacterium, Coprococcus, an undefined genus in family Clostridiaceae, and an undefined 
genus in the family S24-7 (Figure 5.9B).  
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Figure 5.6. Species richness of cecal microbial communities of ovariectomized (OVX) or 
sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD). Alpha 
diversity measures suggested that the high-fat diet led to lower (p<0.05) species richness 
compared to the low-fat diet. 
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Figure 5.7. Unweighted and Weighted UniFrac principal coordinates analysis (PCoA) 
plots of cecal microbial communities of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat (LFD) diets. Unweighted (A) and weighted 
(B) UniFrac distances of cecal microbial communities performed on 97% OTU abundance 
matrices revealed a distinct separation (p=0.01) between mice fed high-fat and low-fat diets. 
Each dot represents a sample from each mouse (n=8-10/group). 
A. Unweighted B. Weighted
PC1 (26.34 %)
PC2 (9.94 %)
PC3 (8.2 %)
PC1 (47.89 %)
PC2 (15.63 %)
PC3 (7.16 %)
OVX/LFD
OVX/HFD
SHM/LFD
SHM/HFD
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Figure 5.8. Cecal microbial communities at the phyla and genera level of ovariectomized 
(OVX) or sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets 
(LFD). * denotes main diet effects; interactions were denoted by superscript letters, p<0.05. 
* a
a
b
b
*
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Quantitative assessment of specific bacterial taxa within the cecal microbial community 
Total bacterial load and specific bacterial taxa were assessed to obtain quantitative 
measurements. By using a universal bacterial primer set, we observed that ovariectomy led to 
greater (p<0.05) total bacteria load compared to SHM when fed a LFD, but this phenomena did 
not exist when fed a HFD (Figure 5.10). Similarly, the abundance of Firmicutes was greater 
(p<0.05) with OVX than SHM when fed a LFD, but this relationship did not occur in mice fed 
HFD. However, the OVX/HFD group had a greater (p<0.05) abundance of Firmicutes than 
SHM/LFD. Similar to our observations in the cecal microbial community from 16S rRNA 
sequencing, targeted qPCR demonstrated that HFD decreased (p<0.05) the abundance of 
Bacteroidetes and Turicibacter compared to HFD, and OVX led to an increased (p<0.05) 
abundance of total Lactobacillus.  
 The differential clustering of cecal microbiota between OVX/LFD and SHM/LFD 
appears to be, in part, due to the increased relative abundance of Actinobacteria 
(Bifidobacterium) in the OVX/LFD group (Figure 5.8A); therefore, we examined the abundance 
of Bifidobacterium using qPCR. Indeed, an interesting interaction was observed, in which the 
OVX/LFD group had a greater (p<0.05) abundance of Bifidobacterium than the SHM/LFD 
group, but it did not differ between the OVX/HFD and SHM/HFD groups.  
 
Aromatase expression in gonadal (GDAT) and subcutaneous (SQAT) adipose tissues 
The gene expression of aromatase was below the detection limit using typical 
methodology; a pre-amplification step was, therefore, performed to increase the abundance of 
this gene of interest. However, only some of the samples expressed sufficient Cyp19a1 to be 
detected using real-time qPCR (data not shown).  
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Correlations between differentially represented cecal microbial taxa and physiological data 
 To examine associations between cecal microbiota and physiological changes observed 
in the current study, Spearman correlation was conducted using MaAsLin analysis and weekly 
body weight, energy intake, body composition, adipocyte size, blood markers, and liver 
triglycerides as described in Chapter 4 (Figure 5.11). The relative abundance of Turicibacter, an 
undefined genus in family S24-7, Allobaculum, an undefined genus in family Clostridiaceae, and 
Bifidobacterium were found to be negatively correlated (p<0.05) with body weight and energy 
intake throughout the 12 wk period except the energy intake at wk 1. These taxa also were found 
to be negatively correlated (p<0.05) with percent fat mass and adipocyte cell size in both GDAT 
and SQAT, but positively correlated with percent lean mass and circulating concentrations of 
ALP. In contrast, the relative abundance of Adlercreutzia, an undefined genus in family 
Erysipelotrichaceae, Lactococcus, and [Ruminococcus] were positively correlated (p<0.05) with 
most of the weekly average body weights and energy intake throughout the study, percent fat 
mass, and adipocyte cell size in both GDAT and SQAT, but negatively correlated (p<0.05) with 
percent lean mass and circulating concentrations of ALP. Liver triglyceride concentration was 
positively correlated (p<0.05) with Adlercreutzia. 
 
Correlations between differentially represented cecal microbial taxa and the expression of cecal 
tight junction protein genes 
The associations between the differentially represented taxa of the cecal microbiota and 
gene expression of cecal tight junction proteins were assessed (Figure 5.12). Among all of the 
tight junction related genes assessed, CLDN5 appeared to be highly associated with changes in 
cecal microbial taxa. Gene expression of cecal CLDN5 was positively correlated (p<0.05) with 
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the relative abundance of Turicibacter, an undefined genus in family S24-7, Allobaculum, and 
undefined genus in family Clostridiaceae and Bifidobacterium, but negatively correlated 
(p<0.05) with the relative abundance of Ruminococcus, Oscillospira, Adlercreutzia, an undefined 
genus in family Erysipelotrichaceae, Anaerotruncus, Lactococcus, [Ruminococcus], an 
undefined genus in order Clostridiales, an undefined genus in family Lachnospiraceae, and an 
undefined genus in family Ruminococcaceae. Other than CLDN5, the relative abundance of 
Turicibacter was positively correlated (p<0.05) with cecal OCLN, CLDN3, and CLDN8 
expression. Similarly, the relative abundance of an undefined genus in family S24-7 was 
positively correlated (p<0.05) with cecal OCLN, CLDN1, CLDN3, CLDN4, and CLDN5 
expression.  
 
Correlations between differentially represented cecal microbial taxa and the expression of other 
cecal genes 
Correlations between the differentially represented taxa and the rest of the cecal genes 
were examined (Figure 5.13). Cecal ANGPTL4, the gene known to inhibit lipoprotein lipase 
activity in adipose tissue that leads to triglycerides deposition, was positively correlated (p<0.05) 
with the relative abundance of an undefined genus in family S24-7, Coprococcus, Turicibacter, 
and undefined genus in family Clostridiaceae. Interestingly, the relative abundance of 
Bifidobacterium was negatively associated (p<0.05) with cecal FGF15 expression.  
 
Correlations between differentially represented cecal microbial taxa and the expression of 
GDAT and SQAT genes 
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The association between the differentially represented cecal microbial taxa and the 
expression of GDAT (Figure 5.14A) and SQAT (Figure 5.14B) genes was assessed. The 
relative abundance of Turicibacter, an undefined genus in family S24-7, Allobaculum, an 
undefined genus in family Clostridiaceae, and Bifidobacterium was positively correlated 
(p<0.05) with ACACA, a rate-limiting enzyme in fatty acid synthesis, in both GDAT and SQAT. 
The relative abundance of Allobaculum was also negatively correlated (p<0.05) with multiple 
pro-inflammatory associated markers, including Adgre1 (i.e. F4/80), CCL2, CCL3, CCR5, 
CD68, ICAM1, ITGAM, ITGAX, MRC1, TLR2, and TNF in both GDAT and SQAT. Similarly, 
the relative abundance of Bifidobacterium was negatively correlated (p<0.05) with pro-
inflammatory markers CCL2, CCL3, CCR5, CD68, ICAM1, ITGAM, ITGAX, MRC1, TLR2, 
and TNF expression in both GDAT and SQAT. Interestingly, the gene expression of LPL was 
positively correlated (p<0.05) with the relative abundance of Bifidobacterium, Allobaculum, and 
Turicibacter in the GDAT, but was negatively associated (p<0.05) with the relative abundance of 
Bifidobacterium and Turicibacter in the SQAT. Leptin expression was positively correlated 
(p<0.05) with the relative abundance of Lactococcus, but negatively correlated (p<0.05) with the 
relative abundance of Bifidobacterium in both GDAT and SQAT.  
 
Correlations between differentially represented cecal microbial taxa and the expression of 
hepatic genes 
The associations between differentially represented taxa in the cecal microbiota and 
hepatic gene expression were assessed (Figure 5.15). Similar to the correlations observed in 
adipose tissue depots, the relative abundance of Allobaculum was positively correlated (p<0.05) 
with hepatic ACACA expression, but negatively correlated (p<0.05) with hepatic CCR5 and 
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TLR2 expression. Interestingly, the relative abundance of Allobaculum was negatively associated 
with hepatic AHSG (also known as fetuin-A), a marker that has been associated with obesity, 
T2D, metabolic syndrome, and non-alcoholic fatty liver disease in humans (23-25). The relative 
abundance of Allobaculum and Bifidobacterium both were positively correlated with hepatic 
PPARG1A (also known as PGC1) expression, a gene marker involved in mitochondria 
biogenesis.  
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Figure 5.10. Quantitative PCR assessment of specific bacterial taxa in the cecal microbial 
community of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed high-
fat (HFD) or low-fat diets (LFD). Asterisk denotes main diet effects; plus sign denotes main 
surgery effects; interactions were denoted by superscript letters, p<0.05.  
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Figure 5.11. Correlations between differentially represented cecal microbial taxa and 
body weight, food intake, body composition, adipocyte cell size, blood parameters and 
liver triglycerides. Red dots represent positive correlations whereas blue dots represent 
negative correlations; yellow square box denotes statistical significance (p<0.05) observed 
using Spearman correlation. 
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Figure 5.12. Correlations between differentially represented cecal microbial taxa and 
the expression of tight junction protein related genes and cecal transmural resistance. 
Red dots represent positive correlations whereas blue dots represent negative correlations; 
yellow square box denotes statistical significance (p<0.05) observed using Spearman 
correlation. 
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Figure 5.13. Correlations between differentially represented cecal microbial taxa and the 
expression of cecal genes examined. Red dots represent positive correlations whereas blue 
dots represent negative correlations; yellow square box denotes statistical significance (p<0.05) 
observed using Spearman correlation. 
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Figure 5.14. Correlations between differentially represented cecal microbial taxa and 
the expression of gonadal (A) and subcutaneous (B) adipose depot tissue genes 
examined. Red dots represent positive correlations whereas blue dots represent negative 
correlations; yellow square box denotes statistical significance (p<0.05) observed using 
Spearman correlation. 
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Figure 5.15. Correlations between differentially represented cecal microbial taxa and the 
expression of hepatic genes examined. Red dots represent positive correlations whereas blue 
dots represent negative correlations; yellow square box denotes statistical significance (p<0.05) 
observed using Spearman correlation. 
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DISCUSSION 
Menopause-related loss of ovarian hormone production has been associated with 
increased risks of obesity and metabolic dysfunction, and obesity has been linked to disrupted GI 
barrier function and shifts in the gut microbial community. However, little is known in regards to 
the GI alterations in menopause-induced obesity in women. Herein, we utilized a HFD-induced 
obesity approach using an ovariectomized female mouse model to characterize the changes that 
occur in cecal barrier function, cecal inflammation and metabolic changes, and cecal microbial 
community, and to examine the relationship between cecal microbiota taxa and host 
physiological and metabolic alterations. We demonstrated that the loss of ovarian hormone 
production promoted cecal barrier disruption, altered bile acid synthesis, and shifted the cecal 
microbial community. Cecal expression of inflammatory-related genes was not altered, but an 
apoptosis-associated gene, BCL2, was upregulated in OVX compared to SHM mice.  We also 
demonstrated that 12 wk of HFD feeding exacerbated the disruption in cecal barrier function and 
led to a greater Firmicutes:Bacteroidetes ratio and lower species richness of the cecal microbiota. 
Interestingly, differential clustering of the cecal microbial community was observed between the 
SHM/LFD and OVX/LFD groups, but not SHM/HFD and OVX/HFD groups, suggesting that 
HFD feeding may mask any cecal microbiota changes occurring from the loss of ovarian 
hormone production.   
Although cecal transmural resistance measured by Ussing chambers did not reveal 
statistical significance among treatment groups, OVX and HFD both lowered the expression of 
tight junction protein-related genes when compared to SHM and LFD, respectively. Furthermore, 
emerging data have suggested that AMPK, a critical energy sensing molecule, is involved in the 
tight junction assembly and is, therefore, important in maintaining intestinal barrier integrity 
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(22). Markedly lower cecal expression of AMPK due to ovariectomy in the current study 
supports the idea that ovariectomy results in altered GI integrity from tight junction protein gene 
expression. LPS, a gut microbiota-derived endotoxin, enters the systemic circulation at a higher 
rate when the GI integrity is compromised, promoting inflammation that affects host health (1). 
Detection of serum LPS can be technically difficult (26); therefore, the LPS-TLR4 pathway 
activation surrogate LPS-binding protein was measured (27). Circulating LPSBP was elevated in 
OVX/HFD compared to OVX/LFD mice, but was not different than either of the LFD-fed 
groups. Along with the cecal expression of tight junction protein-related genes, our data suggest 
that loss of ovarian hormone production is associated with a disrupted cecal barrier, but elevated 
circulating endotoxin concentrations only occur with the presence of obesity induced by HFD 
insult. 
 Bile acids play an important role for efficient nutrient absorption such as fat and fat-
soluble vitamins (28). The existence of intestinal FXR, a major regulator of bile acid 
metabolism, is essential for the development of obesity, insulin resistance, and non-alcoholic 
fatty liver disease (NAFLD) (29, 30). Whole body FXR-knockout mice had a distinct gut 
microbial community than wild-type mice when fed a HFD, suggesting that the modulation of 
FXR with HFD-induced obesity could occur through alterations in the gut microbiota (31).  
Activation of FXR by bile acids initiates the downstream signaling molecule FGF15/19 (mouse 
and human analog, respectively) in the intestine. FGF15/19 then travels to the liver and inhibits 
bile acid synthesis by suppressing transcription of cholesterol 7α-hydroxylase (Cyp7a1) (32). 
FGF15/19 also signals for the gallbladder to fill with bile (33). Our data suggests that FXR and 
FGF15 were downregulated by OVX when compared to SHM, which may lead to elevated bile 
acid synthesis in the liver. The elevation in bile acid synthesis could potentially promote fat 
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absorption and contribute to adiposity after ovariectomy. Interestingly, a recent study has 
demonstrated that supplementing bile acid receptor agonists (INT747 for FXR and INT777 for 
TGR5) to a HFD decreased weight gain and hepatic steatosis in OVX mice (34). Supplementing 
these two bile acid receptor agonists in OVX mice did not affect energy expenditure, but did lead 
to greater body temperature compared to control OVX mice not receiving them, suggesting that a 
bile acid signaling pathway is involved in thermoregulation, possibly by increasing the 
uncoupling of the mitochondria respiratory chain. The expression of UCP3 in skeletal muscle, 
one of the main adaptive thermogenesis mechanisms, was found to be significantly decreased in 
OVX mice compared to SHM in the same study, but was increased with the supplementation of 
INT747, which targets FXR. In the current study, lower expression of cecal FXR and GDAT 
UCP3 was observed in OVX compared to SHM mice, indicating that thermogenesis was affected 
and may play a role in the loss of ovarian hormone production-associated obesity through FXR 
signaling. However, although the function of UCP3 is thought to be dissipation of energy as it is 
with UCP1, evidence has suggested that UCP3 also may be responsible for exporting fatty acid 
peroxides from the mitochondria and, therefore, protects the cells from lipotoxicity (35). 
Whether the downregulated UCP3 expression observed in the current study is involved in 
thermoregulation and/or lipotoxicity in OVX mice needs to be elucidated. An apparent limitation 
is that we were only able to assess these bile acid metabolism-associated genes in the cecum 
although most of the signaling is thought to occur in the ileum. Further investigation is needed to 
confirm the observed alterations that may be involved in the development of obesity and 
metabolic dysfunction associated with loss of ovarian function.  
 In the current study, HFD promoted a greater Firmicutes:Bacteroidetes ratio, which has 
been associated with an obese phenotype (36). Meanwhile, we observed a distinct difference in 
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composition of cecal microbial communities between HFD- and LFD-fed mice with both 
unweighted and weighted UniFrac distance matrices. However, differential clustering of the 
cecal microbial community was observed between the SHM/LFD and OVX/LFD groups but not 
SHM/HFD and OVX/HFD groups in the weighted UniFrac PCoA plot. At the genus level, we 
observed similar differences in the composition of the cecal microbial community in OVX/LFD 
group, namely greater relative abundance of Bifidobacterium and Allobaculum and lower in the 
relative abundance of an undefined genus in the order Clostridiales and an undefined genus in 
the family S24-7 when compared to the SHM/LFD group. Similar alterations in the cecal 
microbiota were not observed in the OVX mice fed a HFD, indicating that macronutrient 
composition of the diet and/or physiological and metabolic response to the insult of the HFD 
potentially outweigh the effect of ovariectomy in the cecal microbiota. The activity of aromatase, 
a critical enzyme in estrogen biosynthesis, has been shown to be overexpressed in the peripheral 
tissues such as adipose tissues, possibly affecting circulating estrogen concentrations (37, 38). 
Furthermore, the increased conversion from androstenedione to estrone by aromatase was 
reported to be especially dramatic in the plasma of obese post-menopausal women (39, 40). We 
speculated that the marked increase in adiposity in the OVX/HFD group may increase the 
peripheral production of estrogen by increasing aromatase activity in the adipose tissue, leading 
to an elevation in systemic estrogen. Unfortunately, we were not able to detect the expression of 
aromatase in the adipose depot tissues in the current study. The interaction of aromatase activity 
and the gut microbial community, therefore, needs to be further investigated.  
Positive associations between tight junction protein-associated genes and the relative 
abundance of Bifidobacterium, Allobaculum, and an undefined genus in the family S24-7 in the 
cecal microbiota was detected in the current study. Multiple probiotic strains within the genus 
 158 
Bifidobacterium are known to enhance intestinal barrier function (41, 42). For instance, 
administration of Bifidobacterium infantis has been shown to maintain intestinal permeability by, 
in part, affecting CLDN4 and OCLN localization in mice with necrotizing enterocolitis, a 
common gastrointestinal disease in premature infants (43). Similar to previous findings (44), the 
relative abundance of Allobaculum decreased with HFD-feeding in the current study. The 
relative abundance of Allobaculum also has been shown to increase with oligofructose 
supplementation (45) and exercise (46). Based on the positive correlations observed in this study, 
Allobaculum may be involved in maintaining GI integrity and, therefore, respond to the 
treatments mentioned above that are known to alter intestinal barrier functions. In this study, the 
relative abundance of Allobaculum was also negatively associated with fetuin-A, a marker that 
has been associated with obesity, T2D, metabolic syndrome, and non-alcoholic fatty liver disease 
in humans, suggesting a beneficial role of Allobaculum in regards to metabolic health. The 
pathogenicity of taxon S24-7 is not clear, but an undefined genus in family S24-7 has been 
identified as being highly coated with IgA and thought to be a “colitogenic” intestinal bacteria in 
a colitis mouse model (47). However, the positive correlations observed between this taxon and 
the expression of multiple cecal tight junction proteins in the current study suggests that S24-7 
may be involved in maintaining the gastrointestinal integrity.  
 In summary, our study demonstrated that ovariectomy promotes disruption in 
gastrointestinal barrier function, with a greater degree of change in mice fed a HFD. The 
composition of the cecal microbial community appears to be altered with the loss of ovarian 
hormone production, but only in mice fed a LFD. Furthermore, the FXR-FGF15/19 pathway may 
be involved in the pathogenesis of the development of estrogen-deficient associated obesity, 
potentially through modulation of the gut microbial community. Direct involvement of the gut 
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microbiota in the loss of ovarian hormone production-related obesity and metabolic dysfunction 
deserves to be further investigated and elucidated.  
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CHAPTER 6: LONGITUDINAL IMPACT OF LOSS OF OVARIAN 
FUNCTION ON THE FECAL MICROBIAL COMMUNITIES WITH OR 
WITHOUT OBESITY INDUCED BY A HIGH-FAT DIET IN C57BL/6J 
MICE 
ABSTRACT 
In Chapter 4, profound physiological changes were observed in ovariectomized (OVX) 
mice fed a high-fat diet (HFD), especially those pertaining to adiposity, inflammation, and 
disrupted gut barrier function. However, differential clustering of the cecal microbial community 
was observed only between OVX and sham-operated (SHM) mice fed a low-fat diet (LFD) and 
not those fed a HFD, suggesting that the impact of ovariectomy on the cecal microbiota was 
masked by the HFD intervention. Elucidating the timing during which the gut microbiota 
changes occurred is, therefore, important to determine the involvement of gut microbiota in the 
progression of the disease. Fecal total estrogen concentrations have been inversely correlated 
with the bacterial β-glucuronidase enzyme activity in post-menopausal women (1), and this 
enzyme activity was elevated in healthy men consuming diets high in animal protein and fat (2). 
Therefore, we hypothesized that an alteration in bacterial -glucuronidase activity in mice fed 
LFD vs. HFD contributes to the lack of differences in the cecal microbiota of SHM and OVX 
mice fed a HFD. We aimed to determine the bacterial -glucuronidase activity level and the 
longitudinal shifts of gut microbiota in the progression of obesity associated with loss of ovarian 
function in mice fed a HFD. Forty 10-wk-old female C57BL/6J mice were purchased and ad 
libitum fed either a LFD (10% kcal from fat) or HFD (60% kcal from fat) for 2 wk. Mice then 
underwent either OVX or SHM surgery at 12 wk of age, resulting in 4 treatment groups 
(n=10/group): 1) SHM/LFD; 2) OVX/LFD; 3) SHM/HFD; 4) OVX/HFD. Mice were fed their 
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allotted diets for 12 wk and then euthanized at 24 wk of age. Fecal pellets were collected at 
baseline (wk 0, prior to ovariectomy surgery, but 2 wk after diet interventions were initiated) and 
4- , 8- , and 12-wk post-surgery intervention. Fecal bacterial -glucuronidase activity was 
measured in the fecal pellets collected at wk 12. DNA from fecal samples was extracted, 
followed by 16S rRNA gene-based amplicon Illumina MiSeq sequencing and analysis using 
QIIME 1.9.1. Fecal -glucuronidase activity was elevated (p<0.05) in the SHM/HFD group 
compared to the SHM/LFD group, but was not different than the OVX groups. Principal 
coordinates analysis (PCoA) of weighted UniFrac distances of fecal microbiota revealed a 
distinct separation (p<0.05) between diets. However, SHM and OVX mice clustered differently 
only in those fed a LFD. The Firmicutes:Bacteroidetes ratio was elevated at wk 8 and wk 12 of 
those fed the HFD, indicating that this elevation was due to increased adiposity instead of 
ovariectomy per se. The relative abundance of Clostridium and an undefined genus in the family 
Clostridiaceae was elevated in the OVX/HFD group at wk 4, but not SHM/HFD, indicating that 
this change may be due to the loss of ovarian hormone production. In summary, we 
demonstrated that changes in the gut microbiota occurred soon after ovariectomy and early on 
during the progression of obesity, indicating a response due to alterations in ovarian hormone 
production.  The response, however, was dependent on dietary intervention.  
 
INTRODUCTION 
The physiological changes observed in OVX mice fed a HFD in Chapter 4 were profound, 
especially those pertaining to adiposity, inflammatory status, and gut barrier function. 
Nevertheless, unlike the differential clustering observed between OVX/LFD and SHM/LFD 
groups, the cecal microbial communities of OVX/HFD mice did not seem to differ compared to 
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those in the SHM/HFD group. The weight gains of OVX/HFD mice happened soon after the 
ovariectomy surgery, suggesting that the changes in host physiology occur early on in the 
progression of ovarian function-associated obesity. Elucidating the timing during which the gut 
microbiota changes occur is important to determine whether the gut microbiota play a role in the 
development of obesity associated with estrogen insufficiency. 
As described in Chapter 5, the gut microbiota are involved in estrogen metabolism and 
recycling through an enterohepatic circulation pathway via bacterial β-glucuronidase (3, 4). 
Fecal β-glucuronidase is known to be negatively correlated with fecal total estrogen in post-
menopausal women but not pre-menopausal women, suggesting that the activity of this enzyme 
is altered after menopause (1). Diets high in meats or fats are known to elevate bacterial β-
glucuronidase activity in the intestinal digesta and feces (2, 5). Therefore, we speculate that the 
bacterial β-glucuronidase activity was altered differently in mice fed a LFD vs. HFD and 
contributed to the differential response observed between OVX and SHM mice fed LFD vs. 
HFD.  
In this study, we aimed to determine the bacterial -glucuronidase activity level and the 
longitudinal shifts of gut microbiota in the progression of obesity associated with loss of ovarian 
function in mice fed a HFD. We hypothesized that the gut microbiota changes would occur soon 
after the loss of ovarian function and in the early development and progression of obesity. We 
also hypothesized that the bacterial -glucuronidase expression would be elevated in the OVX 
mice compared to intact sham mice, and that the degree of expression would be higher in the 
OVX mice fed a HFD than those fed a LFD.  
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MATERIALS AND METHODS 
Fecal collection: Feces were collected from the animals described in Chapter 4 at baseline (prior 
to ovariectomy surgery but 2 wk after diet interventions initiated), and 4- , 8- , and 12-wk post-
surgery and diet intervention. Each mouse was placed in a separate clean cage for fecal 
collection. Fecal pellets were collected as soon as defecation occurred, and immediately snap 
frozen in liquid nitrogen. All fecal samples were stored at -80°C until further analysis.  
 
Fecal DNA extraction, amplification, sequencing, and bioinformatics: Total DNA from fecal 
samples was extracted using Mo-Bio PowerSoil kits (MO BIO Laboratories, Inc., Carlsbad, CA). 
Concentration of extracted DNA was quantified using a Qubit® 3.0 Fluorometer (Life 
Technologies, Grand Island, NY). 16S rRNA gene amplicons were generated using a Fluidigm 
Access Array (Fluidigm Corporation, South San Francisco, CA) in combination with Roche 
High Fidelity Fast Start Kit (Roche, Indianapolis, IN). The primers 515F (5′-
GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′) that 
target a 252 bp-fragment of the V4 region were used for amplification (primers synthesized by 
IDT Corp., Coralville, IA) (6). CS1 forward tag and CS2 reverse tag were added according to the 
Fluidigm protocol. Quality of the amplicons was assessed using a Fragment Analyzer (Advanced 
Analytics, Ames, IA) to confirm amplicon regions and sizes. A DNA pool was generated by 
combining equimolar amounts of the amplicons from each sample. The pooled samples were 
then size selected on a 2% agarose E-gel (Life technologies, Grand Island, NY) and extracted 
using a Qiagen gel purification kit (Qiagen, Valencia, CA). Cleaned size-selected pooled 
products were run on an Agilent Bioanalyzer to confirm appropriate profile and average size. 
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Illumina sequencing was performed on a MiSeq using v3 reagents (Illumina Inc., San Diego, 
CA) at the W. M. Keck Center for Biotechnology at the University of Illinois.  
 
Bioinformatics for fecal microbial analysis: Forward reads were trimmed using the FASTX-
Toolkit (version 0.0.13) and QIIME 1.9.1 (7) was used to process the resulting sequence data. 
Briefly, high-quality (quality value ≥ 20) sequence data derived from the sequencing process 
were demultiplexed. Sequences then were clustered into operational taxonomic units (OTU) 
through an open-reference OTU picking strategy using SortMeRNA (8) in combination with 
SUMACLUST against the Greengenes 13_8 reference database (9) with a 97% similarity 
threshold. Singletons (OTUs that were observed fewer than 2 times) and OTUs that had less than 
0.01% of the total observation were discarded. A total of 4,511,926 16S rRNA-based amplicon 
sequences were obtained, with an average of 33,421 reads (range = 13,215-52,588) per sample. 
An even sampling depth (sequences per sample) of 13,215 sequences per sample was used for 
assessing alpha- and beta-diversity measures. Beta-diversity was calculated using weighted and 
unweighted UniFrac (10) distance measures.  
 
Bacterial -glucuronidase activity measurement: Frozen fecal samples were first weighed and 
rehydrated in 15x weight/volume assay buffer (100 mM HEPES, 250 mM NaCl, pH 7.4). 
Bacterial cells were lysed using a Tissuelyzer II (Qiagen) for two minutes at 30 Hertz. 
Homogenate was sonicated for 3 min, then clarified by centrifugation at room temperature for 5 
min at 13,000  g. Enzyme kinetics were determined by monitoring the change in absorbance of 
p-nitrophenyl glucuronide (PNPG), a synthetic substrate. Reactions were conducted in 
quadruplicate in 96-well clear bottom assay plates (Corning Costar®, Thermo Fisher, San Jose, 
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CA). The 50 μL reaction volume consisted of 10 μL clarified fecal homogenate, 10 μL assay 
buffer and 30 μL PNPG (final concentration 1 mM). Appropriate blanks and controls were 
included. All experimental manipulation until this point occurred at 4°C. Enzyme activity was 
measured for 1 h at 37°C using a PHERAstar Plus microplate reader (BMG Labtech, Cary, NC). 
Initial velocity of each sample was calculated using custom MATLAB scripts, which was then 
normalized to the original weight of the fecal sample, and represented as nmol of PNP catalyzed 
per second per gram of feces using the extinction coefficient of PNP and path length of the assay 
well (11, 12).   
 
Statistical analysis: The longitudinal changes in fecal microbiota were analyzed using a two-part 
mixed-effects model specifically designed for modeling longitudinal microbiome composition 
data [ZIBR package (13) in R (http://www.R-project.org/) (14)]. Time points and surgery 
intervention were included in the covariate matrix for logistic and beta regression within each 
diet treatment, and false-discovery rate (FDR) corrected p values were obtained. Bacterial -
glucuronidase activity data was analyzed using the Mixed Models procedure of SAS 9.3 (SAS 
Institute, Cary, NC) with diet and surgery being fixed effects and animal being a random effect. 
When a main effect was significant, post hoc pairwise comparisons were performed using 
Tukey’s multiple comparison tests. Data normality were checked using the UNIVARIATE 
procedure and Shapiro-Wilk statistic. Statistical significance was set as p<0.05 and p<0.10 
considered as trends. 
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RESULTS 
Fecal -glucuronidase activity 
Fecal -glucuronidase activity was measured in fecal pellets collected at wk 12 post-
surgery and was demonstrated to be elevated (p<0.05) in SHM/HFD mice compared to 
SHM/LFD mice, but not different than either of the OVX groups (Figure 6.1). 
 
Fecal microbiota 
A total of 4,511,926 reads were obtained, with an average of 33,421 reads (range = 
13,215-52,588) per sample. An even sampling depth of 13,215 sequences per sample was used 
for assessing alpha- and beta-diversity measures. Alpha diversity measurement was not different 
among treatment groups at each time point of collections.   
Similar to the cecal microbiota, principal coordinates analysis (PCoA) of weighted and 
unweighted UniFrac distances performed on 97% OTU abundance matrices of fecal microbiota 
revealed a distinct separation (p=0.01) between HFD- and LFD-fed mice. Overall surgery effect 
(OVX vs. SHM, p=0.01) was observed in the unweighted PCoA. In the weighted PCoA, SHM 
mice were more similar (p=0.01) to each other than to OVX mice, but OVX mice were not more 
similar to each other than to SHM mice. Although a main effect was observed, significant 
differences were not observed when accounting for time of collection.  
Throughout the course of our study, the composition of the fecal microbial community 
measured by weighted UniFrac distances revealed that two groups fed a LFD maintained similar 
structure, with OVX and SHM mice clustering differently (Figure 6.2). The fecal microbial 
communities of both HFD-fed groups, on the other hand, shifted at wk 4 and then returned to a 
place similar to baseline (i.e. wk 0). With unweighted UniFrac distances, the fecal microbial 
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communities did not cluster differently between OVX and SHM mice fed a LFD or HFD 
(Figure 6.3). Similar to our observation in weighted UniFrac, the fecal microbial communities of 
HFD-fed mice measured by unweighted UniFrac distances shifted at wk 4 and then returned to a 
level similar to baseline.  
The composition of the fecal microbial communities at the phyla and genus levels at each 
time point throughout the study are shown in Figure 6.4A and B, respectively. Overall, the fecal 
microbiota of the SHM/LFD group was very stable throughout the study.  However, the fecal 
microbiota of OVX/LFD group shifted with time. Similar to our observation using UniFrac 
distance measurements, the fecal microbiota of SHM/HFD and OVX/HFD groups shifted at wk 
4 and returned to a level similar to baseline at wk 8 and wk 12. The relative abundance of the 
phyla, Firmicutes and Bacteroidetes, and the ratio of these two phyla over time, is shown in 
Figure 6.4C. HFD-fed mice had a lower (p<0.05) relative abundance of Firmicutes and a greater 
(p<0.05) relative abundance of Bacteroidetes than LFD-fed mice, resulting in a greater (p<0.05) 
Firmicutes:Bacteroidetes ratio. Main time and surgery effects were observed in the relative 
abundance of Firmicutes of LFD-fed mice, with this phyla being lower (p<0.05) at wk 4 
compared to baseline (wk 0) and greater (p<0.05) in OVX mice than SHM mice. A time effect 
also was observed in the relative abundance of Firmicutes of HFD-fed mice. OVX mice had 
lower (p<0.05) relative abundance of Firmicutes than SHM mice when fed a LFD, whereas only 
a time effect was observed when fed a HFD. An interaction between surgery treatment and time 
was observed for the Firmicutes:Bacteroidetes ratio of LFD-fed mice, whereas only a time effect 
was observed in those fed a HFD.  
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Dynamics of fecal microbiota during the development of obesity associated with loss of ovarian 
hormone production 
Changes in specific genera across time points were assessed using a two-part mixed 
effects model for analyzing longitudinal microbiome composition data. Several genera were 
identified as having a time effect (p<0.05) in mice fed a HFD. The relative abundance of 
Bifidobacterium, Turicibacter, an undefined genus in the family Clostridiaceae, Clostridium, 
SMB53, and an undefined genus in the family Peptostreptococcaceae appeared to increase at 4 
wk post-surgery and returned to levels comparable to baseline (wk 0) at wk 8 and wk 12 post-
surgery in HFD-fed mice (Figure 6.5). The relative abundance of Lactococcus, in contrast, was 
decreased at 4 wk post-surgery and returned to a level similar to baseline at wk 8 and wk 12. 
Most of the changes observed in Lactococcus affected both OVX and SHM mice, suggesting an 
influence due to surgery in general but not loss of ovarian hormone production (Figure 6.5B). 
However, the relative abundance of Clostridium and an undefined genus in the family 
Clostridiaceae increased only in the OVX/HFD mice at wk 4 post-surgery, but not in SHM/HFD 
mice, indicating a response due to the loss of ovarian hormone production. The relative 
abundance of Turicibacter and an undefined genus in family Peptostreptococcaceae were lower 
(p<0.05) in OVX mice fed a LFD than SHM/LFD mice across the time points (Figure 6.5 C and 
G, respectively).   
 The relative abundance of Enterococcus was elevated (p<0.05) throughout the study in 
OVX mice fed HFD compared to SHM mice fed HFD, but did not differ between OVX and 
SHM mice fed LFD (Figure 6.6A). On the other hand, OVX mice had a lower (p<0.05) relative 
abundance of Coprococcus compared to SHM when fed both LFD and HFD (Figure 6.6B). The 
relative abundance of Dorea and Coprobacillus were lower (p<0.05) in OVX mice than SHM 
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mice across all time points when fed HFD, but were not different in mice fed LFD (Figure 6.6C 
and D).  
 The relative abundance of an undefined genus in the family Rikenellaceae was lower 
(p<0.05) in OVX mice than SHM across all time points when fed LFD, but was not different in 
HFD-fed mice (Figure 6.7A). The relative abundance of an undefined genus in family S24-7 was 
greater (p<0.05) in OVX mice compared to SHM when fed LFD, but did not differ between 
surgery treatments when fed HFD (Figure 6.7B). This genus was, however, lower (p<0.05) 
throughout the study in OVX mice than LFD mice fed HFD. Similarly, the relative abundance of 
Lactobacillus was greater (p<0.05) in OVX mice compared to SHM mice when fed LFD, but did 
not differ by surgery status when fed HFD (Figure 6.7C). The relative abundance of 
Lactobacillus increased (p<0.05) with time when fed HFD. The relative abundance of an 
undefined genus in Christensenellaceae increased (p<0.05) with time in both LFD- and HFD-fed 
mice (Figure 6.7D). The relative abundance of an undefined genus in Lachnospiraceae was 
lower (p<0.05) in OVX mice than SHM when fed LFD, but increased (p<0.05) in both surgery 
groups over time when fed HFD (Figure 6.7E). The relative abundance of Oscillospira was 
lower (p<0.05) in OVX mice than SHM mice when fed LFD, but did not differ with time or 
surgery intervention when fed HFD (Figure 6.7F).   
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Figure 6.1. Bacterial -glucuronidase activity in fecal samples collected prior to sacrifice 
in ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed high-fat (HFD) 
or low-fat diets (LFD). Values are means ± SEM, n = 4-9/group. Interactions were denoted 
by superscript letters, with means lacking a common letter being different, p<0.05. 
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Figure 6.2. Weighted UniFrac principal coordinates analysis (PCoA) plots of longitudinal 
fecal microbial communities of ovariectomized (OVX) or sham-operated (SHM) 
C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD). Each dot represents a sample 
from each mouse (n=7-10/group), and the larger dots in each plot are the samples specific to 
the time point listed. 
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Figure 6.3. Unweighted UniFrac principal coordinates analysis (PCoA) plots of 
longitudinal fecal microbial communities of ovariectomized (OVX) or sham-operated 
(SHM) C57BL/6J mice fed high-fat (HFD) or low-fat diets (LFD). Each dot represents a 
sample from each mouse (n=7-10/group), and the larger dots in each plot are the samples 
specific to the time point listed. 
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Figure 6.4. Fecal microbial communities over time at the phylum (A) and genus level (B) 
and the relative abundance of Firmicutes, Bacteroidetes, and Firmicutes:Bacteroidetes 
ratio (C) of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed high-fat 
(HFD) or low-fat diets (LFD). * denotes statistical significance, p<0.05. 
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Figure 6.5. Differential abundant genera across time points observed in fecal microbial 
communities of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed 
high-fat (HFD) or low-fat diets (LFD). The relative abundance was logit transformed after 
correcting for the abundance at baseline. 
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Figure 6.6. Differential abundant genera across time points observed in fecal microbial 
communities of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed 
high-fat (HFD) or low-fat diets (LFD). The relative abundance was logit transformed after 
correcting for the abundance at baseline. 
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Figure 6.7. Differential abundant genera across time points observed in fecal microbial 
communities of ovariectomized (OVX) or sham-operated (SHM) C57BL/6J mice fed 
high-fat (HFD) or low-fat diets (LFD). The relative abundance was logit transformed after 
correcting for the abundance at baseline.  
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DISCUSSION 
Profound physiological changes were observed in OVX mice fed a westernized HFD, 
especially those pertaining to adiposity, inflammation, and disrupted gut barrier function. 
However, unlike the differential clustering observed between OVX/LFD and SHM/LFD groups, 
the cecal microbial communities of OVX/HFD mice were not different from those in the 
SHM/HFD group, in spite of the drastic physiological differences observed between these two 
groups. The weight gain of OVX/HFD mice happened soon after the ovariectomy surgery, 
suggesting that the changes in host physiology occur early on in the progression of the loss of 
ovarian function-associated obesity. Therefore, we aimed to determine the timing of when the 
gut microbiota changes occurred along the development of obesity associated with ovariectomy 
to identify the role of gut microbiota in the progression of this disease. Administration of 
antibiotics to healthy pregnant women leads to substantial increases in the fecal excretion of 
conjugated estrogens(15) and fecal total estrogen concentrations have been inversely correlated 
with the bacterial β-glucuronidase enzyme activity in post-menopausal women (1), suggesting a 
significant role of bacterial β-glucuronidase enzyme activity of the gut microbiome in estrogen 
metabolism. Furthermore, the bacterial β-glucuronidase enzyme activity was elevated in healthy 
men consuming diets high in animal protein and fat (2). We observed a diet by surgery 
interaction of β-glucuronidase enzyme activity, with mice in the SHM/HFD group having greater 
activity level than those in the SHM/LFD group. Changes in the fecal microbiota occurred soon 
after ovariectomy, and the microbial community differences persisted throughout the study 
between SHM and OVX mice fed LFD. However, the fecal microbial communities in the HFD-
fed mice were different at wk 4 and returned to a level similar to baseline without differential 
clustering between SHM and OVX mice, suggesting that the impact of diet outweighed the loss 
 185 
of ovarian hormone production in regards to the gut microbiota. Similar to the cecal microbiota 
as reported in Chapter 5, HFD-fed mice had a greater Firmicutes:Bacteroidetes ratio, which has 
been associated with an obese phenotype (16). The Firmicutes:Bacteroidetes ratio increased over 
time in mice fed HFD, indicating that the elevated adiposity may contribute to this alteration. 
However, the Firmicutes:Bacteroidetes ratio increased in the HFD-fed mice after 2-wk of dietary 
intervention began without a drastic increase in adiposity compared to LFD-fed mice, indicating 
that consuming a diet high in fat is sufficient to affect the Firmicutes:Bacteroidetes ratio. After 
correcting for the relative abundance of each genus at baseline, we identified two genera that 
were elevated at wk 4 in the OVX/HFD group, but not the SHM/HFD group: Clostridium and an 
undefined genus in the family Clostridiaceae. This response suggests that these two taxa within 
the order Clostridiales responded to the loss of ovarian hormone production when fed a HFD. A 
previous study demonstrated a positive association between the order Clostridiales and the ratio 
of all estrogen metabolites to parent estrogen in post-menopausal women (17). Furthermore, the 
species Clostridium perfringens is known to have β-glucuronidase activity (18), suggesting that 
the order Clostridiales in the gut microbiota may be involved in estrogen metabolism. Other 
genera were different between SHM and OVX groups fed LFD, suggesting that loss of ovarian 
hormone production impacts the gut microbial community as previously demonstrated in the 
high- and low- capacity running (HCR/LCR) rat model by Cox-York and colleagues (19). 
Bacterial β-glucuronidase hydrolyzes glucuronidated compounds such as estrogen-
derived metabolites and facilitates the recycling of estrogen. Bacterial β-glucuronidase also 
deconjugates other compounds that are commonly conjugated with glucuronic acid, including 
vitamins, sugar residues, secondary metabolites from plants or animals in the diet, xenobiotics, 
and pharmaceutical compounds (11, 20, 21). A high level of β-glucuronidase activity in the 
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intestine elevates the exposure to deglucuronidated compounds, which may increase the 
exposure of hormones, drugs, bile acids, or other xenobiotics to the host. High level of β-
glucuronidase activity may increase the exposure time to potential carcinogens and/or may 
exacerbate toxicity to certain compounds. For example, colorectal cancer patients are known to 
have a higher level of β-glucuronidase activity in the feces (22). Similarly, the elevated risk of 
cancer in post-menopausal women is thought to be partly attributed to the elevation of this 
enzyme, leading to an elevation of systemic non-ovarian estrogen concentrations (23). Because 
diets high in animal meats and fats are known to cause elevation of β-glucuronidase activity in 
the feces (2), we speculated that its activity would be greater in the OVX/HFD group, leading to 
greater systemic estrogen levels by promoting estrogen recycling. Because this process occurs in 
the intestine, the microbes may be disguised from the loss of ovarian hormone production from 
ovariectomy, which contributes to the lack of differences in the gut microbiota of OVX/HFD and 
SHM/HFD mice. To our surprise, even though a diet  surgery interaction was observed, mice in 
the OVX/HFD group did not have greater fecal β-glucuronidase activity prior to sacrifice. Mice 
in the SHM/HFD group had greater fecal β-glucuronidase activity than those in the SHM/LFD 
group, but neither groups were different from the OVX mice, suggesting that a diet high in fat 
promotes fecal β-glucuronidase activity in intact female mice, but the lack of ovarian function 
affects the activity of this enzyme. A limitation that may contribute to the lack of change in the 
fecal β-glucuronidase activity observed between OVX/HFD and SHM/HFD groups is that the 
fecal samples used for this assay was frozen right after collection and had been freeze-thawed 
one time for DNA extractions; both may affect the enzyme activity. The lack of changes also 
may indicate that non-ovarian estrogen biosynthesis was elevated in the peripheral tissues.  
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The fecal microbiota data examined in the current study suggested that changes in the gut 
microbiota in response to the loss of ovarian hormone production occurred soon after the 
ovariectomy was performed, suggesting a critical window for mechanistic testing in the 
progression of this disease. Changes in the fecal microbiota of mice fed HFD were not retained 
across the entire study, supporting our speculation in Chapter 5 that diet and/or physiological and 
metabolic response to the insult of the HFD potentially outweighs the effects of ovariectomy in 
the cecal microbiota. The Firmicutes:Bacteroidetes ratio gradually increased with time in HFD-
fed mice but not in those fed LFD, supporting the assumption of current literature that obesity is 
associated with an elevation of Firmicutes:Bacteroidetes ratio (16, 24). However, due to the 
observed elevation in the Firmicutes:Bacteroidetes ratio soon after dietary intervention began, 
other factors may affect the ratio of these two major phyla such as pH, transit time, and motility 
of the gut in response to the changes in dietary macronutrient composition. Whether this 
elevation in the Firmicutes:Bacteroidetes ratio influences energy harvest in HFD-fed female 
SHM and OVX mice needs to be elucidated. We did not observe a ovariectomy effect in the 
Firmicutes:Bacteroidetes ratio of the cecal and fecal microbiota as reported by Cox-York and 
colleagues (19). In contrast of the elevation of the relative abundance of Bacteroidetes in OVX 
rats reported in the previous study (19), we observed a decreased in the relative abundance of 
Bacteroidetes in OVX mice fed a LFD compared to SHM mice fed the same diet. Due to the 
differences in the rodent models and diet utilized between our study and the study conducted by 
Cox-York and colleagues, further investigation is needed to resolve the effect of ovariectomy on 
the composition of Firmicutes and Bacteroidetes in the gut microbiota.  
The relative abundance of Clostridium and an undefined genus in the family 
Clostridiaceae was identified to be greater in OVX/HFD mice at wk 4 than that of SHM/HFD 
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mice in this study. Interestingly, a Clostridium perfringens–produced endotoxin is a known 
ligand of claudin-3 and claudin-4 (25). Elevation in the relative abundance of Clostridium in 
OVX/HFD mice may contribute to the disrupted gut barrier function described in Chapter 5. 
Even though the differences were found at wk 4 and not throughout the study, the impact and 
damage could be long-lasting. 
In summary, our study demonstrated that the impact of ovariectomy on the gut microbial 
community occurs soon after surgery and in the early stages of obesity. HFD feeding and/or 
obesity seems to affect the fecal microbial community to a greater extent than ovariectomy, 
potentially due to greater compensatory effect of non-ovarian estrogen biosynthesis in the 
adipose tissues through the activity of aromatase.  
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CHAPTER 7: SUMMARY 
Great advancements in the gastrointestinal microbiome field have been made recently 
due to the development of high-throughput, culture-independent sequencing technologies, 
shedding light on the host-microbial interactions in health and disease. Gastrointestinal-related 
diseases such as inflammatory bowel diseases and colorectal cancer have been linked with 
changes in the overall composition of the gut microbial community as well as specific bacterial 
taxa that are thought to contribute to the initiation and/or progression of disease (1, 2). Obesity 
and related metabolic diseases such as insulin resistance, diabetes, and cardiovascular disease 
have been linked with an altered gut microbial community and disrupted gut barrier function that 
lead to inflammation. Inoculating the gut microbiome of obese male mice to lean recipients 
promotes adiposity, suggesting a causal relationship between the gut microbiome and obesity (3). 
 Obesity is one of the major public health crises of the 21st century and the leading cause 
of numerous chronic diseases. It has been estimated that 66-74% of post-menopausal women are 
overweight or obese, compared to 56% of women at pre-menopausal age (4). With the 
advancement in modern medicine, women now spend between one-third and one-half of their 
lives after menopause has occurred. Biomedical research, however, tends to focus on men and 
male animal models due to the concerns about the metabolic fluctuations that occur with 
hormonal cycles and changes in hormone production throughout the life stages of women such as 
pregnancy, breast feeding, and menopause. Therefore, applying biological responses observed in 
males to females is a common approach in clinical practice, ignoring not only the hormonal 
differences present between men and women, but also the metabolic and body compositional 
differences. Awareness of sex differences has been noted in the pharmaceutical field; for 
instance, effective dose of certain antipsychotic drugs are significantly higher in men than 
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women, which could lead to more side effects in women if given the same dose (5). Therefore, 
hormonal differences between males and females are undoubtedly an important and pressing 
subject.  
Because of the reasons given above, the majority of the research regarding obesity and 
gut microbiota to date has been conducted in male animal models.  Similar to humans, sex-
related differences have been noted in rodent models.  For example, intact female rats are more 
protected against intestinal injury, inflammation, and high-fat diet (HFD)-induced obesity than 
males, suggesting potential modulation of sex hormones on GI health (6, 7). Furthermore, 
administration of estradiol to male mice decreases hypoxia and acidosis-induced ileal mucosal 
membrane permeability and mucosal villi injury (6). With an interest in the health of post-
menopausal women, we aimed to elucidate the gut microbiota and gastrointestinal involvement 
in obesity and inflammation associated with the loss of ovarian estrogen production.  
Our first aim (Chapter 3) was to evaluate the impact of soy on metabolic health, adipose 
tissue inflammation, and the cecal microbiota in ovariectomized (OVX) rats bred for low-
running capacity (LCR), a model that has been previously shown to mimic human menopause. 
Soy and soy products are widely used as alternative and complementary medicine therapies to 
alleviate menopause-related symptoms, and have been shown to reduce obesity and improve 
metabolic health in humans and rodents (8-10). The soy isoflavone-derived metabolite, S-(-) 
equol, is exclusively produced by intestinal microbes. Although it is still unclear, the ability of 
producing equol has been hypothesized to be crucial for obtaining the health benefits from a soy-
rich diet (11). Therefore, we hypothesized that soy consumption would improve whole body 
insulin sensitivity, hinder fat mass gain and adipose tissue inflammation, and beneficially impact 
the gut microbial community by decreasing the Firmicutes:Bacteroidetes ratio, which has been 
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associated with an obese phenotype (3), and increasing the relative abundance of known equol-
producing bacteria such as Lactobacillus, Enterococcus, and Adlercreutzia. Soy consumption 
reduced (p<0.05) body weight gain, adiposity, and circulating cholesterol concentrations and 
improved (p<0.05) insulin sensitivity of LCR rats when compared to those fed a soy-free control 
diet. Principal coordinates analysis (PCoA) of weighted and unweighted UniFrac distances of 
cecal microbiota revealed a sharp separation (p<0.05) between soy- and control-fed rats. The 
soy-fed rats had a markedly lower (p<0.05) Firmicutes:Bacteroidetes ratio, which has been 
associated with a lean phenotype. Ovariectomy led to greater (p<0.05) relative abundance of 
Aggregatibacter and Anaerovibrio, but lower (p<0.05) relative abundance of SMB53 than sham-
operated (SHM) intact rats. The relative abundance of Lactobacillus spp. and Enterococcus spp., 
however, did not differ among treatment groups. On the contrary, the relative abundance of 
Adlercreutzia spp. was lower (p<0.05) in the soy-fed rats than controls. Specific species 
identification, quantitative abundance of bacterial taxa, and equol-producing activity level will 
need to be assessed in the future to confirm changes in the cecal microbiota in response to 
ovariectomy and how soy intervention is involved with the metabolic alterations.  
Although it is a useful outbred model that has genetic variability similar to that in 
humans, the heterogeneity of LCR rats increases the biological variation, making it difficult to 
elucidate the effects of ovarian hormone production loss and soy on the gut microbial 
community. Therefore, a homogeneous mouse model was utilized for our remaining aims that 
were focused on investigating the gut microbial community responses to host physiological and 
metabolic changes from ovariectomy in female mice encountering a HFD.  
Our second aim (Chapter 4) was to determine energy metabolism, lipid accumulation, 
and inflammation in adipose and liver tissues of OVX female C57BL/6J mice in response to a 
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HFD. We hypothesized that ovariectomy would induce obesity and adiposity, increase 
inflammatory markers in adipose and liver tissues, and increase hepatic and adipose tissue 
steatosis compared to intact controls. We also hypothesized that these dysfunctional metabolic 
parameters would be more severe in the OVX mice fed a HFD than those fed a control low-fat 
diet (LFD). As expected, OVX mice fed HFD had substantially greater (p<0.05) body weight 
gain, adiposity, and hepatic triglyceride concentrations than OVX mice fed LFD. Compared to 
intact controls, Ovariectomy led to greater (p<0.05) adipose and hepatic tissue inflammation, 
macrophage infiltration, oxidative stress, hindered insulin signaling and glucose uptake, and 
altered lipid and energy metabolism. Moreover, HFD feeding in OVX mice led to markedly 
greater (p<0.05) inflammation and macrophage infiltration in gonadal adipose tissue (GDAT) 
among groups, potentially mediated by TLR2 signaling. An interesting interaction was observed 
in this study. The degree of adiposity and inflammation coming from HFD in OVX mice vs. 
SHM mice was dramatically greater (p<0.05) than that observed in OVX mice vs. SHM control 
mice fed LFD.  
Our third aim (Chapter 5) was to examine the cecal microbial communities and barrier 
function in mice with loss of ovarian function and when fed a HFD or LFD. We hypothesized 
that ovariectomy would lead to disrupted gut barrier function, altered energy metabolism, and 
elevated intestinal inflammation, and that HFD would exacerbate the severity of these 
conditions. We also hypothesized that ovariectomy would shift the cecal microbial communities 
and lead to an increased Firmicutes:Bacteroidetes ratio and decreased species richness compared 
to intact SHM mice. OVX/HFD mice had greater (p<0.05) serum lipopolysaccharide binding 
protein (LPSBP) than OVX/LFD mice Surprisingly, cecal expression of inflammatory genes was 
not elevated due to ovariectomy, but the expression of BCL2, a marker of apoptosis, was greater 
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(p<0.05) in OVX mice than SHM mice. Cecal permeability measured by Ussing chamber was 
not different among treatment groups. However, OVX mice had lower (p<0.05) cecal expression 
of occludin, claudin3, and AMPK than SHM mice, suggesting that the cecal integrity was 
compromised due to loss of ovarian hormone production. Lower (p<0.05) cecal expression of 
FXR and FGF15 was observed in the OVX mice compared to SHM mice, suggesting an 
interaction between estrogen and the FXR-FGF15 pathway that is known to affect bile acid 
synthesis. The interaction of ovariectomy and bile acid metabolism should be further assessed as 
it may be critical for energy harvest. Similar to our findings in Chapter 3, PCoA plots of 
weighted and unweighted UniFrac distances of cecal microbiota revealed a distinct (p<0.05) 
separation between mice fed HFD and LFD diets. To our surprise, differential clustering of 
microbial communities was observed only between OVX/LFD and SHM/LFD mice, but not 
those fed a HFD despite the profound physiological changes of OVX/HFD vs. SHM/HFD mice. 
As reported previously in male rodent models by multiple research groups (12-14), HFD 
promotes a greater (p<0.05) Firmicutes:Bacteroidetes ratio and lower (p<0.05) species richness 
of the cecal microbial community. However, the change in the Firmicutes:Bacteroidetes ratio in 
obesity is not always observed (15). Ovariectomy led to greater (p<0.05) abundance of 
Lactobacillus and lower (p<0.05) relative abundance of Oscillospira, Ruminococcus, and an 
undefined genus in the order Clostridiales. Positive associations (p<0.05) between tight junction 
protein-associated genes and the relative abundance of Bifidobacterium, Allobaculum, and an 
undefined genus in the family S24-7 in the cecal microbiota were detected. Similar to the 
metabolic changes observed in Chapter 4, an interesting interaction appeared in the cecal 
microbial community of OVX vs. SHM mice fed a HFD vs. LFD. The differences in the cecal 
microbiota between OVX and SHM mice fed a LFD suggests that loss of ovarian hormone 
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production shapes gut microbiota; however, the metabolic consequences from long-term HFD 
ingestion may outweigh the changes in the cecal microbiota due to ovariectomy. If true, proper 
dietary manipulations that modulate gut microbiota may promote metabolic health in post-
menopausal women. Elucidating the timing by which the changes of gut microbiota occur 
following the loss of ovarian hormone production and progression of diet-induced obesity is 
critical for the development of therapeutic strategies that target the gut microbial community.  
Differential clustering of the cecal microbial community was observed only between 
OVX and SHM mice fed a LFD, suggesting that the impact of ovariectomy on the cecal 
microbiota was masked by the HFD intervention. Fecal total estrogen concentrations have been 
inversely correlated with the bacterial β-glucuronidase enzyme activity in post-menopausal 
women (16), and this enzyme activity was elevated in healthy men consuming diets high in 
animal protein and fat (17). We, therefore, hypothesized that a differentially altered bacterial -
glucuronidase activity in mice fed LFD vs. HFD may be contributing to the lack of differences in 
the cecal microbiota of SHM and OVX mice fed a HFD. Thus, our fourth aim (Chapter 6) 
determined the bacterial -glucuronidase activity level and the longitudinal shifts of the gut 
microbiota following the loss of ovarian function and progression of obesity in mice fed a HFD. 
Fecal pellets were collected at baseline (wk 0, prior to ovariectomy surgery but 2 wk after diet 
interventions initiated) and 4-, 8-, and 12-wk post-surgical intervention. Fecal -glucuronidase 
activity was greater (p<0.05) in SHM/HFD than SHM/LFD mice at 12 wk post-surgery, but was 
not different than the OVX mice. As expected, PCoA plots of weighted UniFrac distances of 
cecal microbiota revealed a distinct separation between mice fed HFD vs. LFD. However, SHM 
and OVX mice clustered differently only in those fed a LFD. SHM and OVX mice fed HFD did 
not exhibit differential clustering at each time point examined, but the entire gut microbial 
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community shifted at wk 4, suggesting a potential impact of surgery and recovery. The 
Firmicutes:Bacteroidetes ratio was elevated at wk 8 and wk 12 of those fed the HFD, indicating 
that this elevation was due to increased adiposity instead of ovariectomy per se. The relative 
abundance of Clostridium and an undefined genus in the family Clostridiaceae was elevated in 
OVX/HFD mice at wk 4, but not SHM/HFD, indicating that these changes may be due to the 
loss of ovarian hormone production. 
 In our studies, the gut microbiota response to ovariectomy was much weaker than to 
dietary intervention. While it may indicate that the gut microbiota are not responding to the loss 
of ovarian hormone production and/or significantly contributing to the progression of obesity, 
many other factors should be considered and further investigated. First, the technologies utilized 
in our studies are able only to catalog the relative abundance of the bacterial species that exist in 
the gut rather than their activity and function. Metagenomic, transcriptomic, and metabolomic 
analyses will need to be conducted to better examine the involvement of the gut microbiome in 
ovariectomy- and menopausal-associated obesity. Second, decreased gut barrier function and the 
alteration of FXR and FGF15 in the cecum suggest that signaling and regulation of inflammation 
and bile acid metabolism in the gastrointestinal tract are impacted by ovariectomy. Therefore, 
loss of ovarian hormone production may impact host bile acid metabolism, absorption of dietary 
macronutrients, and systemic inflammatory response. Third, the lack of change in the fecal -
glucuronidase activity between OVX/HFD and SHM/HFD mice suggests that a compensatory 
synthesis of estrogen via Cyp19a1 (aromatase) activity in non-ovarian organs contribute to the 
absence of differential clustering in the cecal microbiota between OVX/HFD and SHM/HFD 
mice. Unfortunately, our standard method was unable to measure a sufficient signal of aromatase 
gene expression. However, testing our hypothesis pertaining to non-ovarian aromatase activity 
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may be possible in the future by using an aromatase knockout mouse model or administrating 
aromatase inhibitors, which have been shown to lower the risk of cancer in post-menopausal 
women. Moreover, host-microbial interactions in the presence/absence of ovarian function may 
be more complicated than expected, potentially involving epigenetic changes and the sex 
chromosome.  
 To the best of our knowledge, the changes in gut barrier function and the microbial 
community was not known between pre-menopausal vs. post-menopausal women or intact vs. 
OVX animal models. Our work established a foundation of GI-related changes in response to 
ovariectomy when encountered with dietary interventions. Elucidating the host-microbial 
interactions and the tissue crosstalk that occurs following the loss of ovarian hormone production 
and progression of obesity mechanistically may provide potential preventative and/or therapeutic 
strategies to positively impact women’s health. Even though our studies have their limitations, 
we identified several host genes and biological pathways and gut microbial taxa that were altered 
in response to ovariectomy that may contribute to the etiology of loss of ovarian hormone 
production-associated obesity. In the future, the utilization of germ-free rodent models may aid 
in elucidating a potential causal effect of microbial-induced obesity, transplanting feces of OVX 
donors to germ-free recipients. Identification of bacterial metabolites that contribute to the 
disease progression of ovariectomy-associated obesity is of interest and may be useful for 
mechanistic testing by, for instance, inoculating a defined microbial community with or without 
certain functions to germ-free recipients.  
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APPENDIX A. Primer sequences of genes assessed in gonadal and subcutaneous adipose tissue and liver of 
C57BL/6J mice using qRT-PCR 
Target Forward Primer Reverse Primer Gene Full Name 
Gene Aliases/ 
Target Protein 
ACACA GACAACACCTGTGTGGTGGAA TGTTTAGCGTGGGGATGTTCC acetyl-Coenzyme A carboxylase alpha Acc1 
ACTB CCCTAAGGCCAACCGTGAAA AGCCTGGATGGCTACGTACA actin, beta Beta-actin 
Adgre1 GCAGAAGCTCTGCAGTGTCA AATCTGGGCAATGGCCTTGAA adhesion G protein-coupled receptor E1 F4/80 
ADIPOQ TCCTGGAGAGAAGGGAGAGAA TCAGCTCCTGTCATTCCAACA adiponectin, C1Q and collagen domain containing 
 
AHSG GTGGCCTGCAAGTTATTCCAA CTGCATTCGCTGTGGGTAC alpha-2-HS-glycoprotein Fetuin-A 
ANGPT2 GAACCAGACAGCAGCACAAA TCGAGTCTTGTCGTCTGGTTTA angiopoietin 2 
 
ARG1 GGATTGGCAAGGTGATGGAA CGACATCAAAGCTCAGGTGAA arginase, liver 
 
BCL2 ATGTGTGTGGAGAGCGTCAA GATGCCGGTTCAGGTACTCA B cell leukemia/lymphoma 2 
 
CASP3 AGTCTGACTGGAAAGCCGAAA TCTGTCTCAATGCCACAGTCC caspase 3 
 
CAT GGGATCTTGTGGGAAACAACAC CTGTGGGTTTCTCTTCTGGCTA catalase Cas1 
CCL2 AGCAGCAGGTGTCCCAAA TTCTTGGGGTCAGCACAGAC chemokine (C-C motif) ligand 2 Mcp1 
CCL3 ACCATGACACTCTGCAACCA GAATCTTCCGGCTGTAGGAGAA chemokine (C-C motif) ligand 3 
 
CCL5 GTGCCCACGTCAAGGAGTA GCGGTTCCTTCGAGTGACA chemokine (C-C motif) ligand 5 
 
CCR2 TGAGGCTCATCTTTGCCATCA GGATTCCTGGAAGGTGGTCAA chemokine (C-C motif) receptor 2 
 
CCR5 TAGCCAGAGGAGGTGAGACA CGGAACTGACCCTTGAAAATCC chemokine (C-C motif) receptor 5 AM4-7|CD195 
CD19 CCATCGAGAGGCACGTGAA ACCACTGGGACTATCCATCCA CD19 antigen 
 
CD3E TGCTACACACCAGCCTCAAA AGGTCCACCTCCACACAGTA CD3 antigen, epsilon polypeptide 
 
CD4 AAGGGACACTGCATCAGGAA CCCATCACCTCACAGGTCAA CD4 antigen 
 
CD68 ATCCCCACCTGTCTCTCTCA CTGTACTCGGGCTCTGATGTA CD68 antigen 
 
CD8A CAGCAAGGAAAACGAAGGCTAC GCAGCACTGGCTTGGTAGTA CD8 antigen, alpha chain Ly-2|Ly-B|Ly-35 
CDK5 CGTGCTACATAGGGACCTGAA AGGCCAAAATCAGCCAATTTCA cyclin-dependent kinase 5 Crk6 
CNR1 ACAAGCACGCCAATAACACA TGGTCACCTTGGCGATCTTA cannabinoid receptor 1 (brain) CB1|CB-R|CB1R 
CPT1A CTGCCTCTATGTGGTGTCCAA ACAACCTCCATGGCTCAGAC carnitine palmitoyltransferase 1a, liver CPTI|Cpt1 
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DGAT2 TTGGCTACGTTGGCTGGTAA GTCTATGGTGTCTCGGTTGACA diacylglycerol O-acyltransferase 2 ARAT|DGAT-2 
EPAS1 AAGCTTTTCGCCATGGACAC CAAGGTCTCCAAATCCAGTTCAC endothelial PAS domain protein 1 HIF2alpha 
FAAH TGGCCTGAAGAGCTGTGTTTA ATGCCAGGCTATCCACATCC fatty acid amide hydrolase AW412498 
FAS TGTTTTCCCTTGCTGCAGAC CCGCCTCCTCAGCTTTAAAC Fas (TNF receptor superfamily member 6) CD95 
FASL CGAGGAGTGTGGCCCATTTA AGCGGTTCCATATGTGTCTTCC Fas ligand (TNF superfamily, member 6) CD95L 
FCGR1 ATCTGCAGGAGTGTCCATCA AGATGACACGGATGCTCTCA Fc receptor, IgG, high affinity I 
CD64|IGGHAFC 
|FcgammaRI 
GSTA2 GCCTTGGCAAAAGACAGGAC GTCTTGTCCATGGCTCTTCAAC glutathione S-transferase, alpha 2 (Yc2) Gstc2|Gst2-2|Gstc-2 
HIF1A TCGACACAGCCTCGATATGAA TTCCGGCTCATAACCCATCA hypoxia inducible factor 1, alpha subunit HIF1alpha 
HSD11B1 AAAATGGGAGCCCATGTGGTA AGTTCAAGGCAGCGAGACA hydroxysteroid 11-beta dehydrogenase 1 
 
ICAM1 AGGGCTGGCATTGTTCTCTA TGTCGAGCTTTGGGATGGTA intercellular adhesion molecule 1 CD54 
IFNG CCACGGCACAGTCATTGAAA GCCAGTTCCTCCAGATATCCAA interferon gamma 
 
IGFBP1 TCTGCCAAACTGCAACAAGAA CCACTCCATGGGTAGACACA insulin-like growth factor binding protein 1 
 
IKBKB GTTCGCTACCCTTCCCCAATA AGGGTGCCACATAAGCATCA inhibitor of kappaB kinase beta IKK2|IKKbeta 
IL10 AAAGGACCAGCTGGACAACA TAAGGCTTGGCAACCCAAGTA interleukin 10 
 
IL10RA GGTCGGAGGAGCAGTGTTTA AAGATGCTCAGGTTGGTCACA interleukin 10 receptor, alpha 
 
IL1B TGGCAACTGTTCCTGAACTCA GGGTCCGTCAACTTCAAAGAAC interleukin 1 beta 
 
IL6 CGATGATGCACTTGCAGAAA ACTCCAGAAGACCAGAGGAA interleukin 6 
 
IRS1 GCAGCCAGAGGATCGTCAATA CGTGAGGTCCTGGTTGTGAA insulin receptor substrate 1 IRS-1 
IRS2 ACCTATGCAAGCATCGACTTCC GGGCTGGTAGCGCTTCA insulin receptor substrate 2 Irs-2 
ITGAM AGCAGCTGAATGGGAGGAC GGCCCCATTGGTTTTGTGAA integrin alpha M CD11b 
ITGAX AAGGCAGCTAAGAGGGTACAC TCCACTTTGGGTGGTGAACA integrin alpha X CD11c 
LEP AGACCATTGTCACCAGGATCA ATGAAGTCCAAGCCAGTGAC leptin ob|obese 
LIPE GCTACACAAAGGCTGCTTCTAC TGGAGAGAGTCTGCAGGAAC lipase, hormone sensitive HSL 
LPL GAGAGCGAGAACATTCCCTTCA CGATGTCCACCTCCGTGTAA lipoprotein lipase Lpl 
MGLL GTCAATGCAGACGGACAGTAC CATAACGGCCACAGTGTTCC monoglyceride lipase Mgl|Magl 
MRC1 AAGGCTATCCTGGTGGAAGAA CTCTCGTGAATTGCCACCAA mannose receptor, C type 1 CD206 
NFKBIA GAGCGAGGATGAGGAGAGCTA GGCCTCCAAACACACAGTCA 
nuclear factor of kappa light polypeptide gene enhancer 
in B cells inhibitor, alpha 
Nfkbi 
NOS2 GAGGAGCAGGTGGAAGACTA GGAAAAGACTGCACCGAAGATA nitric oxide synthase 2, inducible iNOS 
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NR3C1 CAAGTGATTGCCGCAGTGAA AGAAGGGTCATTTGGTCATCCA nuclear receptor subfamily 3, group C, member 1 GR|Grl1|Grl-1 
PCK1 CCGTCTGGCTAAGGAGGAA TCTTCTTGCCTTCGGGGTTA phosphoenolpyruvate carboxykinase 1, cytosolic PEPCK|Pck-1 
PLIN2 AGGATGGAGGAAAGACTGCCTA ACATCCTTCGCCCCAGTTAC perilipin 2 ADPH|Adfp|Adrp 
PPARA TTCCCTGTTTGTGGCTGCTA CCTGCAACTTCTCAATGTAGCC peroxisome proliferator activated receptor alpha 
Ppar|Nr1c1 
|PPARalpha 
PPARG ACCCAATGGTTGCTGATTACA AGGTGGAGATGCAGGTTCTA peroxisome proliferator activated receptor gamma 
 
PPARGC1A AAACCACACCCACAGGATCA GCTCTTCGCTTTATTGCTCCA 
peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha 
PGC1alpha 
PPIA AGGGTTCCTCCTTTCACAGAA TGCCGCCAGTGCCATTA peptidylprolyl isomerase A 
 
RBP4 CTGTGGACGAGAAGGGTCATA CATGTCTGCACACACTTCCC retinol binding protein 4, plasma 
 
RPS13 TCCTGTGCGGCTTGATTTCC GGTCTGGCAGCAAAGAGAGAA ribosomal protein S13 2700063M04Rik 
SERPINE1 CAGACAATGGAAGGGCAACA GAGGTCCACTTCAGTCTCCA 
serine (or cysteine) peptidase inhibitor, clade E, 
member 1 
Plasminogen 
Activator 
Inhibitor|PAI-1 
SFRP5 GAACAGATGTGCTCCAGTGAC CTTTCGGTCCCCGTTGTCTA secreted frizzled-related sequence protein 5 SARP3 
SLC2A1 GCTGTGCTGTGCTCATGAC GATGGCCACGATGCTCAGATA 
solute carrier family 2 (facilitated glucose transporter), 
member 1 
Glut1|Glut-1 
SLC2A4 TGTCGGCATGGGTTTCCA AAGCAGGAGGACGGCAAATA 
solute carrier family 2 (facilitated glucose transporter), 
member 4 
Glut4|Glut-4 
SPP1 TGCCTGACCCATCTCAGAA AAGTCATCCTTTTCTTCAGAGGAC secreted phosphoprotein 1 
Osteopontin|Opn|Ri
c|BNSP|BSPI|Opnl|
Apl-1|ETA-1|Spp-1 
SREBF1 ACCCTACGAAGTGCACACAA CACATCTGTGCCTCCTCCA sterol regulatory element binding transcription factor 1 
ADD1|SREBP1 
|bHLHd1|SREBP1c 
|SREBP-1a 
TLR2 TGCATCACCGGTCAGAAAAC AGCCAAAGAGCTCGTAGCA toll-like receptor 2 Ly105 
TLR4 GTTCTTCTCCTGCCTGACAC GCTGAGTTTCTGATCCATGCA toll-like receptor 4 
 
TNF GGGTGATCGGTCCCCAAA TGAGGGTCTGGGCCATAGAA tumor necrosis factor TNFalpha 
UCP2 GGTCACTGTGCCCTTACCA ATCCCAAGCGGAGAAAGGAA uncoupling protein 2 (mitochondrial, proton carrier) Slc25a8 
UCP3 TGTGCTGAGATGGTGACCTA GCTCCAAAGGCAGAGACAAA uncoupling protein 3 (mitochondrial, proton carrier) UCP-3|Slc25a9 
VCAM1 CCCAAACAGAGGCAGAGTGTA TGACCCAGATGGTGGTTTCC vascular cell adhesion molecule 1 CD106 
VEGFA CCAGCACATAGGAGAGATGAG CTGGCTTTGTTCTGTCTTTCTT vascular endothelial growth factor A   
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APPENDIX B. Primer sequences of genes assessed in cecum of C57BL/6J mice using qRT-PCR 
Target Forward Primer Reverse Primer Gene Full Name 
Gene Aliases/ 
Target Protein 
ACACA GACAACACCTGTGTGGTGGAA TGTTTAGCGTGGGGATGTTCC acetyl-Coenzyme A carboxylase alpha Acc1 
ACACB TTGGAGGCAACAGGGTCATA ATGGAGCGCATACACTTGAC acetyl-Coenzyme A carboxylase beta Acc2 
ACTB CCCTAAGGCCAACCGTGAAA AGCCTGGATGGCTACGTACA actin, beta Beta-actin 
ANGPTL4 CTTGGGACCAAGACCATGAC TGGCTACAGGTACCAAACCA angiopoietin-like 4 
Fiaf|fasting-induced 
adipose factor  
APAF1 CACAGACCTTTCCATCCTTCA CGTTTCCAAGTCCCAGAGAA apoptotic peptidase activating factor 1 fog|Apaf-1 
BCL2 ATGTGTGTGGAGAGCGTCAA GATGCCGGTTCAGGTACTCA B cell leukemia/lymphoma 2 
 
CASP3 AGTCTGACTGGAAAGCCGAAA TCTGTCTCAATGCCACAGTCC caspase 3 
 
CAT GGGATCTTGTGGGAAACAACAC CTGTGGGTTTCTCTTCTGGCTA catalase Cas1 
CCL2 AGCAGCAGGTGTCCCAAA TTCTTGGGGTCAGCACAGAC chemokine (C-C motif) ligand 2 Mcp1 
CCL3 ACCATGACACTCTGCAACCA GAATCTTCCGGCTGTAGGAGAA chemokine (C-C motif) ligand 3 
 
CCL5 GTGCCCACGTCAAGGAGTA GCGGTTCCTTCGAGTGACA chemokine (C-C motif) ligand 5 
 
CCR2 TGAGGCTCATCTTTGCCATCA GGATTCCTGGAAGGTGGTCAA chemokine (C-C motif) receptor 2 
 
CCR5 TAGCCAGAGGAGGTGAGACA CGGAACTGACCCTTGAAAATCC chemokine (C-C motif) receptor 5 AM4-7|CD195 
CLDN1 GCCACAGCATGGTATGGAAAC AGGGCCTGGCCAAATTCA claudin 1 AI596271 
CLDN2 TTCCAGAGCTCTTCGAAAGGAC GTATCTGTGGGTGGCCACAA claudin 2 AL022813 
CLDN3 GTGTACCAACTGCGTACAAGAC GCCAACAGGAAAAGCACTCC claudin 3 mRVP1|Cpetr2 
CLDN4 CGTGGCAAGCATGCTGATTA GGAAGCCACCATAGGGTTGTA claudin 4 Cep-r|Cpetr|Cpetr1 
CLDN5 GCTGGTGGCACTCTTTGTTA AGTGCTACCCGTGCCTTAA claudin 5 
 
CLDN8 TTGCTGACAGCCGGAATCA GAATTGGCAACCCAGCTGAC claudin 8 AI648025 
CXCL2 CCCCTGGTTCAGAAAATCATCC TCCTTTCCAGGTCAGTTAGCC chemokine (C-X-C motif) ligand 2 IL8 
DDIT3 GGGGCACCTATATCTCATCCC CGCAGGGTCAAGAGTAGTGAA DNA-damage inducible transcript 3 chop|CHOP10 
FFAR2 AAGAGCAGCTGGATGTGGTA GACTGCCATGGGAACGAAAA free fatty acid receptor 2 Gpr43 
FFAR3 CAGAGTGCCAGTTGTCCAATAC ACACCAACAGGTAGACGGAAA free fatty acid receptor 3 Gpr41 
FGF15 CGCGGACGGCAAGATATAC ACAGTCCATTTCCTCCCTGAA fibroblast growth factor 15 FGF19 
FOXO1 GAAGAGCGTGCCCTACTTCA GGACAGATTGTGGCGAATTGAA forkhead box O1 
 
 207 
HIF1A TCGACACAGCCTCGATATGAA TTCCGGCTCATAACCCATCA hypoxia inducible factor 1, alpha subunit HIF1alpha 
HSPA5 TGCTGAGGCGTATTTGGGAA TCGCTGGGCATCATTGAAGTA heat shock protein 5 
Bip|Sez7|mBiP|Grp78|SEZ
-7|Hsce70 
HSPA8 GCAGCTGGGCCTACACA GTAGGTGGTGCCGAGATCAA heat shock protein 8 
Hsc70|Hsc71|Hsc73|Hsp73
|Hspa10 
IFNG CCACGGCACAGTCATTGAAA GCCAGTTCCTCCAGATATCCAA interferon gamma 
 
IKBKB GTTCGCTACCCTTCCCCAATA AGGGTGCCACATAAGCATCA inhibitor of kappaB kinase beta IKK2|IKKbeta 
IL10 AAAGGACCAGCTGGACAACA TAAGGCTTGGCAACCCAAGTA interleukin 10 
 
IL10RA GGTCGGAGGAGCAGTGTTTA AAGATGCTCAGGTTGGTCACA interleukin 10 receptor, alpha 
 
IL1B TGGCAACTGTTCCTGAACTCA GGGTCCGTCAACTTCAAAGAAC interleukin 1 beta 
 
IL6 CGATGATGCACTTGCAGAAA ACTCCAGAAGACCAGAGGAA interleukin 6 
 
IRS1 GCAGCCAGAGGATCGTCAATA CGTGAGGTCCTGGTTGTGAA insulin receptor substrate 1 G972R|IRS-1 
IRS2 ACCTATGCAAGCATCGACTTCC GGGCTGGTAGCGCTTCA insulin receptor substrate 2 Irs-2 
LEP AGACCATTGTCACCAGGATCA ATGAAGTCCAAGCCAGTGAC leptin ob|obese 
LIPE GCTACACAAAGGCTGCTTCTAC TGGAGAGAGTCTGCAGGAAC lipase, hormone sensitive HSL 
LPL GAGAGCGAGAACATTCCCTTCA CGATGTCCACCTCCGTGTAA lipoprotein lipase Lpl 
MUC2 CAGCACACCAACCAAAACCA CACAGCCACCAGGTCTCATTA mucin 2 MCM|wnn 
NFKBIA GAGCGAGGATGAGGAGAGCTA GGCCTCCAAACACACAGTCA 
nuclear factor of kappa light polypeptide gene 
enhancer in B cells inhibitor, alpha 
Nfkbi|AI462015 
NLRP3 TGCTCTGCAACCTCCAGAAA AACCAATGCGAGATCCTGACA NLR family, pyrin domain containing 3 
FCU|MWS|FCAS|Cias1|M
mig1|NALP3|Pypaf1 
NR0B2 GAAGGGCACGATCCTCTTCAA GGGCTCCAAGACTTCACACA nuclear receptor subfamily 0, group B, member 2 SHP|Shp1|SHP-1 
NR1H4 GCCTCTGGGTACCACTACAA GTACACGGCGTTCTTGGTAA nuclear receptor subfamily 1, group H, member 4 
Fxr|HRR1|RIP14 
|Rxrip14 
OCLN ACTGGTCTCTACGTGGATCA ACCCCAGGACAATGGCTATA occludin Ocl 
PNPLA2 TGTCTGCAGCACATTTATCCC GAAATGCCGCCATCCACATA patatin-like phospholipase domain containing 2 Atgl|TTS-2.2 
PPARA TTCCCTGTTTGTGGCTGCTA CCTGCAACTTCTCAATGTAGCC peroxisome proliferator activated receptor alpha Ppar|Nr1c1 |PPARalpha 
PPARG ACCCAATGGTTGCTGATTACA AGGTGGAGATGCAGGTTCTA peroxisome proliferator activated receptor gamma 
 
PPARGC1
A 
AAACCACACCCACAGGATCA GCTCTTCGCTTTATTGCTCCA 
peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha 
PGC1alpha 
PPIA AGGGTTCCTCCTTTCACAGAA TGCCGCCAGTGCCATTA peptidylprolyl isomerase A 
 
PRKAA1 ATGTCTCTGGAGGAGAGCTA GGAAAGGATCTGCTGGAACA 
protein kinase, AMP-activated, alpha 1 catalytic 
subunit 
AMPKalpha1 
PRKAA2 CGGAGCTATCTTCTGGACTTCA CGCTGGGGTGTTGAAGAAC 
protein kinase, AMP-activated, alpha 2 catalytic 
subunit 
AMPKalpha2 
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PRKAB1 CTTGTCTGGGTCCTTCAACAAC CAGGTCCAGGATGGCTACAA 
protein kinase, AMP-activated, beta 1 non-catalytic 
subunit 
AMPKbeta1 
PRKAB2 CCTTACTTCCTGAGCCCAATCA TTGCGCTAAGGACCATCACA 
protein kinase, AMP-activated, beta 2 non-catalytic 
subunit 
AMPKbeta2 
PYCARD GAGCAGCTGCAAACGACTAA TGTACTCTGAGCAGGGACAC PYD and CARD domain containing Asc|TNS1|masc|CARD5 
RBP4 CTGTGGACGAGAAGGGTCATA CATGTCTGCACACACTTCCC retinol binding protein 4, plasma 
 
RPS13 TCCTGTGCGGCTTGATTTCC GGTCTGGCAGCAAAGAGAGAA ribosomal protein S13 2700063M04Rik 
SIRT1 CTGAAAGTGAGACCAGTAGCA GATGAGGCAAAGGTTCCCTA sirtuin 1 
Sir2|Sir2a|SIR2L1 
|Sir2alpha 
SLC10A2 TGGAGGAACTGGCTCCAATA GGAGCAAGTGGTCATGCTAA solute carrier family 10, member 2 ASBT|ISBT 
SLC51A TTGCCCCATCAAGAAGAGGAC AGAGACCAAAGCAGCAGAACA solute carrier family 51, alpha subunit Osta|OSTalpha 
SREBF1 ACCCTACGAAGTGCACACAA CACATCTGTGCCTCCTCCA 
sterol regulatory element binding transcription factor 
1 
ADD1|SREBP1|bHLHd1|
SREBP1c|SREBP-1a 
TJP1 TCTGGCATCATTCGCCTTCA TCAACCGCATTTGGCGTTAC tight junction protein 1 Zo-1 
TLR2 TGCATCACCGGTCAGAAAAC AGCCAAAGAGCTCGTAGCA toll-like receptor 2 Ly105 
TLR4 GTTCTTCTCCTGCCTGACAC GCTGAGTTTCTGATCCATGCA toll-like receptor 4 
 
TNF GGGTGATCGGTCCCCAAA TGAGGGTCTGGGCCATAGAA tumor necrosis factor TNFalpha 
UCP2 GGTCACTGTGCCCTTACCA ATCCCAAGCGGAGAAAGGAA uncoupling protein 2 (mitochondrial, proton carrier) Slc25a8 
UCP3 TGTGCTGAGATGGTGACCTA GCTCCAAAGGCAGAGACAAA uncoupling protein 3 (mitochondrial, proton carrier) UCP-3|Slc25a9 
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APPENDIX C. Primer sequences of specific bacterial taxa assessed in cecal digesta using qPCR 
  
  
Forward primer   Reverse primer  
  
Initial 
denaturing 
  Denaturing   Annealing 
#cycles Temp Time   Temp Time   Temp Time 
Bacteroidetes CCGGAWTYATTGGGTTTAAAGGG GGTAAGGTTCCTCGCGTA 35 98 2 min 
 
98 5 sec 
 
60 10 sec 
Bifidobacterium spp. TCGCGTCYGGTGTGAAAG CCACATCCAGCRTCCAC 40 98 2 min 
 
98 3 sec 
 
60 3 sec 
Blautia spp TCTGATGTGAAAGGCTGGGGCTTA GGCTTAGCCACCCGACACCTA 40 98 2 min 
 
98 4 sec 
 
56 4 sec 
Enterococcus CCCTTATTGTTAGTTGCCATCATT ACTCGTTGTACTTCCCATTGT 40 95 3 min 
 
95 10 sec 
 
61 15 sec 
Faecalibacterium spp.  GAAGGCGGCCTACTGGGCAC GTGCAGGCGAGTTGCAGCCT 40 98 2 min 
 
98 5 sec 
 
60 5 sec 
Firmicutes GGCAGCAGTRGGGAATCTTC ACACYTAGYACTCATCGTTT 35 98 2 min 
 
98 5 sec 
 
60 10 sec 
Fusobacterium spp. KGGGCTCAACMCMGTATTGCGT TCGCGTTAGCTTGGGCGCTG 40 98 2 min 
 
98 4 sec 
 
50.5 4 sec 
Rumincoccaceae ACTGAGAGGTTGAACGGCCA CCTTTACACCCAGTAAWTCCGGA 35 98 2 min 
 
98 3 sec 
 
67 3 sec 
Streptococcus spp. TTATTTGAAAGGGGCAATTGCT GTGAACTTTCCACTCTCACAC 40 95 2 min 
 
95 5 sec 
 
54 10 sec 
Lactobacillus spp. AGCAGTAGGGAATCTTCCA CACCGCTACACATGGAG 40 95 2 min 
 
95 5 sec 
 
58 10 sec 
Turicibacter spp. CAGACGGGGACAACGATTGGA TACGCATCGTCGCCTTGGTA 40 98 2 min 
 
98 3 sec 
 
57 3 sec 
Universal CCTACGGGAGGCAGCAGT ATTACCGCGGCTGCTGG 35 98 2 min   98 5 sec   59 5 sec 
 
 
 
 
 
